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 1 
Abstract 
Transient receptor potential vanilloid-4 (TRPV4) is a non-selective cation channel, 
involved in thermosensation, mechanosensation and osmosensation. Emerging 
evidence has identified that the TRPV4 channel is opened by signalling from G-protein 
coupled receptors (GPCR). TRPV4 is widely expressed; we focused on responses 
identified in pain sensing neurons, kidney tubule epithelium and the vascular 
endothelium. The channel has been linked to several pathophysiologies, such as 
mechanical hyperalgesia and peripheral oedema. TRPV4 integrates a wide range of 
stimuli which suggests that direct pharmacological modulation of TRPV4 may be 
difficult. 
We aimed to determine the signalling from GPCRs that open TRPV4 channels, as these 
signalling pathways have not been identified and may prove better targets for 
pharmacological intervention in TRPV4 related pathophysiologies than modulation 
of TRPV4. 
To assess these the ability of GPCRs to open TRPV4 channels in human embryonic 
kidney cells (HEK) were used as they endogenously expressed the pro-inflammatory 
GPCR protease activated receptor-2 (PAR2) and can be stably transfected with 
hTRPV4 (HEK+TRPV4) using the T-REx inducible system. It was shown that 
stimulation of PAR2 with its peptide agonist PAR2-activating peptide (PAR2-AP) 
released intracellular calcium from stores in HEK cells and opened the TRPV4 channel 
in HEK+TRPV4 cells. It was demonstrated that blockade of the Gαq pathway inhibited 
the release of intracellular calcium from stores in both HEK and HEK+TRPV4 but did 
not inhibit the PAR2-dependent opening of TRPV4 in HEK+TRPV4 cells. This indicated 
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that PAR2-dependent opening of TRPV4 does not require release of calcium from 
intracellular or Gαq signalling. 
Therefore to discover the signalling pathways involved in the PAR2-dependent 
opening of TRPV4 we developed and optimised a screening process using short 
interfering ribonucleic acids (siRNAs) to block protein expression  firstly of protein 
kinases, as the PAR2-dependent opening of TRVP4 has evidence that it is kinase 
dependent and secondly, of G-proteins and their associated signalling molecules.  
The screen of the kinome (the expression of the current known kinases in the human 
genome) identified with high confidence four siRNAs, siBUB1, siITPK1, siMAPK13 and 
siITPK1 that were able to interfere with the PAR2-dependent opening of TRPV4 
channels, indicating that these proteins were crucial for this signalling process. These 
results were supported by the qPCR analysis of messenger RNA (mRNA) expression, 
identifying that all four proteins were expressed in HEK cells, but only treatment with 
siBUB1, siMAPK13 and siWNK4 caused a significant reduction in the expression of 
mRNA. Therefore, it was concluded that expressions of the kinases BUB1, MAPK13 
and WNK4 are required for the PAR2-dependent opening of TRPV4. 
The screen of G-proteins and associated signalling molecules identified that treatment 
of HEK+TRPV4 cells with siGNA13, siGNG8, siPLA2G4A and siPLCXD3 were effective 
at blocking the PAR2-dependent opening of TRPV4. It was determined by qPCR 
detection of mRNA expression that GNA13, GNG8 and PLA2G4A but not PLCXD3 were 
expressed in the tested HEK cells and that treatment with siRNA for GNA13, GNG8 
and PLA2G4A caused a significant reduction of mRNA expression, which confirmed 
that expression of these proteins are required for the PAR2-dependent opening of 
TRPV4. 
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The previous results identified molecules which were previously unknown to 
participate in the signalling process between PAR2 and TRPV4. To determine the 
physiological role of the receptor-dependent opening of TRPV4 channels we 
investigated the ability of other GPCRs, with evidence of involvement in the opening 
of TRPV4, to open TRPV4 in this HEK cell model. Therefore we tested pro-
inflammatory receptors neurokinin 1 (NK1), bradykinin 1, 2 (BK1, BK2) and 
prostaglandin receptor EP4 (PGTR4). It was identified that stimulation of NK1 with 
substance P opened TRPV4, as did stimulation of BK2 with bradykinin. These results 
indicated that these receptors can open TRPV4 channels in HEK cells and expands the 
potential to assess receptor-dependent opening of TRPV4 channels in dorsal root 
ganglion neurons.  
The ability of adenosine triphosphate (ATP)-dependent GPCRs, called purinergic 
receptors (P2Y), to open TRPV4 channels were also assessed in HEK293 cells. It was 
determined that P2Y2 and P2Y11, but not P2Y12, were able to transduce signals 
required to open TRPV4 when stimulated with their ligand, ATP. The differential 
ability of these similar receptors; P2Y2, P2Y11 and P2Y12 to open TRPV4 channels 
demonstrated that stimulation of these receptors in the same HEK cells caused  
calcium release from intracellular stores, but the signalling pathway required for 
GPCR-dependent opening TRPV4 is separate. This evidence confirms earlier 
experiments in this thesis identifying that GPCR-dependent opening of TRPV4 does 
not require Gαq signalling but has confirmed this with a different GPCR to PAR2.  
Activation of the muscarinic receptor M3 (M3R) with its ligand acetyl-choline (ACh) 
stimulated TRPV4 channel opening in the HEK293 cell model. This finding implicated 
the vascular endothelium as a potential setting for the receptor-dependent opening 
of TRPV4. 
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The final investigation of this thesis assessed the ability of GPCRs in the vascular 
endothelium of rat cremaster arterioles to open TRPV4 channels. It was shown that 
stimulation of TRPV4 with its specific agonist GSK1016790A caused an endothelium-
dependent vasodilatation that was abolished by the TRPV4 specific antagonists 
HC067047 and GSK2193874, and inhibition of small and intermediate calcium-
dependent potassium channels (SKCa and IKCa). These results demonstrated that 
TRPV4-dependent vasodilatation is dependent on endothelial derived 
hyperpolarising factor (EDH).  
We then determined that TRPV4 function was altered by shear stress on the 
endothelium. TRPV4-dependent vasodilatation was sensitised to GSK1016790A after 
the endothelium had been exposed to shear stress and it was identified that ACh-
induced vasodilatation was only sensitive to TRPV4 inhibition after exposure to shear 
stress. This indicates that the function of TRPV4 was significantly altered in the 
endothelium with shear stress and that the receptor-dependent opening of TRPV4 
required the integration of shear stress into the system. 
In conclusion, the results presented in this thesis have identified previously unknown 
signalling molecules in the receptor-dependent opening of TRPV4. It has also 
identified the complex nature of TRPV4 signalling in the physiological setting of the 
vascular endothelium, as TRPV4 integrates many different stimuli to regulate its 
function. Therefore, the molecules crucial to the receptor-dependent opening of 
TRPV4 identified could prove to be useful targets for future therapeutic intervention 
of TRPV4 related pathophysiologies.   
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1 General Introduction 
1.1 Overview 
 This thesis is divided into 8 chapters. 
Chapter 1 is the general introduction which outlines the structure, function and 
modes of activation of the ion channel TRPV4, concluding with various 
pathophysiologies where TRPV4 is indicated. 
Chapter 2 is the General methods section, which, in detail, highlights the key 
techniques used in this thesis. 
Chapters 3-7 are results chapters. Chapter 3 addressed the role of specific G-proteins 
indicated by published evidence to be involved in signalling from PAR2 to TRPV4 in 
HEK293 cells. Chapter 4 addressed the role of protein kinases in the PAR2-TRPV4 
signalling pathway. Chapter 5 addressed the role of other signalling molecules linked 
with GPCR activation and their ability to open TRPV4. Chapter 6 identified other 
GPCRs that can signal to and open TRPV4 and gave these cell based assays some 
physiological relevance. Chapter 7 focused on the function of TRPV4 in the 
vasculature and the link between muscarinic receptors and TRPV4.  
Chapter 8 is the general discussion, which highlighted the key findings of this thesis 
in the context of the current literature and identifies the limitations of the current 
techniques used and finally identified future directions for investigation in this field.  
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1.2 Ion Channel function and signalling 
The maintenance of ion balance across cellular membranes is vital for cell function 
and the alteration of this balance initiates a broad range of cellular functions. The 
propagation of neuronal action potentials, the dilatation of blood vessels, the 
contraction of muscles fibres and the beating of the heart and many other functions 
rely on the movement of ions across cellular membranes and between compartments 
of the cell. Therefore, the molecular gates in these membranes which facilitate the 
movement ions are vital for cellular function. A class of these proteins are ion 
channels; the understanding of the opening, function, regulation and modulation of 
these channels can illuminate multiple physiological processes as well as help identify 
why the dysfunction of ion channels can lead to disease.  
The opening of ion channels is initiated by a wide range of stimuli, for instance ligand-
gated ion channels, whereby a specific agonist binds to the channel to cause opening. 
The nicotinic acetyl choline channel which binds ACh to open the channel (Miyazawa 
et al., 2003) allowing Na+ to enter the cells and initiate muscle contraction and 
neuronal transmission (McGehee, 1999). Voltage dependent channels open and close 
in response to changes in membrane potential. Voltage dependent sodium channels 
transmit the depolarisation of a neuron along the axon to propagate action potentials 
(Marban et al., 1998). Similarly, voltage dependent calcium channels (VDCCs) in 
cardiac myocytes open in response to neuronal induced depolaristion of the 
membrane allowing calcium to flow into the cell leading to contraction (Bers, 2002). 
The identification of the structure and function of VDCCs has given crucial insights 
into the role of these channels in disease and lead directly to the discovery of 
therapeutics targeting these ion channels. For instance the identification that small 
molecule inhibitor nifedipine targeted calcium channels in cardiovascular system was 
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made possible by the appropriate understanding of how these channels functioned 
(Strauer, 1974). This study focuses on a member of the transient receptor potential 
(TRP) ion channel family, a class of ion channels that is opened by many stimuli, using 
a range of mechanisms, some of which remain poorly understood.    
1.3 Transient Receptor Potential ion channels  
The first of the TRP ion channels was discovered in a mutant of the Drosophila 
melanogaster fly that was unable to respond to repeated or constant bright light 
stimulation (Cosens and Manning, 1969). The trp mutation was in a gene encoding an 
integral membrane protein with six trans-membrane domains (Wong et al., 1989). 
Electrophysiological analysis revealed that it was a calcium-permeable, non-selective 
cation channel that opens in response to signalling from activated rhodopsin (Hardie 
and Minke, 1992). TRP channel opening was shown to be due to phospholipase C 
(PLC) activation by rhodopsin, resulting in the hydrolysis of phosphoinositol 4,5 
bisphosphate (PIP2) to generate inositol trisphophate (IP3) and diacylglycerol, which 
alters the physical composition of the membrane. The resulting rapid physical 
changes in the lipid bilayer leads to movement of the rabdomere microvilli, 
mechanically opening TRP (and the related TRPL) ion channels (Hardie and Franze, 
2012).  
1.4 Mammalian TRPs 
The number of human TRP ion channel homologues has increased since the discovery 
of TRPC1A (Zitt et al., 1996). There are currently 28 known mammalian TRP channels, 
divided into 6 subfamilies: canonical (TRPC), vanilloid (TRPV), melastatin (TRPM), 
mucolipin (TRPML), polycystic (TRPP) and ankyrin (TRPA), based on sequence 
homology. TRP channels are tetrameric proteins with subunits having six 
transmembrane domains and cytoplasmic C- and N-terminal tails, most TRPs are non-
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selective cation channels with a high permeability for sodium, potassium and calcium, 
but each has unique characteristics for ion permeability, conductance, voltage 
dependence, and gating; and is activated by different ligands or physiological stimuli.  
 
Many TRP channels open in response to physical stimuli including: temperature, pH, 
shear stress and other mechanical forces such as stretch and hypoosmolarity. 
Moreover, there are many TRP channels which are ligand-gated and voltage sensitive. 
For example TRPV1 is opened by temperatures greater than 420C and capsaicin, the 
hot component of chilli peppers (Caterina et al., 1997). Conversely, TRPM8 is opened 
by temperatures below 230C (Peier et al., 2002) and by the cooling agents, menthol 
and icillin. Low temperature and icillin can potentiate each other and hence TRPM8 
acts as a coincidence detector for these stimuli (Chuang et al., 2004). However, 
menthol, icillin and capsaicin are not endogenous compounds, and the physiological 
mechanisms of activation of TRPM8 and TRPV1 are only partially understood. TRPV4 
is also a polymodal ion channel that can be activated and sensitised via diverse 
agonists and signalling pathways. The following sections will focus on the current 
knowledge of TRPV4 gating and its relevance to physiological and pathological states. 
1.5 Introduction to TRPV4  
The physiological mechanisms for opening of TRP ion channels is an area of intense 
study. TRP ion channel vanilloid type 4 (TRPV4) is a particularly interesting case 
because it appears to be involved in a wide range of physiological responses and it is 
activated by many stimuli. The dysfunction of TRPV4 is liked to numerous 
pathophysiological states, indicating an important role in many vital physiological 
responses. This review summarizes the current understanding of the way in which 
the TRPV4 ion channel responds to different stimuli, to act as an integrator of diverse 
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signalling pathways. We focus on sensitisation and opening of the TRPV4’s ion 
channel by distinct receptors and signalling mechanisms. The structure and function 
of TRPV4 has been recently extensively reviewed (White et al., 2016).  
Experiments with TRPV4 knockout mice show that TRPV4 is involved in many 
processes, both physiological and in disease states. However, the mechanism of 
TRPV4 involvement in these states is poorly understood. While the activation of 
TRPV4 by its synthetic agonists has been assessed in many tissues, the physiologically 
relevant regulators are still poorly characterized. Understanding the signalling 
pathways which open or sensitise TRPV4, could identify new targets for novel 
therapeutics that can modulate TRPV4 activation as an alternative to the potentially 
dangerous use of TRPV4 agonists or antagonists.  
 
1.6 TRPV4 expression  
 TRPV4 was discovered by cloning cDNAs with homology to the conserved coding 
regions of mammalian TRPV1 and TRPV2 and Osm-9 the osmosensor from C. elegans 
(Liedtke, W. et al., 2000; Liedtke, Wolfgang  et al., 2000) and was identified as the 
possible sensor for osmolarity in the kidney, liver and heart (Strotmann et al., 2000). 
TRPV4 is widely expressed in mammalian tissues, and is likely to play important roles 
in physiological processes. For example, TRPV4 is highly expressed in lung 
epithelium, predominantly in the cilia of bronchial epithelium, and participates in 
mucociliary transport and ciliary beating frequency (Lorenzo et al., 2008). TRPV4 is 
also found in epithelial cells of the nephron in the kidney (Tian et al., 2004), and in 
urothelial cells of the renal pelvis, ureter and urinary bladder where it plays a role in 
osmosensation and bladder voiding (Birder et al., 2007; Gevaert et al., 2007). TRPV4 
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expressed in osteoclasts, osteoblasts and chondrocytes is thought to play a role in 
bone remodelling, affecting bone development (Ritsuko et al., 2008).  
TRPV4 is abundant in the vascular endothelium, but is also found in the smooth 
muscle of pulmonary, aortic and cerebral arteries (Earley et al., 2005; Fian et al., 2007; 
Tanaka et al., 2008; Xiao-Ru et al., 2006; Yin et al., 2008) where it is thought to mediate 
vascular tone described in (section 5.5). 
TRPV4 is a key regulator of neuronal function in specific regions of the peripheral and 
the central nervous system. TRPV4 senses temperature in the hypothalamus (Guler 
et al., 2002) to modulate the excitability of dopaminergic neurons of the substania 
nigra at physiological temperatures (Guatteo et al., 2005) and regulating a population 
of serotonergic neurons in the brainstem thermoafferent pathway which modulates 
physiology and behaviour (Lowry et al., 2009). In the hippocampus TRPV4 is active 
above 37oC and regulates neuronal excitability (Shibasaki et al., 2007). Hippocampal 
astrocytes express TRPV4, where its activity increases post ischemia and hypoxia 
(Butenko et al., 2012) and plays a role in oxidative stress-induced cell death relevant 
to stroke (Bai and Lipski, 2010).  
 
TRPV4 is expressed in sensory neurons of the dorsal root and trigeminal ganglia, and 
plays a role in pain sensation (Delany et al., 2001; Grant, Andrew D. et al., 2007; Guler 
et al., 2002; Liedtke, Wolfgang  et al., 2000; Strotmann et al., 2000; Ulrich et al., 2000). 
This role of TRPV4 in pain sensation is explored further in section 5.4. 
1.7 TRPV4 Agonists and Antagonists 
1.7.1 Agonists 
Many endogenous and synthetic agonists have been found to activate TRPV4. The 
endogenous lipid arachidonic acid, and its epoxyeicosatrienoic acid (EET) metabolites 
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are thought to directly bind to and open TRPV4 channels (Watanabe et al., 2003). Both 
5’,6’-EET and 8’,9’-EET open TRPV4 in murine aortic endothelial cells (Vriens et al., 
2005). Whereas, 11’,12’-EET has been shown to open TRPV4 in vascular smooth 
muscle cells to cause hyperpolarization and vascular relaxation in porcine coronary 
arteries (Zhang et al., 2014) and human internal mammary arteries (Ma et al., 2015). 
14’, 15’-EET enhanced neurite out growth in PC12 and rat hippocampal neurons 
through a TRPV4-dependent mechanism (Oguro et al., 2018). The synthetic ligand 4-
α-Phorbol 12,13-didecanoate (4-αPDD) is a weak agonist with an EC50 in the 
micromolar range (Vriens et al., 2007); whereas, the potent and specific agonist 
GSK1016790A has an EC50 in the low nanomolar range (Thorneloe et al., 2008). 
Intravenous administration of the GSK1016790A agonist was shown to cause serious 
vascular effects in vivo, leading to disruption of the endothelial barrier, particularly in 
the lung, intestine and kidney. This resulted in pulmonary oedema and cardiovascular 
collapse in rats, mice and dogs (Willette et al., 2008b). Thus it is unlikely that TRPV4 
agonists will be useful therapeutics. 
 
1.7.2 Antagonists 
The discovery of selective and potent TRPV4 antagonists has led to better 
understanding of the roles of TRPV4. RN1734 was discovered using cellular assays 
which identified it to be selective over the other TRP channels (IC50 = 5.9 μM) (Vincent 
et al., 2009). The most widely used inhibitor to date is the potent and selective TRPV4 
antagonist HC067047, was shown to increase bladder function in mouse and rat 
models of cyclophosphamide-induced cystitis (IC50 of 133 nM and 17 nM respectively) 
(Everaerts et al., 2010). However, both RN1734 and HC067047 are often used at 
concentrations that may be non-selective. A study in pulmonary vasculature 
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determined that RN1734 and HC067047 used at concentrations 30 μM and 5 μM 
respectively, caused vasodilatation in TRPV4-/- mice (Xia et al., 2013), indicating that 
these antagonists may have off-target effects when used at high concentrations. 
A newer antagonist, GSK2193874, is orally active and prevents pulmonary edema in 
a mouse model of heart failure and in isolated human lung tissue (Thorneloe et al., 
2012). GSK2798745 is currently undergoing clinical trials in a model of congestive 
heart failure in attempt to improve pulmonary gas transfer and respiration 
(NTC024979937).  
Pfizer has recently developed a series of specific TRPV4 antagonists PF-05214030 
from this series had an IC50 of 4nM at human TRPV4 and 27nM at rat TRPV4 and 
inhibited GSK1016790A-induced bladder hypersensitivity, however, the compound 
was not developed furthers as it was ineffective at blocking pain or improving 
genitourinary efficacy (Skerratt et al., 2013). 
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1.8 TRPV4 Knockout and Mutation 
1.8.1 TRPV4 Knockouts show a mild phenotype 
Two strains of TRPV4 knockout mice have been produced by different methods. 
Suzuki and colleagues generated a TRPV4-/- strain using cassette insertion 
mutagenesis of exon 5 (Suzuki et al., 2003) whereas Liedtke and colleagues used cre-
lox-mediated excision of exon 12. Both strains were generated in C57BL/6 mice. 
TRPV4 knockout impairs many physiological processes, but often does not completely 
abolish the responses, suggesting redundancy in physiological mechanisms and the 
existence of compensation mechanisms in the absence of TRPV4 during development. 
Despite the severe and debilitating bone deformities and neuropathies observed with 
TRPV4 mutation (see section 1.3.2), TRPV4 knockout mice have no obvious 
abnormalities. They are normal in size, appearance, growth and temperature (Suzuki 
et al., 2003). The detection of innocuous mechanical stimuli in TRPV4 wild type and 
knockout mice was found not to be different; however, TRPV4-/- mice did show 
impaired responses to noxious pressure stimuli (Alessandri-Haber et al., 2006; Suzuki 
et al., 2003). Similarly, wild-type and TRPV4-/- mice showed equivalent regulation of 
osmolarity under normal conditions. However, TRPV4 -/- mice drank less water and 
were more sensitive to becoming hypo-osmolar when administered antidiuretic 
hormone, than wild-type littermates (Liedtke and Friedman, 2003) Differences in 
strain generation could help to explain some different effects seen.  
1.8.2 Mutations in TRPV4 alter Bone and Joint Health and Development 
A number of studies have identified mutations in the TRPV4 gene that lead to various 
skeletal dysplasias and arthropathies. The structure and distribution of these and 
other TRPV4 mutations was recently reviewed (White et al., 2016). In some cases, 
there is no apparent link between mutation site and phenotype. For example, the 
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more than 50 mutations which cause brachyolmias are spread throughout the TRPV4 
gene (Nilius and Voets, 2013).  
Skeletal dysplasias encompass a heterogeneous group of over 200 diseases that range 
from mild to fatal (McNulty et al., 2015; Nilius and Voets, 2013; Nonaka et al., 2019). 
Some mutations lead to minor complications such as scoliosis, and shortened stature, 
limbs and digits. Whereas metatropic dysplasia results in a severe phenotype with 
‘hooked joints’ (arthrogryposis), joint contracture, hip dislocation, clubfoot, muscle 
weakness, and lack of foetal movement. In heterologous expression systems, TRPV4 
mutations associated with skeletal dysplasias lead to higher basal and stimulated 
whole-cell currents or calcium signals and were labelled gain-of-function mutants 
(Loukin et al., 2011; Nilius and Voets, 2013; Nonaka et al., 2019). The gain-of-function 
mutants R616Q and V620I introduced into osteoclasts of TRPV4-/- mice resulted in 
decreased femoral bone mass and bone mineral density (Masuyama et al., 2012). 
Skeletal dysplasias likely result from increased calcium influx into chondrocytes 
through the mutant TRPV4 channels, lead to upregulation of follistatin, inhibition of 
bone morphogenic protein growth factors, and altered endochondrial ossification as 
well as lowering their sensitivity to bone morphogenic protein signalling (McNulty et 
al., 2015).  
Familial Digital Arthropathy Brachyolmia FDAB is a mild TRPV4-related bone disease, 
which is distinct from skeletal dysplasias. FDAB patients appear clinically normal at 
birth, but develop irregularities in the joints of their fingers and toes over the first 
decade of life (Lamande et al., 2011). By adulthood, all joints are deformed and 
affected by painful osteoarthritis. However, no malformations of other parts of the 
skeleton are observed in these patients. Unlike mutations associated with dysplasias 
and arthropathies (which are dispersed), it appears that FDAB-causing mutations are 
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restricted to finger loop 3 of the ankyrin repeat domain of TRPV4. FDAB mutations 
examined in heterologous expression systems showed reduced activity, suggesting 
loss of channel function, and impaired trafficking of TRPV4 channels to the cell 
membrane (Lamande et al., 2011).  
These different phenotypes that are the result of both reduced function or 
hyperactivity of TRPV4 demonstrate the physiological importance of normal 
regulation of TRPV4 gating. Thus the identification of stimuli that can increase or 
decrease the probability of TRPV4 opening are vital for understanding its 
physiological function and are possible targets for therapeutic intervention in disease 
states. Interestingly, TRPV4-/- mice do not display any of these phenotypes, suggesting 
that there are physiological compensation mechanisms.  
1.9 Sensitisation and activation of TRPV4 
TRPV4 is subject to both sensitisation, and to opening by intracellular signalling. The 
definitions of sensitisation and channel opening are often blurred for a polymodal ion 
channel like TRPV4. Sensitisation is augmentation of the TRPV4 response to 
subsequent stimulation by a direct agonist. Whereas opening of TRPV4 by 
intracellular signalling does not require exogenous agonist, rather signalling leads to 
post-translational modification of the protein (e.g. phosphorylation) which of itself 
leads to channel gating, perhaps due to the presence of low levels of endogenous 
agonist. Distinguishing between these two operating mechanisms is difficult where 
they exert their effect in the same direction. For example, sensitisation may appear to 
be activation if the temperature threshold of TRPV4 is not taken in to account. A clear 
distinction between studies which assess the modulation of channel activity by 
signalling and those which investigate direct agonism, is important. Despite this 
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difficulty, we describe mechanisms of TRPV4 sensitisation and its known 
physiological effects below.  
 
Figure 1.1. Activation of TRPV4 by diverse stimuli is sensitised by protein 
kinases. Sensitising kinases that enhance TRPV4 opening to range of stimuli shown 
in orange boxes. Arrows indicate where a particular mode of opening is sensitised by 
an identified protein kinase. These include serine/threonine kinase-1 (SGK-1), cyclic-
AMP dependent protein kinase A (PKA), protein kinase C (PKC) and Src family kinases 
(Src). 
 
1.9.1 Signalling and Post-translational modification  
TRPV4 is a target for post-translational modification, which leads to sensitisation of 
the channel to a range of stimuli. Mutation of putative phosphorylation sites has been 
shown to ablate sensitised TRPV4 responses in transfected cell lines in many cases. 
Thus, phosphorylation of serines 162 and 189, and threonine 175 by protein kinase C 
was shown to sensitise TRPV4-expressing HEK293 cells to hypotonic stress (Fan et 
al., 2009). Whereas, protein kinase A (PKA)-dependent phosphorylation of serine 824 
sensitised hypotonic responses (Fan et al., 2009). Sensitisation of TRPV4 to agonist 
4α-PDD and heat can occur via a serum glucocorticoid protein kinase-1 (SGK1) 
mechanism (Lee et al., 2010). In HeLa cells, tyrosine 110 and 805 phosphorylation by 
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Src family kinases was shown to sensitise TRPV4 to heat, shear stress, hypotonic 
swelling and phorbol 12-myristate 13-acetate activation (Wegierski et al., 2009). 
Thus it is well established that phosphorylation can modulate TRPV4 activity in 
response to a wide variety of stimuli.  
Mice injected with the inflammatory mediators bradykinin, PGE2, substance P, 
serotonin and histamine, where hypersensitised to mechanical stimuli, but TRPV4-/- 
mice were not (Alessandri-Haber et al., 2006), indicating a role for TRPV4 in sensing 
mechanical force.  
Activation of the Protease Activated Receptor 2 (PAR2) with trypsin or SLIGRLNH2, 
caused TRPV4-dependent inflammatory, mechanical hyperalgesia in mice (Grant, 
Andrew D. et al., 2007). Activation of PAR2 with neutrophil elastase caused 
sensitisation of TRPV4 to the agonist GSK1016790A in Xenopus oocytes, which was 
dependent on Rho kinase (Sostegni et al., 2015) and cAMP activation of PKA (Zhao et 
al., 2015). Furthermore, stimulation of PAR2 by the protease cathepsin S, sensitised 
TRPV4 responses to the agonist GSK1016790A in Xenopus oocytes via cAMP-
dependent activation of PKA. TRPV4-/- in C57BL6 mice caused a reduction to 
prolonged paw oedema induced by cathepsin S in PAR2-dependent inflammation 
(Zhao et al., 2014) (see Figure 1. 1). These studies which assess effects of sensitising 
stimuli on exogenous agonist responses are important for a thorough understanding 
of TRPV4 modulation, however, they do not directly address the physiological 
opening of TRPV4, which are discussed below. 
1.9.2 Receptor-dependent activation of TRPV4 
The potential importance of opening of TRPV4 by stimuli such as shear stress heat 
and osmotic swelling has been steadily growing since they were initially highlighted 
(Gao et al., 2003; Guler et al., 2002; Liedtke, Wolfgang  et al., 2000; Strotmann et al., 
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2000; Watanabe et al., 2002). More recently, a role for GPCR signalling in opening 
TRPV4 has become apparent. For example, serotonin, which plays an important role 
in pulmonary hypertension, has been shown to cause TRPV4 activation in 
intrapulmonary arterial smooth muscle cells, and this is due in part to generation of 
arachadonic acid by phospholipase A2 (PLA2)-and its subsequent conversion by P450 
epoxygenase into active metabolites (Ducret et al., 2008). The understanding of 
interaction between GPCRs and TRPV4 was extended when the sustained phase of 
increased intracellular calcium induced by activation of P2Y receptors was found to 
be TRPV4-dependent in aldosterone sensitive distal nephron (ASDN) kidney cells 
(Mamenko et al., 2011). PAR2 activation has been shown to sensitise TRPV4 in dorsal 
root ganglion neurons (Grant, A. D. et al., 2007), while further investigation showed 
that TRPV4 could be opened by PAR2 activation in HEK293 cells and that this was 
dependent on phosphorylation of TRPV4 tyrosine 110 (Grace et al., 2014; Poole et al., 
2013). Furthermore, the tyrosine kinase inhibitor bafetinib was shown to inhibit PAR2 
agonist-evoked mechanical hyperalgesia in mice (Grace et al., 2014). In addition 
activation of PAR2 by diesel exhaust in human respiratory epithelial cells was shown 
to open TRPV4 via a PLCβ3-dependent mechanism (Li et al., 2011), providing 
circumstantial support for the signalling mediated opening of TRPV4 in many tissues.  
Thus, evidence is emerging that TRPV4 is activated by intracellular signalling from 
GPCRs and mechanoreceptors (see Figure 1. 1), which may include arachadonic acid 
metabolites, other second messengers and protein kinases. Understanding how the 
results from cellular assays and ex vivo tissue assays compare will be a key step in 
determining the mechanisms by which TRPV4 is involved in physiological and 
pathophysiological processes. 
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Figure 1. 2. Activation of TRPV4 by specific G-protein coupled receptors. TRPV4 
has been shown to be opened by several GPCRs, as outlined in the text. These include 
5-HT, P2Y PAR2 and Muscarinic acetylcholine receptors. These receptors have been 
shown to open TRPV4 via signalling that includes cyclic-AMP dependent protein 
kinase A (PKA), protein kinase C (PKC), Src family kinases (Src) and phospholipase C 
β3 (PLCβ3), as indicated. 
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1.10 Physiological and Pathophysiological Roles of TRPV4 
1.10.1  TRPV4 and osmoregulation and mechanosensation 
The capacity of cells to monitor and respond to their environment is fundamentally 
important, and is critical for cell function and survival. When TRPV4 was initially 
discovered, it was thought to be directly opened by changes in osmolarity, and was 
also proposed as a possible candidate for the mammalian mechanosensor (Liedtke 
and Friedman, 2003; Mizuno et al., 2003). 
Osmoregulation is the active control of the osmotic pressure of intra- and 
extracellular fluids to maintain homeostasis. Changes in compartmental osmolarity 
causes cell deformation (swelling or shrinkage) and lipid bilayer tension, and may 
therefore involve aspects of mechanosensation. Cell deformation and lipid bilayer 
tension can affect cellular processes such as transepithelial transport, regulation of 
metabolism, hormone and transmitter release, cell proliferation, and cellular 
differentiation (Hoffmann et al., 2009). Strong evidence suggests that TRPV4 plays an 
important role in sensing and responding to osmotic changes. In cell-based assays, 
mammalian TRPV4 is reportedly activated by hypoosmotic stress through indirect 
mechanisms requiring phosphorylation of tyrosine 110 on the intracellular N-
terminus, signalling via phospholipase A2 and the generation of lipid metabolites 
(Vriens et al., 2004a; Wegierski et al., 2009).  
 
TRPV4-/- mice show impaired osmotic regulation, supporting a role for TRPV4 as an 
osmotic sensor (Liedtke and Friedman, 2003; Mizuno et al., 2003). TRPV4 expression 
is restricted to water-impermeant segments of the rodent kidney, where a substantial 
transcellular osmotic gradient is expected (Tian et al., 2004). It is also expressed on 
hepatic sensory nerve endings, and TRPV4-/- mice reportedly lack osmosensitive 
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inward currents in hepatic neurons, or activation of peripheral osmoreceptors in vivo 
(Lechner et al., 2011). In primary afferent nociceptive nerves, TRPV4 is thought to 
function as an osmotransducer, thereby mediating the nociceptive response to 
hypotonic stimulation (Alessandri-Haber et al., 2004; Alessandri-Haber et al., 2003).  
TRPV4 has been shown to functionally interact with aquaporins to control regulatory 
volume decrease (RVD) in astrocytes and salivary glands (Benfenati et al., 2011; Jo et 
al., 2015; Liu et al., 2006). RVD is a mechanism for volume control that serves to 
prevent detrimental cell swelling in response to hypoosmotic stress, and is a 
mechanism that is tightly controlled. Disruption of cell volume regulation may have 
deleterious consequences for cell signalling, barrier dysfunction, and cell viability 
(Benfenatti et al., 2011). Studies indicate that TRPV4/aquaporin complexes may play 
a key role in the maintenance of cell volume, and could be important in the formation 
of macula or brain oedema under prolonged osmotic stress or pathological conditions 
(e.g. diabetes or glaucoma) which are associated with excessive cell swelling (Iuso and 
Krizaj, 2016). 
1.10.2 TRPV4 and mechanosensation 
Osmosensation is likely to involve aspects of mechanosensation as the cell stretches 
or contracts under osmotic forces. Other types of mechanical stress, such as flow-
induced shear stress also act through TRPV4. Shear stress-induced vasodilation is 
critically dependent on endothelial TRPV4 expression, and is absent from TRPV4-/- 
mice (Hartmannsgruber, Heyken et al. 2007). Shear stress opens TRPV4 to increase 
intracellular calcium in HEK293 cells and vascular endothelial cells (Baratchi et al., 
2014); Hartmannsgruber et al. (2007); (Mendoza et al., 2010). Such opening requires 
intracellular signalling (Wegierski et al., 2009). Shear stress causes TRPV4 to traffic 
from cytoplasmic vesicles to the plasma membrane (Baratchi et al., 2015). The 
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mechanoreceptive structures which signal to TRPV4 vesicles could include caveolae, 
Integrins and cadherins in the adherens junctions which stabilize adjacent cells.  
1.10.3 Role of interacting proteins  
Caveolae are membrane microdomains enriched with key protein components of 
signal transduction (Calaghan and White, 2006; Pani and Singh, 2009) and caveolins, 
integral membrane scaffolding proteins which bind various signalling molecules 
(Parton and Simons, 2007). In endothelial cells, TRPV4 associates with Caveolin-1 
which mediates colocalization of TRPV4 and KCa ion channels, potentially of 
importance to flow-induced vasodilation (Goedicke-Fritz et al., 2015). 
TRPV4 interacts with α2β1 integrin and Src tyrosine kinase in rat dorsal root ganglion 
cells and is important for development of mechanical hyperalgesia (Alessandri-Haber 
et al., 2008). In capillary endothelial cells, TRPV4 activation is essential for activation 
of β1 integrins and reorientation of the cells in response to mechanical stress (Thodeti 
et al., 2009). Mechanical stimulation of β1 integrins activates TRPV4 through 
distorting the sub membrane cytoskeleton connected to the focal adhesion kinase, 
rather than lipid bilayer deformation (Matthews et al., 2010; Thodeti et al., 2009). 
However, the exact mechanism is not well understood. In both keratinocytes and 
urothelial cells, TRPV4 is located at the cell-cell adherens junctions, and is required 
for interaction of beta-catenin at adherent junctions with cytoskeleton (Janssen et al., 
2011; Sokabe and Tominaga, 2010). TRPV4 channel activation also modulates 
epidermal tight junction barrier function (Akazawa et al., 2013).  
The TRPV4 C-terminus interacts with both monomeric and soluble forms of 
cytoskeletal tubulin and actin, in both forms, and the dynamics of the cytoskeleton is 
important for TRPV4 channel function in response to mechanical stress (Goswami et 
al., 2010). 
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1.10.4 Thermal Sensation 
All mammals require precise assessment of body temperature for thermoregulation, 
and the ability to sense noxious temperatures to activate rapid avoidance reflexes 
(Benham et al., 2003). Mammals can detect a wide range of temperatures, with 
extremes outside the range of approximately 15-43°C evoking pain by activating 
subsets of nociceptive neurons. TRPV4 has been shown to respond to non-noxious 
warm temperatures encompassing normal body temperature (above 27°C), leading 
to the suggestion that TRPV4 may play a role in normal thermoregulation (Guler et 
al., 2002; Watanabe et al., 2002). However, it has no evident role in the detection of 
noxious temperatures, since TRPV4-/- mice show normal thermal escape latencies 
when exposed to hot plates or radiant paw heating; and normal temperature 
homeostasis when exposed to cold (Liedtke and Friedman, 2003; Suzuki et al., 2003). 
Conversely, in electrophysiological studies it has been shown that TRPV4-/- mice 
exhibit reduced sensory nerve discharge frequency, and a decrease in the number of 
responding fibres, in response to warm temperatures and a loss of fibres responding 
to noxious temperatures (>42°C) (Todaka et al., 2004). Moreover, when hyperalgesia 
was induced, TRPV4-/- mice took significantly longer to escape from hotplates at 35-
45°C (Todaka et al., 2004). This was in contrast to TRPV4-/- mice without hyperalgesia, 
which showed normal aversion to a hotplate test (35-50°C) (Todaka et al., 2004). Yet 
another study found that TRPV4-/- mice without hyperalgesia exhibited delayed tail 
withdrawal to moderately hot temperatures, and a strong preference for warmer 
34°C floor temperatures, whereas wild-type mice did not discriminate between 30 
and 34°C (Lee et al., 2005). Overall, these studies demonstrate a likely role for TRPV4 
in warmth detection, and the avoidance of moderately hot temperatures in the 
noxious range under pathological conditions. 
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1.10.5 Pain 
The detection of TRPV4 protein in dorsal root and trigeminal ganglion neurons and 
discovery that TRPV4 was necessary for hypotonicity-evoked pain (Alessandri-Haber 
et al., 2003) and chemotherapy-induced neuropathic pain (Alessandri-Haber et al., 
2004; Costa et al., 2018) implicated TRPV4 in the transduction of mechanical pain 
either alone or in complexes with TRPC1 or TRPC6 (Alessandri-Haber et al., 2009). 
TRPV4 now has a well-established role in various pathological pain states, and 
represents a promising target for development of novel analgesics. The role of TRPV4 
in pain has been reviewed elsewhere (Veldhuis et al., 2015). Briefly, studies using 
selective agonists/antagonists, TRPV4-/- mice and siRNA demonstrate an important 
role for TRPV4 in models of inflammatory mechanical hyperalgesia (Alessandri-
Haber et al., 2006; Alessandri-Haber et al., 2003; Chen et al., 2013; Grace et al., 2014; 
Grant, Andrew D. et al., 2007; Moore et al., 2013; Poole et al., 2013; Sipe et al., 2008; 
Todaka et al., 2004; Zhao et al., 2014), peripheral neuropathy (Alessandri-Haber et al., 
2008; Alessandri-Haber et al., 2004), and visceral hypersensitivity (Brierley et al., 
2008; Cenac et al., 2008). 
The role of TRPV4 in different pain states is mediated by distinct intracellular 
signalling pathways, for example, carigeenan-induced inflammatory effects are 
mediated via a cAMP pathway, involving the downstream activation of PKA or PKC 
(Alessandri-Haber et al., 2006). PAR2-induced sensitisation or activation of TRPV4 in 
the pain pathway is multifaceted, partly due to the ability of different proteases to 
cleave the protein at different sites to reveal tethered ligands with different signalling 
profiles (Zhao et al., 2014). Synthetic PAR2 peptide (SLIGRL-NH2) and trypsin 
sensitised TRPV4 via PLC, PKA, PKC and PKD-mediated intracellular signalling 
mechanisms (Grant, Andrew D. et al., 2007) by a mechanism which requires tyrosine 
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kinase (Grace et al., 2014; Poole et al., 2013). Conversely, the biased agonist Cathepsin 
S cleaves PAR2 at an alternate site, revealing a tethered ligand that stimulates cAMP 
and PKA-dependent mechanisms leading to TRPV4 activation (Zhao et al., 2014) 
(Figure 1. 2). TRPV4 expressed in trigeminal ganglion neurons that innervate the 
temporomandibular joint have been suggested to act upstream of MEK/ERK 
phosphorylation to cause temporomandibular joint pain (Chen et al., 2013). 
Furthermore, UVB radiation is thought to directly evoke TRPV4 responses in 
keratinocytes, which subsequently increase endothelin-1 expression (a 
proalgesic/algogenic mediator) leading to sunburn pain (Moore et al., 2013). In a 
model of peripheral neuropathy, taxol-induced TRPV4-mediated hyperalgesia was 
dependent on integrin and Src tyrosine kinase signalling (Alessandri-Haber et al., 
2004). 
While a role for TRPV4 in inflammatory hyperalgesia is well established, its role in 
thermal hyperalgesia is less clear. One study showed no difference between TRPV4-/- 
and wild type mouse responses to radiant heat (Todaka et al., 2004); whereas another 
study demonstrated higher withdrawal latencies in TRPV4-/- mice in a tail immersion 
assay (Lee et al., 2005). Recently, dimethylallyl pyrophosphate, an endogenous 
activator of TRPV4 produced via the mevalonate pathway, was demonstrated to cause 
mechanical pain (Bang et al., 2012). This could be important in pathological 
conditions where damage of adjacent tissues may cause dimethylallyl pyrophosphate 
to be released, leading to TRPV4 activation and subsequent nociception (Bang et al., 
2012). Taken together, these studies suggest that TRPV4 serves as a molecular 
transducer of pain signals associated with a range of pathological conditions, wherein 
TRPV4 is either sensitised by inflammatory processes, or directly activated by 
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endogenous mediators which may act directly or via separate, receptor-mediated 
signalling pathways. 
1.11 Vascular function 
In this section will focus on the endothelial-dependent dilatory factors nitric oxide 
(NO) and endothelium-derived hyperpolarising factors (EDH). Endothelial cells were 
discovered to play a role in vasodilatation, when it was noted that in vitro artery 
preparations which had been rubbed on the intimal surface would not relax when 
stimulated by acetylcholine (Furchgott and Zawadzki, 1980). Nitiric oxide was 
determined to be the signalling molecule causing the endothelium-dependent 
relaxation. However, there are other endothelial-derived factors that can cause 
vasodilatation; Prostaglandins, generated by cyclooxygenase (COX 1 and 2), act on EP 
receptors on vascular smooth muscle cells (VSMC) and EDHs cause the 
hyperpolarisation of VSMC via potassium channels causing relaxation. 
Epoxyeiconsanoids are EDHs derived from arachidonic acid by several enzymes 
including cytochrome P450 monoxygenase and lipoxygenase. The level that each of 
these components contributes to the vasodilatatory response differs, as the vessels 
diameter reduces through generations the EDH signalling becomes more influential 
and NO effect is less marked (Tomioka et al., 1999).  
The endothelium-derived constricting factors (EDCF) are generated from arachidonic 
acid metabolism and these act upon thromboxane receptors (TP) on VSMC to cause 
contraction. Prostaglandins generated by COX from AA such as PGE2 and 
thromboxane A2 (TX2) cause vasoconstriction and pro-inflammatory states which can 
lead to further exacerbation and vasospasm.  
Blood vessels exist in a state of partial contraction and this ‘tone’ of a blood vessel is 
determined by the equilibrium of dilatory and constrictor factors,, blood pressure, 
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flow and shear stress acting upon it, multiple factors such as age, inactivity, glucose 
metabolism and obesity can alter this balance and lead to disease (Vanhoutte et al., 
2009). Currently a family of ion channels have been identified at as potential 
modulators of vascular function. 
1.11.1 Vessel Tone 
The vascular endothelium secretes factors that control vessel tone in response to 
vasoactive factors and shear stress elicited by blood flow. TRPV4 is expressed both in 
the endothelium and smooth muscle cells of the vasculature; and in the astrocytic 
endfeet processes in the CNS, which wrap around blood vessels (Alvarez et al., 2006; 
Benfenati et al., 2007; Martin et al., 2012; Vriens et al., 2005; Watanabe et al., 2008; 
Willette et al., 2008a; Yang et al., 2012). It is thus appropriately located to contribute 
to the regulation of vascular tone (Filosa et al., 2013). Indeed, activation of TRPV4 
channels has been shown to mediate local calcium signals and cause maximal dilation 
of resistance arteries (Sonkusare et al., 2012); and shear stress-induced vasodilation 
is inhibited in TRPV4-/- mice (Hartmannsgruber et al., 2007). As mentioned above, 
EETs cause vascular smooth muscle cell hyperpolarisation and vascular relaxation 
(Campbell and Fleming, 2010). This occurs independently of nitric oxide and 
prostacyclin, and has been suggested to involve activation of TRPV4 channels and 
BKCa potassium channel, either in vascular smooth muscle cells, endothelial cells, or 
both(Campbell and Fleming, 2010; Earley et al., 2005; Earley et al., 2009b; Loot et al., 
2008; Plant and Strotmann, 2007; Vriens et al., 2005; Vriens et al., 2004b). Similar 
pathways exist in the brain, where astrocytes signal PLA2-dependent release of 
arachidonic acid metabolites (e.g. EETs) which may activate TRPV4, although this has 
yet to be demonstrated (Filosa and Iddings, 2013; Filosa et al., 2013; Takano et al., 
2006; Zonta et al., 2003). TRPV4 may also be involved in nitric-oxide and 
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endothelium-derived hyperpolarising factor (EDH) dependent vascular relaxation, as 
these mechanisms are impaired in the small mesenteric arteries of TRPV4-/- mice 
(Zhang et al., 2009). TRPV4 channels can form complexes with other ion channels, for 
example the IP3 receptor (Garcia-Elias et al., 2008). Induced vasodilatory responses 
could be via interaction of TRPV4 with SKCa and IKCa in endothelial cells to enable 
rapid opening of the calcium-activated potassium channels due to localized influx of 
calcium (Sonkusare et al., 2012).  
The regulation of TRPV4 in multiple disease states shows dysfunction of the 
endothelium and irregular vasculature tone. In both a DOCA model of hypertension in 
rats and an angiotensin-II induced hypertension model in mice indicated the role of 
TRPV4 in vessel tone in the hypertensive animals but not in normotensive animals 
(Dash et al., 2019; Diaz-Otero et al., 2018).  
Strong evidence for TRPV4 opening by a receptor-dependent mechanism is emerging 
in the vascular endothelium, where muscarinic receptors have been shown to open 
TRPV4 (Adapala et al., 2011) in various vascular beds. Muscarinic-dependent opening 
of TRPV4 was first discovered in isolated aortic endothelial cells, where acetylcholine 
induced a TRPV4-dependent increase in intracellular calcium (Adapala et al., 2011). 
Receptor-dependent opening of TRPV4 has been observed in acetylcholine-induced 
vasodilatation in cerebral (Earley et al., 2009b; Zhang et al., 2009), mesenteric 
(Sonkusare et al., 2012), skeletal muscle (Bagher et al., 2012) and carotid arteries 
(Hartmannsgruber et al., 2007) (see Figure 1. 2). In mesenteric arteries TRPV4 is co-
localized with PKC to the myo-endothelial projections, enabling multiple TRPV4 
channels to have a functional effect by opening calcium sensitive potassium channels. 
However, TRPV4 was not found to be involved in the ACh-induced vasodilatation in 
rats in vivo (Pankey et al., 2014a).  
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The regulation of TRPV4 function in endothelium-dependent vasodilatation has been 
shown to be altered in disease models. The muscarinic-dependent opening of TRPV4 
in mice was altered in an Alzheimer’s disease model (Zhang et al., 2013). In an 
angiotensin-II model of hypertension the endothelium-dependent carbachol-induced 
vasodilatation was TRPV4 mediated in parenchymal arteries (Diaz-Otero et al., 2018).   
 
1.11.2 Epithelial/Endothelial Barrier Integrity 
Epithelial barriers are characterized by intracellular tight junctions and endothelial 
barriers consist of either or both intercellular tight junctions and adherens junctions 
(Bazzoni, 2006). These junctions restrict the paracellular passage of fluid and proteins 
across tissue membranes. Pathophysiological states such as inflammation can disrupt 
the integrity of these barriers. TRPV4 activation results in epithelial and endothelial 
permeability both in vitro and in vivo via the activation of large-conductance calcium-
activated potassium channels (BKca) (Alvarez et al., 2006; Reiter et al., 2006). 
Activation of TRPV4 with GSK1016790A leads to circulatory collapse in mice via a 
nitric oxide-independent mechanism (Willette et al., 2008a). TRPV4 was shown to 
mediate an increase in acute pulmonary vascular permeability associated with 
ventilator-induced lung injury in the mouse, which could be prevented with inhibitors 
of arachadonic acid production and cytochrome P450 epoxygenases, implicating 
PLA2-mediated signalling pathways (Hamanaka et al., 2007). This stimulated an 
interest in the role that TRPV4 activation plays in damage to the pulmonary 
vasculature, and TRPV4 has since been demonstrated to contribute to damage of the 
vascular barrier leading to pulmonary oedema in disease-relevant models. Huh and 
colleagues demonstrated that IL-2-induced pulmonary oedema (exhibited by cancer 
patients receiving IL-2 therapy) was reduced using a TRPV4-selective antagonist 
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(Huh et al., 2012). In a rodent model of heart failure, TRPV4 blockade was also shown 
to inhibit the development, and stimulated the resolution, of pulmonary oedema 
resulting from high pulmonary venous pressure (Thorneloe et al., 2012). Moreover, 
chemically-induced lung injury in mice may lead to vascular leakage via the formation 
of N-acyl amides and subsequent activation of TRPV4 (Balakrishna et al., 2014). 
Importantly, these studies establish the potential of TRPV4 inhibitors to be used as 
therapeutics for both the prevention and treatment of tissue damage and vascular 
leak in pulmonary pathologies (Balakrishna et al., 2014; Thorneloe et al., 2012). 
However, the use of antagonists of TRPV4 in pulmonary injury may be 
contraindicated by the role that TRPV4 plays in the complex signalling cascade that 
mediates hypoxic pulmonary vasoconstriction (Yang et al., 2012). This mechanism 
helps to redistribute blood flow from poorly ventilated to more well aerated lung 
areas, and inhibition of this response could be detrimental to patients with lung 
disease (Morty and Kuebler, 2014). 
 
1.12 Touch, Hearing and Balance 
Studies in Drosophila melanogaster point to the importance of TRPV channels in 
mechanosensory signalling, with the TRPV isoforms nanchung and inactive, which are 
members of the TRPV and Y gene families in Drosophila melanogaster species, 
respectively. These genes are essential for several mechanically-mediated processes, 
including proprioception, hearing and touch (Lumpkin and Caterina, 2007). A role of 
TRPV4 in touch comes from Osm-9 mutant C. elegans (a homologue of TRPV4), as 
these worms do not avoid nose touch (Tobin et al., 2002); and expression of 
mammalian TRPV4 in C. elegans ASH neurons restores avoidance behaviour (Liedtke 
et al., 2003). By contrast, mice lacking TRPV4 show impaired responses to harmful 
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mechanical force, but not gentle mechanical touch sensation (Liedtke and Friedman, 
2003; Suzuki et al., 2003). This indicates that, although it is important in transmitting 
mechanosensory information, TRPV4 does not play a major role in touch in mammals. 
Inner ear disorders affect the senses of hearing and balance. Hearing and balance are 
mediated by mechanosensory ion channels located on the hair cells of the inner ear. 
In Drosophila melanogaster, inactive and nanchung are essential for hearing (Gong et 
al., 2004; Kim et al., 2003), implicating a role for TRPV channels in vertebrates 
(Cuajungco et al., 2007). TRPV4 is expressed in mechanosensory hair cells, and spiral 
ganglion neurons of the murine cochlea and somatosensory system (Liedtke, 
Wolfgang  et al., 2000; Shen et al., 2006; Zou et al., 2008). Stimulation of the outer hair 
cells of wild type mice with TRPV4 activators (hypotonicity or 4αPDD) causes calcium 
flux and nitric oxide release (Shen et al., 2006; Takeda-Nakazawa et al., 2007); 
whereas no calcium flux is observed in hair cells from TRPV4-/- mice (Shen et al., 
2006). However, TRPV4-/- mice and wild type littermates respond similarly to an 
acoustic startle, and do not reveal gross abnormalities indicative of vestibular 
dysfunction (Liedtke and Friedman, 2003). Moreover, 3 month-old homozygous 
TRPV4-/- mice do not show deficits in auditory brain stem responses or distortion 
product otoacoustic emissions compared to wild type controls (Cuajungco et al., 
2007; Tabuchi et al., 2005). On the other hand, 6 month-old TRPV4-/- mice do show 
increased auditory brain stem response thresholds and increased vulnerability to 
acoustic injury compared wild type littermates. In a cellular model of hearing loss 
TRPV4 over expression showed a potential beneficial cell survival and rescue after 
high glucose treatment (Xing et al., 2018). These results suggest that TRPV4 
disruption causes delayed-onset hearing loss, may have protective function in hearing 
loss, and is therefore important in the murine chochlea; but TRPV4 does not play a 
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developmental role, and is probably not the mechanosensitive channel in cochlea hair 
cells (Cuajungco et al., 2007; Tabuchi et al., 2005). 
 
1.13 Airway Regulation & Respiratory Function 
TRPV4 is expressed widely throughout the airway tissues, and in several immune cell 
types that play important roles in lung function (Alvarez et al., 2006; Arniges et al., 
2004; Earley et al., 2005; Fernandez-Fernandez et al., 2008; Hamanaka et al., 2010; 
Yang et al., 2006). Therefore, it is not surprising that emerging data implicates an 
important role for TRPV4 in a broad spectrum of lung and airway functions and 
disease processes. These include oedema formation, control of pulmonary vascular 
tone, and the lung response to local or systemic inflammatory insults, some of which 
have been discussed in the preceding sections. 
1.13.1 Cystic Fibrosis 
Ion transport processes, including regulatory volume decrease, are compromised in 
the epithelial cells of cystic fibrosis patients. This deficit is linked to the lack of 
swelling-dependent activation of calcium-dependent potassium channels (Arniges et 
al., 2004). It has been suggested that TRPV4 functions as the calcium entry pathway 
that triggers regulatory volume decrease after hypotonic stress, and that this pathway 
is defective in cystic fibrosis airway epithelial cells (Arniges et al., 2004).  
1.13.2 Ciliary Beat 
Ciliated epithelial cells are responsible for the clearance of mucus and trapped 
substances from the airways, and ciliary beat frequency is regulated by a variety of 
chemical and mechanical stimuli (Andrade et al., 2005). TRPV4 was originally 
identified as a candidate for regulating ciliary beat frequency in response to high fluid 
viscosity in Hamster oviductal ciliated cells, requiring PLA2 signalling (Andrade et al., 
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2005). An important role for TRPV4 in ciliary beat frequency in the airways was 
subsequently confirmed, whereby tracheal epithelial cells derived from TRPV4-/- mice 
failed to respond to an ATP stimulus (Lorenzo et al., 2008). Moreover, human nasal 
epithelial cells stimulated with a TRPV4 agonist show increased ciliary beat 
frequency, which was prevented with a TRPV4 antagonist (Alenmyr et al., 2014). 
1.13.3 Bronchoconstiction 
Activation of TRPV4 with a selective agonist contracts isolated human bronchial 
tissue via the actions of cysteinyl leukotrienes (McAlexander et al., 2014). Hypotonic 
solutions are also reported to cause smooth muscle contraction via TRPV4 expressed 
on the muscle cells (Jia et al., 2004). In healthy subjects, tight junctions between the 
airway epithelium serve as a barrier, thus protecting the smooth muscle cells from 
being exposed to airway surface fluid, which even in the healthy population has an 
osmolarity approximately 80% of isotonic body fluids (Jia et al., 2004). However, the 
osmolarity of airway surface fluid is significantly decreased in some airway diseases, 
and in combination with epithelial damage may expose the smooth muscles to 
hypotonic fluid. Indeed, inhalation of hypotonic solutions has been reported to cause 
bronchoconstriction in asthmatic patients (Schoeffel et al., 1981). Therefore, TRPV4 
may contribute to bronchoconstriction in airway diseases where the epithelial barrier 
is compromised (Jia et al., 2004; Zhu et al., 2009). 
1.13.4 COPD 
Chronic obstructive pulmonary disease (COPD) is characterised by epithelial damage, 
parenchymal destruction, mucus hypersecretion and bronchoconstriction. As TRPV4 
is known to play an important role in mucociliary transport, endothelial permeability 
and smooth muscle contraction, it was suggested that it may also be involved in COPD 
pathogenesis. Studies on two independent data sets showed significant association of 
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TRPV4 polymorphisms with COPD phenotypes (Zhu et al., 2009). One of these TRPV4 
variants showed a gain-of-function phenotype associated with enhanced calcium 
influx and MMP1 activation in human respiratory endothelial cells exposed to diesel 
exhaust particles (Li et al., 2011). It has been postulated that the calcium overload 
associated with this gain-of-function mutation might impair ciliary movement, which 
is an early sign of COPD (Kaneko and Szallasi, 2014). 
1.13.5 Pulmonary Hypertension 
Regulation of pulmonary vascular tone is largely calcium-dependent, and TRPV4 has 
been shown to be a critical component of the response to serotonin-induced 
vasoconstriction as well as acute and chronic hypoxic pulmonary hypertension 
(Goldenberg et al., 2015b; Xia et al., 2013; Yang et al., 2012). 
1.13.6 Acute Lung Injury and Acute Respiratory Distress Syndrome 
Acute lung injury (ALI) can directly result from positive pressure ventilation and acid 
inhalation following aspiration of gastric contents, and is an important factor 
contributing to mortality of critically ill patients (Goldenberg et al., 2015a). Acute 
respiratory distress syndrome (ARDS) is a severe manifestation of ALI, and can arise 
due to insults originating either in the lung or systemically (Goldenberg et al., 2015a). 
The role of TRPV4 in ALI-induced oedema following damage to the epithelial and 
endothelial barriers has already been discussed (Balakrishna et al., 2014). TRPV4 is 
also expressed on a number of immune cells, and thus has been suggested to play an 
important extrapulmonary role in ALI and ARDS (Goldenberg et al., 2015a). 
Treatment with a TRPV4 inhibitor following acid exposure, and acid injury in TRPV4-
/- mice, resulted in significantly lower levels of infiltrating macrophages and 
neutrophils as well as a reduction in lung injury scores (Balakrishna et al., 2014). 
Moreover, perfusion of TRPV4-/- mouse lungs with macrophages isolated from wild-
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type mice restored ventilator-induced lung injury which is usually blunted in 
knockout animals (Hamanaka et al., 2010). 
1.13.7 Cough 
Hypotonic solutions are reported to cause cough in asthmatic subjects, and are used 
as a tussive agent in the clinic (Fuller and Collier, 1984; Morice et al., 2007). TRPV4 is 
functionally expressed on the vagal ganglia, which innervate the airways and mediate 
the cough reflex (Belvisi et al., 2013). Recently, it was shown that a TRPV4 agonist 
provokes sensory nerve firing via activation of mechanosensitive Aδ fibres, and 
coughing in conscious guinea pigs, an effect which was blocked with TRPV4 inhibitors 
(Adcock et al., 2014; Belvisi et al., 2013). 
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1.14 Scope of Thesis  
1.14.1 TRPV4 signalling processes 
TRPV4 is widely expressed and detects a range of different stimuli, perhaps by 
receptor operation as opposed to directly sensing varied stimuli. This is consistent 
with activation by endogenous ligands such as the EET’s and by signalling through 
phosphorylation of TRPV4. It is likely that signalling components will differ between 
tissues and cell types, however there may be common elements allowing varied 
stimuli to converge and integrate to open TRPV4. The ion channel may require 
concurrent post-translational modification to prime it and agonist binding to open it, 
thereby integrating the kinase stimuli and production of endogenous agonists. TRPV4 
requires a collection of activators that may be short lived and be produced in close 
proximity to TRPV4 and hence it has been difficult to ascertain the exact molecular 
mechanism(s) of physiological opening.  
By elucidating and targeting cell-specific signalling processes, it may be possible to 
affect tissue-specific responses and inhibition, presenting advantages over direct 
TRPV4 agonism or antagonism by reducing potential impacts on systemic physiology. 
Current clinical trials will inform us about the suitability of TRPV4 antagonists to treat 
symptoms of congestive heart failure, and possibly other pathophysiological 
conditions involving TRPV4, as well as and an indication of any liability for off-target 
effects.  
This study hypothesized that GPCRs, in HEK293 cells, can signal to and open TRPV4 
via specific intracellular signalling processes. The initial studies of this thesis will 
highlight the specific signalling molecules in this process activated by PAR2 that can 
open TRPV4 and subsequently identify multiple GPCRs which can utilise this 
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signalling to open TRPV4 and implicate possible physiological settings where this 
process is required.  
1.14.2 TRPV4 function in the vasculature 
The last results chapter of this thesis attempts to link the GPCR-dependent activation 
of TRPV4 to a physiological process, in this case in the vasodilatation. It is known that 
TRPV4 is a vital integrator of key stimuli in the vascular endothelium that regulates 
vascular tone. These sections aimed to demonstrate: that TRPV4 is functionally 
expressed in the vascular endothelium of rat skeletal muscle resistance arterioles, 
TRPV4 opening caused vasodilatation and that TRPV4 is opened by intracellular 
signalling from GPCRs in the vascular endothelium to cause vasodilatation.  
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2 Methods 
2.1 HEK293 cell model and assays 
2.1.1 Chemicals and Reagents 
 PAR2–activating peptide SLIGRL-NH2 (PAR2-AP) was synthesised by GL Biochem Ltd. 
(Shanghai, China). Specific TRPV4 agonist GSK1016790A, TRPV4 antagonists 
GSK2193874, HC067047, endothelium independent agonist histamine, small calcium 
sensitive potassium channel (SKCa) inhibitor apamin, intermediate KCa (IKCa) inhibitor 
TRAM-34 and cyclooxygenase inhibitor indomethacin were obtained from Sigma-
Aldrich (Castle Hill, NSW, Australia). Bovine serum albumin (Bovostar), was from 
Bovogen (Keilor, Vic, Australia). All compounds were dissolved in water, except for 
GSK1016790A, GSK2193874 and HC067047 which were dissolved in dimethyl 
sulfoxide (DMSO) and L-NAME and indomethacin which were dissolved in 0.1 M 
sodium bicarbonate. Effectene transfection reagent was purchased from Qiagen 
(Frankfurt, Germany). pcDNA3.1 +DYK (GPCRs) were synthesized by and purchased 
from Genscript (New Jersey, USA) (Table 1). Cell culture products: Dulbecco’s 
modified eagle media (DMEM, Life Technologies, Mulgrave, Victoria, Australia), foetal 
bovine serum (FBS) and Hygromycin B from Sigma Aldrich (Castle Hill, NSW, 
Australia). Cell calcium imaging: FURA-2 and pluronic acid were purchased from 
Jomar Life Sciences (Adelaide, SA, Australia).  
2.1.2 HEK293 cell line culture 
All cell lines were generated from FlpIn Tetracycline-inducible (FRT/TO) Human 
Embryonic Kidney 293 (HEK) cells (Life Technologies, Mulgrave, Victoria). Parental-
HEK293 (HEK) cell lines were maintained at 37oC with 5%CO2, in culture Dulbecco’s 
Modified Eagle’s Medium (DMEM, Life Technologies, Mulgrave, Victoria) with 10% 
Foetal bovine Serum (FBS) and 5µg/ml of Blasticidin. Stably-expressing human 
 39 
TRPV4 HEK cells (HEK+TRPV4) were maintained in the same media with 100 µg/ml 
Hygromycin B. Wild type hTRPV4 HEKs were generated by Yuan Yuan (Lamande et 
al., 2011). Cells were dissociated using trypsin (TrypLE express, Life Technologies) 
and passaged in a Biological safety cabinet class II upon reaching 80-90% confluence. 
Cells for assays were frozen at 1.6x107cells/ml in freezing media (70% Culture 
medium, 20% FBS and 10% DMSO). Cells were thawed and immediately resuspended 
in supplemented DMEM seeding density and growth time was dependent on the 
assay.  
2.1.3 Transient expression of GPCRs in HEK293 cells. 
Cells were thawed and immediately resuspended in supplemented DMEM with FBS 
10% to 4x105 cells/ml plated onto poly-L lysine coated 384-well plates at 3,750 
cells/well, 72 h prior to assay. Effectene transfection reagent (0.31 µl/well) was 
combined with 2.5 ng of Green fluorescent protein (GFP) cDNA and 25ng of GPCR 
plasmid (table 2.1) (pcDNA3.1+DYK Receptor, Genscript, New Jersey,USA) or 25ng of 
cDNA for myristolated bovine phosducin (a generous gift for Dr. Geza Berecki, 
(Berecki et al., 2016)) and added to each well in a 384 well plate containing either 
HEK293 cells (HEK) or HEK293 cells expressing TRPV4 (HEK+TRPV4) which were 
plated 24 h prior. Cells were assessed for function in FLIPR calcium assay. 
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Receptor 
Gene 
name acronym Plasmid Accession number 
Purinergic 2Y 2 
P2RY2 P2Y2 
pcDNA3.1 
DYK 
NM_176071 
Purinergic 2Y 11 P2RY11 P2Y11 
pcDNA3.1 
DYK 
NM_002566 
Purinergic 2Y 12 P2RY12 P2y12 
pcDNA3.1 
DYK 
NM_176876 
Tachykinin receptor 1 TACR1 NK1 
pcDNA3.1 
DYK 
NM_001058 
Bradykinin receptor B1 BDKRB1 BK1 
pcDNA3.1 
DYK 
NM_000710 
Bradykinin receptor B2 BDKRB2 BK2 
pcDNA3.1 
DYK 
NM_000623 
Cholinergic receptor 
muscarinic 3 
CHRM3 M3 
pcDNA3.1 
DYK 
NM_000740 
Prostaglandin receptor 
4 
PTGER4 PGTR4 
pcDNA3.1 
DYK 
NM_000958 
 Table 2.1 GPCRs transfected into HEK293 cells 
2.1.4 siRNA transfection 
We screened the human kinome (comprising 721 kinase genes) with four individual 
“SMARTpool” siRNAs (Human siGENOME RTF – Protein Kinases, H-003505) targeting 
each gene, per well. siRNAs were transfected using high throughput liquid handling 
robotics (Calliper ALH3000) in 96-well format in HEK+TRPV4. siRNA library plates 
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were transfected in duplicate. DharmaFECT1 lipid (DF1, 0.2 μL/well; Dharmacon) 
was mixed with Opti-MEM basal medium (Life Technologies) and complexed with 
siRNA (40 nM final concentration, 10 nM for each siRNA in the pool) for 20 min (final 
volume 20 μl per well). Each plate included controls in columns 1 and 12 which 
consisted of mock transfection with DF1 only (Mock) in 6 wells, non-targeting control 
siRNA (siOTP-NT, D-001810-0X) in 2 wells and positive cell-death-inducing control 
siPLK1 (Entrez gene ID 5347, catalogue number M-003290-01) in 2 wells. Frozen cell 
stocks were resuspended in DMEM containing 10% FBS at 1.6x105 cells/ml (100 fold 
from frozen stock) and 80 µl of the cell suspension was added to the siRNA lipid 
complex per well. Cells were incubated (37oC, 5% CO2) for 24 h. After that time, an 
additional 100 µl of media was added to each well, to avoid dislodging the weakly 
adherent HEK293 cells with a complete media change. Tetracycline (50 μL of 0.5 
μg/mL stock to a final concentration of 0.1 µg/mL) was added 32 h later to induce 
expression of TRPV4 and 16 h later the cells were tested for PAR2-dependent calcium 
flux in a plate reader (Table 1). Confirmation screens were performed, transfected as 
above except the SMARTpool deconvoluted siRNAs (individual duplex) were 
screened at a final concentration of 25nM, in duplicate assays. The following 
individual SMARTpool siRNAs were purchased for follow up experiments: (Entrez 
gene ID, Dharmacon catalogue number), siBUB1 (699, M-004102-01), siITPK1 (3702, 
M-006741-01), siMAPK13 (5603, M-003591-02) and siWNK4 (65266, M-005031-
02). 
2.1.5 Plate-based fluorescent calcium imaging (Flexstation) 
72 h after transfection, cells were loaded with Fura-2AM (2.5 µM) and pluronic acid 
(0.5 µM) diluted in HEPES solution (10 mM HEPES, 140 mM NaCl, 2 mM CaCl2, 5 mM 
KCl, 1 mM MgCl2, 11 mM D-glucose, 2 mM probenecid, pH 7.4 at 37oC) for 30 min. After 
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washing with HEPES solution (80 μl) to remove excess Fura-2 dye, cells were allowed 
to recover for 30 min at 37oC in 5% CO2. Fura-2 fluorescence was read in a Flexstation 
III plate-reading fluorimeter (Molecular Devices, Sunnyvale, CA, USA) using excitation 
wavelengths of 340 nm and 380 nm and emission at 520 nm every 3.9 s. The 
Flexstation plate-reader is equipped with a fluidics module that can deliver up to 
three injections per well. The cells were treated with two agonist injections; first at 
15 s with a PAR2-activating peptide (50 μM) and second at 80 s with GSK1016790A 
(30 nM) the specific TRPV4 agonist, each column was read for 150 s, an entire 96-well 
plate takes approximately 40 min to read. The ratio of 340 nm/380 nm was 
determined by the Softmax Pro 5.4 software (Molecular Devices) as a relative 
measure of the intracellular Ca2+ concentration ([Ca 2+]i).  
2.1.6 FLIPR Calcium Assay  
HEK+TRPV4 were grown for 56 h prior to inducing expression of hTRPV4 by addition 
of tetracycline (0.1 µg/ml final concentration) for 16-20 h. On the day of the 
experiment, cells were loaded for 30 min with calcium indicator Fura-2AM (2.5 µM ) 
and pluronic acid (0.5 µM) diluted in HEPES solution (10 mM HEPES, 140 mM NaCl, 2 
mM CaCl2, 5 mM KCl, 1 mM MgCl2, 11 mM D-glucose, 2 mM probenecid, pH 7.4 at 
37oC). Cells were washed with HEPES solution to remove excess Fura-2 dye and 
allowed to recover for 30 min at 37oC in 5% CO2. Assays used a FLIPR Tetra plate-
reading Fluorimeter (Molecular Devices, Sunnyvale, CA, USA). Excitation wavelengths 
of 340 nm and 380 nm were used and emission measured at 520 nm every 0.75 
seconds. The ratio of 340nm/380nm was determined by Molecular Probes 
Screenworks 4.0 software as a measure of change in free cytosolic intracellular Ca2+ 
concentration over time. 
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2.1.7 Quantitation of mRNA expression 
To quantify siRNA knockdown of mRNA expression, RNA was extracted and pooled 
from 6 replicate siRNA-treated wells, after calcium imaging experiments were 
completed. RNA was extracted using a QIAGEN RNeasy mini kit with a QIAcube 
robotic system according to the manufacturer’s specifications. RNA concentration 
was determined using a Nandrop2000, measuring absorbance at 240 nm. RNA (1 μg) 
from each sample was digested using DNase I (1 unit, Applied Biosystems, Foster City, 
CA, USA) for 10 min at RT and it was inactivated by addition of EDTA (2 mM) and 
heating at 65oC for 10 min. RNA was reverse transcribed to cDNA (High capacity RNA-
to-cDNA kit, Applied Biosystems) in a 20 μL reaction.  
qPCR reactions were performed in a 384-well plate using Taqman® Fast Advanced 
MasterMix protocol with specific TaqMan® Gene Expression Assay (20X) (Applied 
Biosystems) for specific targets and GAPDH as the internal loading control for 
normalisation. The protocol was performed according to the manufacturer’s 
specifications, using a QuantStudio 7 flex real-time PCR system (Applied Biosystems). 
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2.2 Cremaster arteriole assays 
2.2.1 Pressure myography of cremaster arterioles  
Adult male Wistar rats weighing between 200-400 g were killed using CO2 
asphyxiation, using protocols which complied with NHMRC requirements for the 
ethical treatment of animals and were approved by the RMIT University animal ethics 
committee. The cremaster muscle was removed and placed in modified Kreb’s 
solution (in mM, KCl 5, MgSO4 1.2, KH2PO4 1.2, CaCl2 2.5, NaCl 111, NaHCO3 25.7, D-
glucose 11.5 and HEPES 10) at 4oC. The arterioles were dissected and cannulated 
between two glass pipettes with matching tip diameters of approximately 100 µm. 
Vessels were subjected to a pressure of 120 mmHg using a height adjustable 
reservoir, lengthened to remove lateral bowing and tested for leaks and were not used 
if they continued to display bowing or if they leaked. Once pressurised (70 mmHg), 
the vessels were warmed to 34oC  in modified Kreb’s solution bubbled with 5% CO2 
in nitrogen and allowed to spontaneously develop myogenic tone. Arterioles were 
considered suitable for further experimentation if they constricted by greater than 
40% of the maximal diameter. Maximal diameter was determined by removing 
extracellular calcium, using Kreb’s zero calcium solution (CaCl2 0 mM, EGTA 1 mM) at 
the end of each experiment. The lumen was filled with Kreb’s solution containing 1% 
bovine serum albumin to protect the endothelium from damage during shear 
conditioning. Kreb’s solution was superfused through the baths at approximately 4 
ml/min, all inhibitors were placed in the superfusate and allowed to equilibrate for 
10 min prior to administration of agonists. All agonists were added cumulatively, 
directly to the bath every 2 min, using a 1:1000 dilution. In the event that two 
concentration effects curves were performed, the bath volume was replaced twice 
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and vessels were allowed to re-generate myogenic tone before the response curve 
was determined.  
When needed, the endothelium was removed by passing an air bubble through the 
lumen 3-6 times until the vessels no longer responded to ACh (10 μM), after 
concentration response curves were determined, vessels were maximally dilated to 
Kreb’s zero calcium solution. Shear stress was generated on the vessels by using a 
pressure regulated-servo controlled pump (Living Systems) at the distal end of the 
arterioles. To generate shear stress a pressure difference of 60 mmHg across the 
vessels was used, the input pressure was increased from 70 to 100 mmHg and the 
distal pressure was decreased to 40 mmHg thus maintaining intraluminal pressure in 
the vessel at approximately 70 mmHg. To shear-condition them, arterioles were 
exposed to an average flow rate of 200 μl/min for 6 min, flow was then stopped and 
the arterioles allowed to re-generate myogenic tone for 2-10 min prior to testing 
agonist responses as described above. 
2.2.2 Immunocytochemistry 
Cremaster arterioles were cannulated as described above, then viable vessels were 
either exposed to shear conditioning or control (no flow) conditions. All vessels were 
maximally dilated by exposure to 0 mM Ca2+ Kreb’s solution (1 mM EGTA) and then 
fixed in situ with 1% paraformaldehyde for 20 min and stored in PBS (in mM; NaCl 
137, NaH2PO4 10, KCl 2.7, and KH2PO4 1.5 ; pH 7.4) at 4oC. Arterioles cannulated onto 
custom made stainless steel cannulae were labelled using the method described by 
Dan et al., (2003) (Dan et al., 2003). In brief, arterioles were exposed via the lumen to 
solutions containing glycine (100 mM) for 10 min, to remove residual PFA and 
permeabilized for 10 min with PBS 0.1 % Triton X-100. Arterioles were then washed 
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with PBS and blocked with antibody buffer (NaCl 75 mM, Na3 citrate 18 mM, 2% goat 
serum, 1% BSA and 0.02% NaN3) for 1 h at room temperature and incubated with the 
primary TRPV4 antibody (ab39260 5 μg/ml, Abcam, Melbourne, Australia) and 
Hoescht 34580 dye (1μM, Life Technologies, Mulgrave, Australia) overnight at 4oC. 
Arterioles were washed with antibody buffer and incubated with Alexa555 goat anti-
rabbit fluorophore conjugated secondary antibody (40 μg/ml, Life Technologies, 
Mulgrave, Victoria, Australia). Arterioles were washed with PBS, mounted in aqueous 
mounting solution (Fluomount, Dako, Glostrup, Denmark) and imaged on a Nikon A1 
laser scanning confocal microscope. 
Extracellular TRPV4 antibody labelling was performed using a primary antibody to 
the extracellular domain of TRPV4 (Alomone ACC124, Jerusalem, Israel) and was used 
to measure the level of TRPV4 cell surface expression. The immunolabelling protocol 
was as described above, with the following modifications: after fixation, arterioles 
were not permeabilised, after blocking and washes the arterioles were labelled with 
primary TRPV4 antibody (1:300).  
2.2.3  Data analysis 
Pressure myography of rat cremaster arterioles. For each arteriole, in response to an 
agonist, the change in diameter (ΔD) from baseline was measured and was then 
defined as the response minus the baseline diameter before agonist injection. ΔD was 
then normalised to the diameter determined in the absence Ca2+ (maximum 
dilatation) and expressed as a percentage (ΔD %). All values are expressed as mean ± 
S.E.M. Graphpad Prism 6 was used to generate pEC50 (-log(effective concentration to 
cause a 50% response) M) and ΔDmax % (maximum dilatation) values using the 
nonlinear regression functions, then these measures were tested for statistical 
 47 
differences using, one-way ANOVA with Sidak's post hoc test, and significance 
designated at p < 0.05. The limited solubility of GSK1016790A prevented its 
administration at concentrations sufficient to achieve a maximal response in the 
presence of the antagonists GSK2193874 and HC067047. In those cases the pEC50 was 
determined by constraining the maximum to 100%.  
Fluorescence immunocytochemistry. Maximum brightness images were obtained by 
merging each stack of images from approximately the centre of the lumen to the 
outside of the arteriole and the background and the mean pixel intensity of a 
rectangular region of interest was measured over three areas of each arteriole which 
had received either control conditions or shear conditioning. The TRPV4 labelling 
(ALEXAfluor 555 channel) was normalised to the green auto-fluorescence of the 
internal elastic lamina, which corrected for the differences in stack sizes between 
vessels. Control and shear conditioned vessels from the same rat were fixed for the 
same time to ensure that the internal elastic lamina would have equivalent 
autofluorescence. All values are expressed as intensity/cm2 ± S.E.M. A paired 
Student’s t-test was performed between control and shear conditioned vessels. 
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3 PAR2-dependent opening of TRPV4 is independent of Gαq 
signalling 
 
3.1 Introduction  
Activation of a G-protein coupled receptor (GPCR) creates a conformational change in 
the receptor that begins a cascade of intracellular signalling that can have many 
possible biological effects. GPCRs consist of seven transmembrane domains that 
traverse the cellular membrane, with an extracellular N-terminus which can be 
involved in agonist signalling and an intracellular C-terminus which regulates activity 
and downregulation and may influence the receptor signalling. GPCRs effect change 
in cells by transducing signals from extracellular stimuli through the receptor which 
activates other signalling molecules. The functional effects on cells can range from 
altered gene expression, activating enzymes to modify proteins and opening ion 
channels to change intracellular ion concentrations and alter the membrane potential 
of cells. For instance, bradykinin is a painful nonapeptide (Inoki et al., 1979) and it 
and its des-Arg9 metabolites selectively bind to and activate the bradykinin B1 or B2 
receptors respectively on afferent sensory neurones (Higashida et al., 1986). Since 
GPCRs are not ion channels, they cannot depolarize pain sensing neurons directly to 
initiate an action potential. Bradykinin causes intracellular signalling from the GPCR 
that is transduced to ion channels in the neuron’s cellular membrane, the channels 
then open, generating an action potential.  
The unique signalling pathways activated by these receptors depend on specific 
heterotrimeric GTP-binding proteins (G-proteins) that are bound to the intracellular 
domains of the receptor. Heterotrimeric G-proteins have three subunits termed α, β 
and γ (Hurowitz et al., 2000). As a GPCR agonist binds, it alters the conformation of 
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the receptor to exchange the GDP molecule bound to the α-subunit for a GTP molecule. 
This exchange releases the α, β and γ subunits and results in signalling within the cell. 
Currently it is known that there is a canonical set of pathways associated with each 
Gα-subunit. However, it is also likely that there are pathways that have yet to be 
discovered.  
The specific Gα-subunits assessed in this chapter have previously been associated 
with the activation of the proinflammatory receptor protease activated receptor-2 
(PAR2). Gαs activates adenylate cyclase which converts ATP to cAMP which in turn 
activates the protein kinase A (PKA) (Grant, Andrew D. et al., 2007; Zhao et al., 2014); 
Gαi/o which inhibits the adenylate cyclase (Soh et al., 2010); Gα12/13 which activates 
the Rho kinase pathway (Ramachandran et al., 2011) and Gαq which activates 
phospholipase C which cleaves PIP2 into DAG and IP3 and leads to the release of 
calcium from intracellular stores (Table 3.1)(Grace et al., 2014; Poole et al., 2013). The 
β and γ subunits activate their own signalling pathways, for instance with Gαi coupled 
receptors the βγ subunits activate PLC to cause release of intracellular calcium (Koch 
et al., 1994), or they can translocate from the receptor and open the G-protein-gated 
inwardly rectifying potassium channels (GIRK) ion channels to hyperpolarise the cell 
membrane (Lüscher and Slesinger, 2010).  
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Gα Effector 
enzymes 
2nd Messengers Example responses 
S Activates 
adenylate 
cyclase 
Increased cAMP, 
which activate 
Protein kinase A 
Smooth muscle relaxation, 
increase heart rate,  
i/o Inhibits 
adenylate 
cyclase 
Decreases cAMP Smooth muscle migration,  
12/13 Activate 
RhoA 
Activates Rho kinase Smooth muscle contraction 
and cytoskeletal remodelling 
q/11 Activates PLC Releases IP3 and 
DAG which increase 
intracellular calcium 
Smooth muscle contraction 
Table 3.1. Example of signalling processes for specific Gα subunits. 
Stimulation of GPCRs can also lead to signalling pathways that do not depend on the 
activity of heterotrimeric G-proteins. Thus, activation of the β-adrenoceptor lead to 
engagement of β-arrestins which inhibited the signalling of the receptor by binding to 
the receptor and caused internalisation (Benovic et al., 1987). -arrestins have been 
shown to form complexes with and activate Src family tyrosine kinases, ERK 1/2 and 
JNK3 MAP kinase signalling cascades upon binding to GPCRs, indicating multiple 
actions in addition to internalisation alone (Luttrell and Lefkowitz, 2002).  
PAR2 can be activated by proteolytic cleavage of the N-terminus of the receptor by 
pro-inflammatory proteases such as trypsin, cathepsin S, elastase and matrix 
metalloproteinase 9 (Ramachandran and Hollenberg, 2008) to reveal a tethered 
ligand or by synthetic peptide agonists which mimic the N-terminal tethered ligand 
(Berger et al., 2001; Molino et al., 1997) (Figure 3.1). We have found that activation of 
PAR2 initiates uncharacterised signal pathways that lead to the opening of the TRPV4 
ion conduction pore in HEK293 cells (Poole et al., 2013). Agonist activation of PAR2 
results in signalling through several heteromeric G-protein pathways, including 
multiple different Gα-protein complexes; Gαq (Grace et al., 2014), Gα12/13 
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(Ramachandran et al., 2011), Gαs (Zhao et al., 2014) and Gαi/o (Macfarlane et al., 
2005).  
Pro-inflammatory proteases released from immune cells such as mast cells and 
macrophages activate PAR2 and are critical in nociception (Bunnett, 2006). Deletion 
of the PAR2 receptor (PAR2-/-) in mice revealed its involvement in pain signalling 
(Alessandri-Haber et al., 2006). The stimulation of PAR2 in afferent neurons caused a 
prolonged mechanical and thermal hyperalgesia in rats and mice which was 
attenuated in mice lacking the neurokinin 1 receptor (NK1R) (Vergnolle et al., 2001). 
This suggests that PAR2 activation caused the release of substance P, which is an 
agonist of NK1R. PAR2 has also been identified in models of visceral pain. For example, 
in colitis cathepsin S caused hyperalgesia which is PAR2-dependent (Cattaruzza et al., 
2011). In addition, sensitivity of sensory neurons was increased by trypsin activation 
of PAR2 in patients with irritable bowel syndrome (Cenac et al., 2007). The observed 
visceral pain was attributed to PAR2 signalling through the release intracellular 
calcium and activation of extracellular signal-regulated kinase 1/2 (ERK1/2) in 
prostatitis (Roman et al., 2014). Despite these models of PAR2-dependent 
hyperalgesia that have been described, the intracellular signalling pathways activated 
by PAR2 to cause hyperalgesia have not been well studied. 
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Figure 3.1. PAR2 activation by proteolytic cleavage of the N-terminus begins 
specific Gα signalling processes to alter cellular function via second 
messesngers (Table 3.1). Small GTPase RhoA, Intracellular calcium ([Ca2+]i), 
cyclic adenosine monophosphate (cAMP).  
 
TRPV4 activation sensitises sensory neurons to noxious mechanical (Alessandri-
Haber et al., 2006), thermal stimuli (Ding et al., 2010); to ultraviolet B-induced 
epidermal pain (Moore et al., 2013) as well as migraine pain (Wei et al., 2011). 
Critically, the injection of a mixture (or “soup”) of proinflammatory stimuli, including 
bradykinin, substance P, prostaglandin E2 and serotonin into the paw of the mouse, 
caused a profound mechanical hyperalgesia which was not observed in TRPV4 
knockout mice (Alessandri-Haber et al., 2006).  
Subsequently, PAR2 receptors were found to sensitise TRPV4 to its agonists 4α-PDD 
and GSK1016790A (Grant, Andrew D. et al., 2007; Zhao et al., 2014; Zhao et al., 2015). 
Dorsal root ganglion neurons, which express PAR2 and TRPV4 responded to 4α-PDD 
and hypotonic solutions and these responses were sensitised after treatment with a 
PAR2-agonist (Grant, Andrew D. et al., 2007). In an effort to define the signalling 
pathways responsible for this sensitised response of TRPV4 to its agonists, this model 
was replicated in HEK293 cells which endogenously express PAR2 receptors and were 
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transfected with TRPV4 (Grant, Andrew D. et al., 2007). Sensitisation in both types of 
cells was blocked by inhibitors of PKA, PKC, PKD and PLCβ (Grant, Andrew D. et al., 
2007).  
Despite these discoveries, little was known about the physiological mechanism by 
which TRPV4 was opened, therefore the aim of this study was to find: What is the 
physiological mechanism of opening for TRPV4 observed in HEK293 cells, and is it of 
physiological relevance?  
Previous work from our laboratory showed that TRPV4 can be opened by intracellular 
signalling pathways in HEK293 cells (Poole et al., 2013). Thus, TRPV4 can be 
considered a receptor-operated ion channel. It has been reported that Gαq activation 
of phospholipase Cβ (PLC) leading to release of calcium from stores is necessary for 
canonical TRP channel activation (Hardie and Minke, 1995) that the release of calcium 
from stores may open TRPV4 and that TRPV4 may in fact be a store-operated channel 
(Pizzoni et al., 2018) as opposed to other signalling from GPCRs.  
Inhibitors of PLA2 and src family kinases which inhibit sensitisation or opening of 
TRPV4 by GPCRs have been identified in HEK293 cells (Poole et al., 2013). However, 
the selectivity of these inhibitors used at high concentrations is in question and they 
may have exerted non-specific effects (Grace et al., 2014; Poole et al., 2013). Thus, a 
comprehensive understanding of the intracellular pathways involved in the PAR2-
dependent opening of TRPV4 is not available at present. It is possible that multiple 
pathways converge on the channel, complicating this task.  
This chapter addressed key questions about the signalling pathways between PAR2 
and TRPV4 and determined if PAR2 activated Gαq signalling pathways which release 
calcium from intracellular stores which led to the opening of TRPV4. The specific 
questions addressed were, 1) is the release of calcium from intracellular stores 
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necessary for TRPV4 opening (Figure 3.2) and 2) is Gαq signalling necessary for this 
process?  
3.1.1 Hypothesis 
That PAR2 signals via Gαq to release intracellular calcium from stores which leads to 
the opening of TRPV4 (Figure 3.2). 
 
Figure 3.2. Hypothesis: PAR2 signals via Gαq to cause the release of intracellular 
calcium that may open TRPV4. Trypsin cleaves PAR2 to activate the receptor and 
initiate the Gαq signalling pathway which cause PLCβ to cleave PIP2 into DAG and IP3, 
IP3 then binds to its receptors on the endoplasmic reticulum (ER) to release calcium 
from the stores, does this cause the opening of TRPV4? Protease activated receptor 2 
(PAR2), diacylglycerol (DAG), inositol triphosphate (IP3), phospholipase C beta 
(PLCβ), guanosine di- and triphosphate (GDP, GTP), IP3 receptor (IP3R), sarcoplasmic 
endoplasmic reticulum calcium ATPase (SERCA), Transient receptor potential 
vanilloid -4 (TRPV4).  
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3.2 Experimental design  
Fura-2 based measurements of free cytosolic intracellular calcium (Δ Fluorescence 
ratio (340/380 nm)) described in the methods chapter, to measure the rise in [Ca2+]i 
evoked by PAR2-actvating peptide (PAR2-AP) or elastase in HEK293 cells (Methods 
chapter 2.1.2-2.1.5). We compared treatment of cells with various inhibitors of G-
protein signalling: thapsigargin, Gαq-blocker (UBO-QIC), gallein and phosducin. 
Thapsigargin is a potent inhibitor of the sarcoplasmic endoplasmic reticulum calcium-
ATPase pumps (Sagara et al., 1992) treatment prevents endoplasmic calcium stores 
from replenishing. UBO-QIC binds to Gαq to inhibit the release of GDP, thereby 
stopping the G-protein from becoming active (Fujioka et al., 1988). Gallein a 
reversible non-covalent blocker of Gβγ that inhibits the Gβγ-dependent opening of 
GIRK ion channels and PLC activation (Lehmann et al., 2008; Seneviratne et al., 2011). 
Also to inhibit Gβγ the regulatory protein we used phosducin (Gaudet et al., 1996) by 
transiently expressing it in HEK293 cells (methods chapter 2.1.3). This study 
performed the cellular assays in the presence and absence of extracellular calcium in 
order to determine the contribution of influx of external calcium to each signal.  
Area under the curve (AUC) was calculated from fluorescence ratio time courses as 
the sum of readings from 50-80s multiplied by the time in seconds these values were 
used for statistical analysis. In this chapter we performed one-way ANOVA analysis to 
determine significance, with Dunnett’s post hoc test where multiple test conditions 
were tested to one control and Sidak’s post hoc test where multiple test conditions 
were compared to a control and another test condition. All technical replicates, 
controls and test conditions, compared in each analysis were performed 
contemporaneously on the same 96-well plate. Plates were replicated a minimum of 
4 times for each experiment.  
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3.3 Results  
PAR2 activation caused an initial transient increase intracellular calcium levels 
(fluorescence ratio 340/380 nm) in HEK293 cells (HEK), which was unaltered by the 
removal of extracellular calcium (HEK [Ca2+]0, Figure 3.3), therefore the change in 
intracellular calcium levels was due to the release of calcium from the endoplasmic 
reticulum (ER). However, PAR2 activation resulted in sustained elevation of [Ca2+]i 
when TRPV4 was expressed (HEK+TRPV4). The removal of extracellular calcium 
([Ca2+]0) or the absence of TRPV4 (HEK) ablated the sustained calcium increase 
Therefore the increase in [Ca2+]i was due to influx of Ca2+ through TRPV4 which we 
have previously reported (Grace et al., 2014; Poole et al., 2013) and presented here. 
This technique can distinguish between increases in [Ca2+]i from stores or from influx 
from the external medium through ion channels. 
 57 
Figure 3.3. PAR2 receptor activation opened TRPV4 in HEK293 cells. 
A. Intracellular calcium levels (Δ Fluorescence ratio (340/380 nm)) in response to PAR2-
AP (50 µM) in non-transfected HEK293 cells (HEK) and hTRPV4 expressing HEK293 cells 
(HEK+TRPV4) and without extracellular calcium ([Ca2+]0). B. Data derived from A. 
integrated area under the curve from 50 – 80 s represents the intracellular calcium levels 
post the PAR2 peak response. (* p<0.05 compared to HEK, + p<0.05 compared to 
HEK+TRPV4, Oneway ANOVA, Sidak post hoc test.) (N=4).  
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The intracellular stores of HEK cells can be depleted with thapsigargin (Rogers et al., 
1995). The PAR2-dependent increase in [Ca2+]i in HEK cells was blocked by 
thapsigargin treatment (1 µM) (HEK Thaps, Figure 3.4A). Despite depletion of 
intracellular stores, a PAR2-dependent calcium signal remained in HEK+TRPV4 cells 
(HEK+TRPV4 Thaps) but was absent in control cells (HEK Thaps) and the response 
was abolished by removal of extracellular calcium (HEK+TRPV4 [Ca2+]0), indicating 
that the calcium influx was through TRPV4 (Figure 3.4B). Thus, release of intracellular 
calcium did not significantly affect PAR2-dependent opening of TRPV4 in HEK293 
cells. Thapsigargin treatment significantly increased the plateau phase in response to 
PAR2-AP (50 µM) in HEK+TRPV4 cells (Figure 3.5).  
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 Figure 3.4. PAR2-dependent opening of TRPV4 did not require the release of 
calcium from intracellular stores. Intracellular calcium levels (Δ Fluorescence ratio 
(340/380 nm)) in response to PAR2-AP (50 µM) in non-transfected HEK293 cells 
(HEK) and hTRPV4 expressing HEK293 cells (HEK+TRPV4). A: Thapsigargin (Thaps, 
1 µM) treatments effect on PAR2 stimulated increases in intracellular calcium in HEK 
and HEK+TRPV4 cells. B: Comparison of [Ca2+]0 and thapsigargin treatment effects on 
PAR2 stimulated increases in (Ca2+)i. (N=4).  
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In order to determine if the PAR2-dependent opening of TRPV4 required the Gαq 
signalling pathway we used a selective Gαq-blocker, UBO-QIC. UBO-QIC dose-
dependently blocked the release of calcium from intracellular stores in HEK cells 
(Figure 3.6A). However like thapsigargin treatment, the influx of calcium through 
TRPV4 was not blocked by UBO-QIC and the [Ca2+]i reached a similar sustained 
plateau, to untreated HEK+TRPV4 cells, (Figure 3.6B). Analysis of the average plateau 
phase showed that there was no significant difference between UBO-QIC treated 
HEK+TRPV4 cells and the HEK+TRPV4 control treatment (Figure 3.6C).  
Figure 3.5. Thapsigargin treatment did not significantly reduce the PAR2-
dependent opening of TRPV4. Data derived from Figure 3.4. Comparison of area 
under the curve, integrated from 50-80 s (AUC) with pre-injection baseline 
removed from measurements. (* p<0.05 compared to HEK, + p<0.05 compared to 
HEK+TRPV4, Oneway ANOVA, Sidak’s post hoc test.) (N=4). 
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Figure 3.6. UBO-QIC did not block the PAR2-dependent opening of TRPV4. 
Intracellular calcium (Δ Fluorescence ratio (340/380 nm)) levels in response to PAR2-
AP (50 µM) in non-transfected HEK293 cells (HEK) and hTRPV4 expressing HEK293 
cells (HEK+TRPV4). A: HEK cells intracellular calcium levels treated with increasing 
concentrations of UBO-QIC. B: HEK and HEK+TRPV4 cells treated with UBO-QIC (100 
nM). C: Comparison of area under the curve, integrated from 50-80 s (AUC) with pre-
injection baseline removed from measurements. (* p<0.05 compared to HEK, Oneway 
ANOVA, Dunnett's post hoc test.) (N=4). 
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To determine if Gβγ signalling is involved in the PAR2-dependent opening of TRPV4, 
we used the Gβγ inhibitors, gallein and phosducin (Figure 3.7). Neither gallein 
treatment (Figure 3.8A) nor phosducin expression inhibited the PAR2-dependent 
opening of TRPV4 (Figure 3.8B), AUC for PAR2 responses was tested for significance 
(data not shown). Both phosducin and gallein used were tested by a Dr. Geza Berecki 
in parallel experiments and were found to be active at inhibiting the Gβγ-dependent 
opening of GIRK channels in Xenopus oocyte cells (Berecki et al., 2016).  
 
Figure 3.7. Hypothesis: PAR2 signals via Gβγ to cause the release of intracellular 
calcium that may open TRPV4. Trypsin cleaves PAR2 to activate the receptor sIP3, 
IP3 then binds to its receptors on the endoplasmic reticulum (ER) to release calcium 
from the stores this calcium, does this cause the opening of TRPV4? Protease activated 
receptor 2 (PAR2), diacylglycerol (DAG), inositol triphosphate (IP3), phospholipase C 
beta (PLCβ), guanosine di- and triphosphate (GDP, GTP), IP3 receptor (IP3R), 
sarcoplasmic endoplasmic reticulum calcium ATPase (SERCA), Transient receptor 
potential vanilloid-4 (TRPV4).  
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Figure 3.8. Inhibition of Gβγ-dependent signalling did not block the PAR2-
dependent opening of TRPV4. Intracellular calcium ((Ca2+)i) levels in response to 
PAR2-AP (50 µM) in HEK293 cells (HEK) and hTRPV4 expressing HEK293 cells 
(HEK+TRPV4). A: Cells treated with gallein. B: Cells transiently transfected with either 
the control plasmid green fluorescent protein (GFP) or the Gβγ regulatory protein 
phosducin (Phos). (N=4). 
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3.4 Discussion  
Sensitisation of TRPV4 agonist activation has been linked to calcium release from 
stores and the associated Gαq signalling pathways (Fernandes et al., 2008; Garcia-
Elias et al., 2008; Garcia-Elias et al., 2013; Grant, Andrew D. et al., 2007). Based on 
this previous work, we hypothesized that PAR2 signalling opened TRPV4 by 
activating Gαq and releasing calcium from intracellular stores. The experiments 
described demonstrated that PAR2 signalling opened TRPV4 independently of 
Gαq signalling and calcium release from stores, the data didn’t support the 
hypothesis. Signalling pathways were further assessed and we determined that 
Gβγ signalling was not necessary for the PAR2-dependent opening of TRPV4 in 
HEK293 cells. The multiple strategies assessed in this chapter: small molecule 
inhibitors and expression of regulatory proteins, have demonstrated the utility of 
HEK293 cell functional assays for investigating the mechanisms of TRPV4 
opening. 
We have specifically assessed the receptor-dependent opening of TRPV4 and our 
findings are contrary to these previous studies (Fernandes et al., 2008; Garcia-
Elias et al., 2008; Grant, Andrew D. et al., 2007). The inhibitor UBO-QIC prevented 
the release of calcium from stores in HEK cells, but did not inhibit the PAR2-
dependent opening of TRPV4 in HEK+TRPV4 cells. Hence the Gαq signalling 
pathway is not critical for PAR2 to open TRPV4. The use of thapsigargin supported 
this by similarly blocking the PAR2-dependent release of calcium from stores but 
did not prevent the TRPV4-dependent calcium entry with PAR2 activation. When 
considered together these findings give a clear indication the increase in 
intracellular calcium in HEK +TRPV4 is biphasic with the initial peak attributed to 
the release of calcium from intracellular stores and the later plateau phase 
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response due to entry through TRPV4 and is independent of the initial peak phase. 
This determination can be used to assess the function of an inhibitor in this 
system, whether it is targeting the signalling from PAR2 to TRPV4, the plateau 
phase, or the signalling linked to the release of calcium from stores.  
A limitation of thapsigargin is that the release of calcium form stores still occurs 
prior to the imaging period, as thapsigargin only inhibits the stores from 
replenishing the stocks. Hence, the related signalling effects caused by the release 
of intracellular calcium can still occur. Potentially this was observed, as cells 
treated with thapsigargin had a significantly greater increase in intracellular 
calcium due to the PAR2-dependent opening of TRPV4, than the cells treated with 
UBO-QIC which had no calcium related signalling from intracellular stores. This 
increase may be due to effect of calcium release increase prior to the imaging 
period or the reduced clearance of calcium after the response due to SERCA 
inhibition by thapsigargin. However, it is not possible to separate the cause of this 
from these results. 
It has been reported that UBO-QIC can inhibit the Gβγ-dependent release of 
intracellular calcium from stores caused by Gαi coupled receptors (Gao and 
Jacobson, 2016). Since UBO-QIC does not inhibit the PAR2-dependent opening of 
TRPV4 in HEK293 cells, PAR2 is not signalling via Gβγ to open TRPV4. We further 
showed that Gβγ signalling was not responsible for signalling to TRPV4, since the 
Gβγ inhibitors gallein and phosducin were without effect. Since neither of these 
inhibitors affected the initial calcium peak, which is due to the release of calcium 
from intracellular stores, we conclude that the PAR2-dependent release of calcium 
from intracellular stores is due to the Gαq pathway not the Gβγ-dependent 
pathway. 
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This HEK293 cell model has characteristics due to the overexpression TRPV4. 
Overexpression of TRPV4 could conceivably alter its interactions with PAR2 which 
may enhance the activation of TRPV4 in this system. Despite a large portion of this 
work being completed in the HEK293 cell model, the cellular perspective is 
important and the physiological relevance of GPCR activation opening TRPV4  
needs to be assessed in more physiological systems. The evidence that functional 
coupling between GPCRs and TRPV4 does occur in primary cells and tissues 
(Adapala et al., 2011; Mamenko et al., 2011; Poole et al., 2013) provides scope and 
further applications for the discoveries made in this cell model. We view this 
current HEK293 cells model as an intermediate tool for screening a large number 
of potential signalling pathways to identify pathways which could then be tested 
in more physiologically relevant systems.  
In conclusion, this chapter has determined that the PAR2-dependent opening of 
TRPV4 in HEK293 cells is not Gαq or Gβγ dependent. It is evident from these 
studies, and the current literature that this signalling pathway is difficult to 
decipher. A different type of strategy to better understand this signalling would 
be to use an unbiased screening approach such as screening libraries of siRNA 
targeting potential signalling molecules. 
 
67 
4 A functional kinase siRNA screen using PAR2-dependent 
opening of TRPV4 
4.1 Introduction 
The previous chapter identified that signalling processes from PAR2 can open 
TRPV4, however the identity of the pathways are currently unknown. We have 
shown in the last chapter that they differ from the pathways which are suggested 
to open TRPV4 in the literature (Adapala et al., 2011; Fernandes et al., 2008). To 
investigate the signalling pathway(s) from PAR2 activation which open TRPV4, we 
used HEK+TRPV4 cells and measured intracellular calcium in a real-time, as in the 
previous chapter. 
The premise of this chapter is that TRPV4 activity may be modulated by the action 
of protein kinases. For example, it is sensitised by protein kinase C (Grant, Andrew 
D. et al., 2007), protein kinase A (Zhao et al., 2015), serum glucokinase-1 (Lee et 
al., 2010) and src family kinases (Wegierski et al., 2009). In addition, kinases are 
the best candidates for possible members in this signalling pathway as we have 
previously shown that the kinase inhibitors wortmannin and bafetinib inhibited 
the PAR2-dependent opening of TRPV4 (Grace et al., 2014), however both 
inhibitors were only effective at concentrations above which the specific kinase of 
action can be identified (Davies et al., 2000; Rix et al., 2010). This led to the 
hypothesis that protein kinases play a vital role in sensitising and opening TRPV4. 
In order to determine their molecular identity, we used an unbiased siRNA 
knockdown assay to find kinases that are important for the PAR2-dependent 
opening of TRPV4. We established a novel screening approach, measuring 
intracellular calcium levels in real time so that we could monitor calcium influx 
through TRPV4 as well as release of calcium from stores, to decipher the 
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multiphase responses in a high throughput manner and screened all human 
kinases using Dharmacon SMARTpool siRNAs (GE Dharmacon RNAi 
Technologies).  
4.2 Experimental design 
4.2.1 Conditions for the siRNA transfection 
HEK293 TRPV4 cells were assayed in a calcium assay described in the previous 
chapter (see 2.1.6).  
 We initially explored the optimal conditions for the transfection of siRNAs into 
HEK293 cells using multiple concentrations of transfection reagents assessed by 
the function of the available control siRNAs, non-targeting control siRNA (siOTP-
NT) and positive cell-death-inducing control siPLK1. Since the signalling 
pathways in the PAR2-dependent opening of TRPV4 are unknown, we were unable 
to include a known positive control siRNA which inhibits the PAR2-dependent 
opening of TRPV4.  
The screening process was separated into three phases: an initial large screen in 
a 96-well format, assessed HEK+TRPV4 cells where each well was transfected 
with a pool of four individual SMARTpool siRNAs (Human siGENOME RTF – 
Protein Kinases, H-003505) for each of the 721 kinases targets gene per well. 
siRNA library plates were transfected in duplicate. Each plate included controls, 
which consisted of transfection with transfection reagent alone (Mock), non-
targeting control siRNA (siOTP-NT) and positive cell-death-inducing control 
siPLK1. Post transfection the cells were tested for PAR2 responses in calcium 
assays (Figure 4.1).  
Effective siRNAs were identified and used in a confirmation screen with 
SMARTpool deconvoluted siRNAs (individual duplex per gene) were screened at 
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a final concentration of 25nM, in duplicate assays (Figure 4.1). The deconvolution 
process was used to assess the off target effects of the siRNAs, the highest 
confidence siRNAs were those identified from the SMARTpools that had multiple 
individual duplexes that were able to inhibit the signalling process. The final 
validation phase utilised the high confidence siRNAs from the deconvolution 
screen as SMARTpool siRNAs and assessed their function to block the PAR2-
dependent opening of TRPV4 in calcium assays and also confirm the efficacy of the 
siRNAs to knockdown the genes identified by using qPCR analysis of mRNA 
(Figure 4.1). 
 
Figure 4.1 Work flow for siRNA screening process. 
 
4.2.2 Initial identification of effective siRNAs 
siRNAs which we were able to disrupt the signalling between PAR2 and TRPV4 
were called effective. In order to set the limits of functional inhibition, we 
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established the expected thresholds of knockdown for effective siRNAs. The PAR2-
TRPV4 calcium assay measures several different phases of intracellular calcium 
(Figure 4.2). Therefore, identification of siRNAs that were effective in inhibiting 
TRPV4 opening in response to PAR2 activation required controls to confirm that 
the siRNAs had only blocked the PAR2-dependent opening of TRPV4 and that they 
had not affected cell viability or TRPV4 expression, brightfield images were taken 
of each well post calcium imaging for visual verification of cell confluence and 
confirmation of toxic siRNA treatments. Cell confluence was determined visually 
by estimating the percentage of the well that was covered by cells in the field of 
view and assigning a percentage value in 10% increments. A microscope field of 
view (40 X) that was fully covered was assigned a score of 100%, transfections 
were deemed successful if siPLK-1 treatment resulted in 10% or less coverage. 
The non-targeting control, siOTP-NT treatment required at least 90% coverage to 
be acceptable. Only plates which met the confluence requirements were included 
in the primary and the confirmation screens. siRNA library plates were screened 
in duplicate and responses for peak and plateau phases were normalised to the 
transfection reagent control (mock). Gene knockdown that resulted in a reduction 
of the plateau phase (Figure 4.2ii) greater than the response to transfection with 
the non-targeting control (siOTP-NT) but did not reduce the initial peak response 
(Figure 4.2i) were considered as effective and the siRNAs suitable for further 
validation.  
4.2.3 Data analysis 
For all time traces the baseline was defined as the average of the first 3 readings 
prior to agonist injection. The baseline was subtracted from each subsequent time 
point to determine the relative increase in calcium fluorescence (Δ Fluorescence 
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ratio (340/380 nm)). The peak PAR2 response was calculated as the average of the 
three highest readings between 15 s and 40 s (Figure 4.2i). The plateau PAR2 
response was calculated as the area under the curve from 50-80 s (Figure 4.2ii), 
(integrated fluorescence ratio). In the primary screen, we performed duplicate 
assays in a single well for each siRNA sample, on separate plates. To normalise 
results between plates, both the average peak response to the PAR2 agonist for 
each condition (Figure 4.2i) and the averaged integrated plateau response (see 
Figure 4.2ii) were divided by the corresponding average response for all mock 
transfected wells (6 wells) on that plate. All other values are expressed as mean ± 
s.e.m. Intracellular calcium time traces shown in Figure 4.5 and 4.6 collected data 
for full 150 s but we have only presented the first 80 s, the duration of the PAR2-
dependent response, excluding the GSK1016790A response for clarity. The area 
under the curve from 50-80s was calculated and significance was tested using a 
one-way ANOVA with a Dunnett’s post hoc test significance was accepted when 
p<0.05. All statistical analysis used Graphpad Prism 7.0. The qPCR data generated 
by Quantstudio 7 were normalised to the housekeeping gene GAPDH mRNA levels 
for each sample. The relative fold change of mRNA levels was compared to the 
mock transfection conditions, a value of 1 indicating the target had the same 
mRNA level as in the mock transfection.  
Z’-factor calculations: The Z’ factor is a statistical measure of the difference 
between positive and negative controls that is adjusted to take into account 
variation of each control. This is used in high throughput screening to determine 
if an assay has sufficient dynamic range to identify hits as it weighs the effect size 
against the inherent variability in the assay.  
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Where μp and σp are the mean and standard deviation of the plateau phase for 
HEK+TRPV4, μn and σn are the mean and standard deviation of the plateau phase 
for HEK293 cells.  
Coefficient of variation calculation (CV): The coefficient of variation is a quality 
control metric used to evaluate plate to plate variability by reporting on the 
positive and negative control wells per plate. We monitored this since excessive 
variation in the transfection controls would mask the effect of SMARTpool siRNAs 
that were effective at blocking the PAR2-dependent opening of TRPV4. For siRNA 
screening assays a CV < 24% has been shown to have sufficient signal to noise 
ratio to be able to identify effective siRNAs (Birmingham et al., 2009).  
𝐶𝑉 =  
𝜎𝑛
𝜇𝑛
 × 100 
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4.3 Results 
 
4.3.1 PAR2-response in HEK293 cells 
 
HEK+TRPV4 cells we used enabled us to assess the function of TRPV4 in 
comparison to HEK cells. PAR2 is endogenously expressed in these cells and when 
stimulated with the agonist, PAR2-AP (50 μM) it caused calcium to be released 
from stores, seen as a transient, initial peak (Figure 4.2i). HEK+TRPV4 cell 
stimulation with PAR2-AP caused PAR2–dependent calcium release from stores as 
well as a (TRPV4-dependent) sustained influx of extracellular calcium, generating 
a second calcium plateau, as previously described (Grace et al., 2014) (Figure 
4.2ii). When testing the effects of transfection of siRNAs on TRPV4, we assessed 
the initial peak to ensure that siRNAs were not affecting cell viability or PAR2 
function. We first showed that the peak PAR2 responses of the non-targeting 
siRNA control transfected (siOTP-NT), mock transfected and untreated cells, were 
not significantly different (Figure 4.4A). We next assessed the plateau phase of the 
response (Figure 4.2ii), since a reduction of this value would indicate inhibition of 
the PAR2-dependent opening of TRPV4. To prove that treatments did not affect 
TRPV4 function directly, we injected the TRPV4 agonist GSK1016790A (30 nM), 
which normally caused a large sustained influx of intracellular calcium through 
TRPV4 (Figure 4.2iii). An increase of [Ca2+]i greater than 50% from the reading at 
80s (just prior to GSK1016790A injection) was considered to be an 
acceptable.TRPV4 response. 
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Figure 4.2. PAR2-dependent opening of TRPV4 in HEK293 cells. Intracellular 
calcium ([Ca2+]i) levels in response to PAR2-AP (50 µM) and GSK1016790A (30 
nM) in non-transfected HEK293 cells (HEK) and hTRPV4 expressing HEK293 cells 
(HEK+TRPV4). Arrows indicate agonist injections PAR2-AP (50 μΜ) at 15 s and 
GSK1016790A (abbreviated to GSK101; 30 nM) at 80 s. i). Peak response to PAR2-
AP (red), ii). Plateau phase of PAR2-AP response which is TRPV4-dependent 
(green), iii). TRPV4 response to GSK1016790A which is indicative of TRPV4 
function (blue). (N=5)  
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4.3.2 Optimisation of siRNA transfection  
To determine the dynamic range of the PAR2-dependent opening of TRPV4 and to 
confirm we would be able to identify target genes from the screen, we used two 
concentrations of PAR2 agonist and a Z’-factor calculation to compare their 
reliability(Birmingham et al., 2009). We compared the HEK293-TRPV4 cells 
(positive control, 16 wells) with parental cells (negative control, 16 wells). The Z’-
factor comparison of the plateau response of [Ca2+]i between these cell lines was 
performed using two different concentrations of PAR2-AP and we found that 30 
μM PAR2-AP gave a value of 0.43 and 50 μM gave a value of 0.66 . A Z’-factor 
greater than 0.3 is generally considered acceptable for RNAi screens(George et al., 
2013) but a more robust response is desirable, therefore we chose 50 μM as the 
treatment concentration of PAR2-AP.  
We optimised the transfection conditions for the HEK293 cell line using the 
DharmaFECT lipid series 1-4 and settled on DF1 as the most robust. In the absence 
of a biological control, we established the screening conditions using siPLK1 
(Entrez Gene ID, 5347), which induces cell death, as a control, cell viability was 
visually confirmed as a readout for reproducibility each week. We evaluated DF1 
transfection efficiency at increasing concentrations of 0.15, 0.18 and 0.2 μl/well of 
DF1 in a total transfection volume of 100 μl in 96 well plates. Mock transfection 
0.2 μl/well did not reduce cell confluence measured by visual inspection, siPLK1 
treatment reduced the cell number compared to mock transfection at all three DF1 
concentrations (Figure 4.3). We then compared untreated cells (untreated) to 
mock transfection (mock) and to a non-targeting control siRNA (siOTP-NT) and 
neither treatment significantly reduced the plateau phase, PAR2-dependent 
increase in [Ca2+]i, (mock compared to untreated, DF1 0.15 μl/well p= 0.88, 0.18 
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μl/well p= 0.99, 0.2 μl/well p= 0.98), (siOTP-NT compared to untreated, DF1 0.15 
μl/well p= 0.99, 0.18 μl/well p= 0.91, 0.2 μl/well p= 0.97, using ANOVA as 
described in methods) (Figure 4.4A-D). By contrast the siPLK1 control caused a 
significant reduction of the PAR2-dependent increase in [Ca2+]i at all three 
concentrations of DF1 (siPLK1 compared to untreated, DF1 0.15 μl/well p= 0.003, 
0.18 μl/well p= 0.005, 0.2 μl/well p= 0.004, using ANOVA as described in methods) 
(Figure 4.4D). Therefore, we selected 0.2 μl/well of DF1 in a total transfection 
volume of 100 μl. Reduction in the initial PAR2 peak response with siPLK1 
treatment (Figure 4.4A-C) correlated with the reduction of cell confluence (Figure 
4.3) any siRNA identified in the screen which reduced the PAR2 peak to a similar 
extent as siPLK1 treatment we deemed as toxic to cells and were visually verified 
for reduced cell confluence. We used the non-targeting negative control (siOTP-
NT) and the apoptosis-inducing positive control (siPLK1) in columns 1 and 12 of 
each plate and each assay was performed twice.  
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Figure 4.3. Treatment of HEK293 cells with siPLK-1 induced death. 
Brightfield images (40X) of HEK293 cells following mock transfection (top left) or 
treated siPLK1 with DF1 at different concentrations ([DF1] μl/well). Image taken 
at 72 hours post-transfection following the calcium imaging assay. 
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Figure 4.4. siRNA transfection optimisation. A-C Intracellular calcium levels in 
HEK+TRPV4 stimulated with PAR2-AP (50 μM) and GSK1016790A (30 nM). Cells 
are Untreated, treated with mock transfection (Mock) or siRNAs: negative 
transfection control (siOTP-NT), positive death control siPLK1. At different 
concentrations of DF1: A 0.15 μl/well, B 0.18 μl/well and C 0.2 μl/well. D. The area 
under the curve shown in graphs A-C was calculated at 50-80s, normalised to 
Untreated cells and expressed as a percentage. (N=4)  
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4.3.3 Screening the kinase siRNAs for inhibition of PAR2-dependent TRPV4 opening  
4.3.4 Primary screen 
We screened 721 SMARTpool siRNAs targeting kinases in a 96-well plate format. 
Plates were controlled each week by inclusion of 2 positive (siPLK1) and 2 
negative (siOTP-NT) controls which were compared to 6 mock transfections per 
plate. For each gene knockdown we reviewed the calcium response curves, 
quantifying the PAR2 responses, the peak response from 15-40 s and the plateau 
response as the area under the curve 50-80 s as shown in Figure 4.2 and 4.3. The 
effect of the non-targeting control siRNA (siOTP-NT) was assessed for across the 
18 plates screened and when normalised to the average mock transfection control 
wells, we calculated a peak response of 92.8 ± 1.6%, with a CV 7.4% (standard 
deviation of 6.9%) and a plateau response of 90.6 ± 1.6% with a robust CV of 
7.02%, which was well within thresholds from other siRNA screens(Birmingham 
et al., 2009). Based on the siOTP-NT response, we set the threshold for 
identification of an effective siRNA as having a PAR2 peak response within two 
standard deviations of the mean (i.e. >79%) and having a plateau response 
(integrated from 50-80 s) less than mean plateau phase of the siOTP-NT control 
treatment (mean of 90%). A representative trace for cells treated with an siRNA 
irrelevant to TRPV4 function, RPS6KA5 (“non-hit”), shows the siRNA had no effect 
on either the peak (100%) or plateau phase (102%), that is it was not toxic to PAR2 
activation and did not inhibit signalling to TRPV4 (Figure 4.5A). By contrast, 
knockdown of siRNA for the “hit”, MAPK13, did not affect the initial PAR2 peak 
response (98%), but did reduce the plateau phase to 87% when normalised to 
mock (Figure 4.5A). Values for the plateau phase were averaged and normalised 
to the mock transfection for assessment of the peak and plateau responses (Figure 
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4.5B). We identified 33 genes that fell within these defined thresholds which were 
ranked according to their ability to inhibit the plateau phase, the PAR2-dependent 
opening of TRPV4 (Table 4.1). 
This screen also identified 2 potentially toxic siRNAs; diacylglycerol kinase kappa 
(DGKK) and checkpoint kinase 1 (CHEK1). These siRNAs reduced the initial PAR2 
peak response and the GSK101 response to a similar extent as siPLK1 treatment, 
as these responses are independent it indicated that knockdown of these kinases 
is affecting cell number in the well. However further confirmation of cytotoxicity 
needs to be confirmed. The full data set is reported in the PubChem repository 
(AID 25549). 
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Figure 4.5. Representative trace of Intracellular calcium for selected targets. 
A. Represents [Ca2+]i levels in response to PAR2-AP (50 μM) in HEK+TRPV4 
treated with mock transfection (Mock), the non-targeting control (siOTP-NT), an 
ineffective siRNA, a “non-hit” siRSP6KA5 and an siRNA which effectively 
attenuated the PAR2-dependent opening of TRPV4, siMAPK13 a “hit”. Note the 
curves in this figure are only shown up to 80 s. B. Quantitation of the PAR2-
dependent opening of TRPV4 shown in A (highlighted as gray areas) represented 
as the area under the curves from 50-80 s, normalised to the Mock and expressed 
as a percentage. Values are reported as mean of N=2 biological replicates.  
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4.3.5 Confirmation of the SMARTpool siRNA screen 
We took the 33 hits from the primary SMARTpool screen and performed a 
secondary confirmation screen by deconvolution of the SMARTpool into its 4 
constituent siRNAs. Each individual duplex siRNA was re-screened in the same 
assay, and were scored using the same defined thresholds identified in the 
primary screen. Targets were considered a high confidence hit if 3 or more of the 
siRNAs scored the same as the SMARTpool (Table 4.2).  
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EntrezGene 
Symbol 
EntrezGene 
ID 
Peak > 79% Plateau < 90% 
SIK2 23235 80 71 
NEK7 140609 87 79 
ITPK1 3705 92 79 
FASTK 10922 86 82 
RIPK2 8767 84 82 
FGFR4 2264 94 82 
HK2 3099 91 82 
SRMS 6725 92 82 
EFNB3 1949 91 83 
BUB1 699 79 84 
PRKAB2 5565 95 85 
ACVRL1 94 96 85 
NEK2 4751 90 85 
TAF1L 138474 88 85 
UMP-CMPK 51727 90 86 
STK39 27347 89 86 
ALS2CR7 65061 89 86 
MAPK9 5601 90 86 
PIK3C3 5289 97 86 
IGF2R 3482 98 87 
KIAA0999 23387 93 87 
MAPK13 5603 98 87 
PTK9L 11344 87 87 
SAST 22983 92 87 
WNK4 65266 99 87 
LYK5 92335 94 87 
PIK3C2A 5286 93 87 
MLKL 197259 98 88 
CAMKK1 84254 102 88 
COMMD3 23412 91 88 
STK29 9024 91 88 
CHKA 1119 88 89 
PLK4 10733 95 89 
Table 4.1. Effective siRNAs from the initial screen of the kinome for 
signalling molecules between PAR2 and TRPV4. Entrez gene symbol and gene 
ID are listed alongside the peak and plateau response of [Ca2+]i to PAR2-AP (50 μM) 
in HEK+TRPV4. Duplicate responses for a given treatment were averaged and 
normalised to the mock transfection and expressed as a percentage. Hits were 
ranked by their ability to inhibit the plateau phase. The thresholds for effective 
siRNA treatments were a peak response > 79% and a plateau response < 90% of 
mock control.  
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Confidence 
siRNA 
Target 
Entrez 
ID 
Individual siRNA hits 
High BUB1 699 3/4 
  ITPK1 3705 3/4 
  MAPK13 5603 3/4 
  WNK4 65266 3/4 
Medium SAST 22983 2/4 
  MLKL 197259 2/4 
  SRMS 6725 2/4 
Low CAMKK1 84254 1/4 
  FASTK 10922 1/4 
  HK2 3099 1/4 
  MAPK9 5601 1/4 
  PIK3C3 5289 1/4 
  PRKAB2 5565 1/4 
  SIK2 23235 1/4 
Table 4.2. Deconvolution screen for primary screen hits. Targets were given 
a confidence ranking dependent on the number of effective individual duplex 
siRNAs identified from each SMARTpool (out of 4) when measuring PAR2-
dependent opening of TRPV4.  
4.3.6 Confirmation of high confidence hits 
After the SMARTpool deconvolution we identified 4 high confidence hits, BUB1 
(budding uninhibited by benzimidazoles 1), ITPK1 (inositol tetrakisphosphate 1-
kinase), WNK4 (with no lysine kinase 4) and MAPK13 (mitogen activated kinase 
13), involved in the PAR2-dependent opening of TRPV4. To further validate these 
hits we returned to the SMARTpool siRNA format and transfected 6 wells per 
target gene to generate sufficient material for qPCR evaluation of gene expression 
after we measured the calcium signalling and we compared the results. 
Independent knockdown of ITPK1, MAPK13 and WNK4 caused a significant 
reduction of the PAR2-dependent opening of TRPV4 by attenuating the plateau 
phase Δ[Ca2+]I (Figure 4.6B-D) to 49.2 ± 2.9%, 34.12 ± 2.0% and 50.28 ± 2.4% 
respectively when normalised to mock transfection (compared to siOTP-NT using 
ANOVA as described in methods: ITPK1, MAPK13 and WNK4 had p< 0.002) 
(Figure 4.7). Conversely knockdown of BUB1 did not cause a significant reduction 
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to the plateau phase in response to PAR2-AP in this assay, 63.1 ± 2.8% when 
normalised to mock transfection, (compared to siOTP-NT using ANOVA as 
described in methods, BUB1 p= 0.12) (Figure 4.6A, 4.7). Confirmation of on-target 
activity was evaluated by RT-PCR at 72 hours post transfection (Table 4.3). All the 
high confidence targets were expressed in HEK293 cells with threshold values 
above controls and knockdown with siBUB1, siMAPK13 and siWNK4 significantly 
reduced the mRNA levels when compared to the siOTP-NT. However, knockdown 
of ITPK1 did not cause a significant reduction of mRNA (Table 4.3). Without 
detailed off-target analysis, we have concluded that ITPK1 and BUB1 require 
further validation, whereas MAPK13 and WNK4 are robust targets for modulation 
of TRPV4. 
 
 
siRNA treatment Gene Target Fold change of 
mRNA expression 
p-value 
siOTP-NT BUB1 1.0 ± 0.42 p = 0.009 
siBUB1 BUB1 0.17 ± 0.05 
siOTP-NT ITPK1 0.61 ± 0.26 p = 0.198 
siITPK1 ITPK1 0.16 ± 0.11 
siOTP-NT MAPK13 0.99 ± 0.32 p = 0.003 
siMAPK13 MAPK13 0.04 ± 0.02 
siOTP-NT WNK4 1.04 ± 0.33 p = 0.02  
siWNK4 WNK4 0.23 ± 0.11 
Table 4.3. Quantitative PCR data for relative levels of mRNA expression in 
HEK293 cells treated with siRNA for specific gene targets. Significance was 
defined as a p< 0.05, using one-way ANOVA, Dunnett’s post hoc test compared fold 
change from control siOTP-NT to si for each gene, N=5. 
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Figure 4.6. Key signalling molecules in the PAR2-dependent opening of 
TRPV4 in HEK293 cells. Graphs A-D Represent [Ca2+]i levels in response to 
PAR2-AP (50 μM) HEK+TRPV4 treated with either non-targeting control siOTP-NT 
(siOTP- NT) or SMARTpool siRNA for specific gene targets. Note the curves in this 
figure are only shown up to 80 s. A siBUB1. B. siITPK1. C. siMAPK13. D. siWNK4.  
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Figure 4.7. siRNA targeting BUB1, ITPK1, MAPK13, WNK4 significantly 
inhibited the PAR2-dependent opening of TRPV4. The area under the curve 
from graphs Figure 4.6 A-D from 50-80s normalised to the Mock as a percentage, 
which represents the TRPV4 component of the increase in [Ca2+]i showed a 
significant difference between OTP-NT siRNA treatment and the four genes of 
interest, * p<0.05 compared to OTP-NT, Oneway ANOVA, Dunnett’s posthoc test 
(N=5). 
4.4 Discussion 
 
Here, we have used a real-time functional assay and siRNA knockdown to identify 
kinases that modulate the opening of TRPV4 by PAR2-activation in HEK293 cells. 
In combination with siRNA transfection, the intracellular calcium assay is even 
more demanding than most end-point assays, so its development required 
multiple steps of optimisation. These included identifying optimal siRNA 
transfection conditions, appropriate on-plate controls for transfection and 
assessment of siRNA function, well to well variation, cell viability and off-target 
effects.  
Polo-like kinase 1 (PLK1), a regulator of mitotic cell division, induces apoptosis in 
cancer cells (Spankuch-Schmitt et al., 2002) and was used as a control siRNA as it 
also killed HEK293 cells. Using siPLK1 we monitored the efficacy of transfection 
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on each plate by measuring the remaining cell density after transfection. If the 
treatment with siPLK1 did not reduce the cell count by 90%, then the results from 
that transfection were rejected. We assessed the coefficient of variance (CV) 
values of the PAR2 plateau responses between transfections, to ensure the assay 
variability was within strict parameters, CV < 24% (Birmingham et al., 2009) so 
an effective difference in [Ca2+]i could be assessed. The use of these controls gave 
us confidence in the assay results. We have used a novel screening assay that can 
dissect a real-time, multiphase cellular response to TRPV4 stimuli, enabling us to 
use a systematic approach to define the processes involved, and to identify 
molecular targets in this signalling pathway. 
We identified 2 kinases, MAPK13 and WNK4, as novel kinases involved in the 
PAR2-dependent opening of TRPV4. The approach we have used will enable 
identification of other signalling proteins which play an important role in opening 
TRP ion channels by signalling processes in HEK293 cells and in other cell types. 
However, we need to interpret our negative results with the understanding that a 
lack of inhibition from a particular SMARTpool siRNA does not prove that the 
target was unimportant in all cell types and assay conditions. We consider that the 
two genes identified in the current study are likely to play an important role the 
PAR2-dependent opening of TRPV4 in a variety of cell types and we are actively 
investigating this possibility.  
WNK4 has previously been linked to TRPV4 expression and function in 
hypertension (Gamba, 2006) and it has been shown to downregulate cell surface 
expression of TRPV4 in HEK293 cells (Fu et al., 2006). We observed that the 
knockdown of WNK4 expression caused a decrease in the PAR2-dependent 
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opening of TRPV4, which confirms a functional interaction between TRPV4 and 
WNK4.  
Both MAPK13 and TRPV4 are implicated in UV-induced pain (Moore et al., 2013) 
and are activated by UV irradiation in keratinocytes (Efimova, 2010). Like TRPV4, 
MAPK13 is activated by osmotic stress (Efimova, 2010; Liedtke, W. et al., 2000; 
Vriens et al., 2004b). Thus there is a coincidental activation of these proteins by 
the same stimuli in the same cells that has been overlooked until now, these 
results confirm the link between the two.  
Several hits from the confirmation screen were not verified but are of note. For 
example, the mixed lineage kinase domain-like protein (MLKL) was a medium 
confidence hit and has been reported as a pseudokinase which has ion channel 
activity in HEK293 cells (Latorre et al., 2009) and has been shown to be an active 
upstream of an ion channel TRPM7 (Cai et al., 2014).  
TRPV4 contains a carboxy-terminus PDZ-like domain (Garcia-Elias et al., 2008). 
The medium confidence hit, microtubule associated serine/threonine kinase 1 
(SAST), is a PDZ-domain binding protein (Lumeng et al., 1999) which suggests a 
potential mode of interaction for the regulation of TRPV4 function.  
Kinases such as PKC, PKA and SGK-1 (Grant, Andrew D. et al., 2007; Lee et al., 
2010) which have been linked to TRPV4 function were not identified as targets in 
this screen. Previously identified kinases that interact with TRPV4 were found 
using protein interaction or activation with specific TRPV4 agonist or hypotonic 
stress, whereas we have uniquely focused on the PAR2-dependent opening of 
TRPV4, which is likely to be mechanistically different. For instance it has been 
shown that inhibition of PKC did not block the PAR2-dependent opening of TRPV4 
(Poole et al., 2013). In addition, the nature of the assay we describe here means 
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that there will be also be false negatives. For this reason, the genes for siRNAs that 
were ineffective at blocking the PAR2-dependent opening of TRPV4 were not 
eliminated as potential candidates but they were not prioritized in the current 
study.  
The confirmation screen, using individual deconvoluted SMARTpool siRNAs, 
enabled the identification of false positive siRNAs from the primary screen. 
However, the identification of siBUB1 as an siRNA which caused significant 
reduction of mRNA but did not significantly inhibit the PAR2-dependent opening 
of TRPV4, and siITPK1 which caused a significant reduction of PAR2-dependent 
opening of TRPV4 without a significant reduction in mRNA are examples of false 
positives. These confounding results highlighted the need for further validation of 
these identified targets, potentially using CRISPR knockout of the relevant genes, 
however, these experiments were not within the scope of this project.  
We have stored the full data set annotated from the primary and confirmation 
screens on PubChem (AID 25549). The unbiased assay methodology described 
has uniquely enabled the identification of novel enzymes in the PAR2-TRPV4 
signalling pathway, whereas previous studies have used a candidate based 
approach, using small molecule inhibitors to identify specific modulation of the 
pathway. This novel assay overcomes some of the ambiguities associated with 
using chemical inhibitors to dissect signalling pathways, which we have 
previously identified as an issue (Grace et al., 2014). 
This novel screen has helped to identify kinases which are important in the PAR2 
activation-dependent opening of TRPV4 in HEK293 cells. We believe that this 
approach will be useful to identify other upstream components of GPCR signalling 
which have a major role in TRPV4 opening, such as heterotrimeric G protein 
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subunits and phospholipases. Functional assays such as the one described here, 
are a general approach that is well suited to identifying functional components of 
intracellular pathways that regulate proteins which control intracellular calcium 
levels.  
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5 G-proteins and GPCR associated signalling molecules that 
are involved in the PAR2-dependent opening of TRPV4  
5.1 Introduction 
In the previous chapter we identified kinases that are involved in the PAR2-
dependent opening of TRPV4. In doing so, we demonstrated that a broad 
discovery-based approach could be applied to a medium throughput assay, 
measuring the calcium responses of live cells. In this chapter we aimed to further 
dissect the signalling pathways initiated by PAR2 that lead to the opening of 
TRPV4. 
Thus far we have discovered that Gαq signalling is not crucial for the PAR2-
dependent opening of TRPV4 but at least two kinases are. There are several 
published studies implicating Gα-signalling pathways that can affect the function 
of TRPV4 when stimulated with GSK1016790A and hypotonic stress (Ducret et al., 
2008; Garcia-Elias et al., 2013; Grant, Andrew D. et al., 2007). Ηοwever, the 
identity of the signalling components that initiate the receptor-dependent 
opening of TRPV4 remain unknown. In addition, arachidonic acid metabolites and 
other poly unsaturated fatty acids have been postulated as the endogenous 
agonists for TRPV4 (Watanabe et al., 2003). Lastly TRPV4 function has been 
identified to be regulated by PKA (Ducret et al., 2008) and PKC (Adapala et al., 
2011) these findings indicate that the activation of adenylate cyclase and 
phospholipase C, may be involved in the receptor-mediated opening of TRPV4.   
Hence, to further elucidate how activation of PAR2 is able to open TRPV4 in 
HEK293 cells, 93 targets were selected and screened in an siRNA screen. To assess 
G-proteins function we targeted the 15 Gα-variants and isoforms, 7 Gβ-variants 
and isoforms, 12 Gγ-variants and isoforms to ascertain the composition of the 
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heteromeric G-proteins that PAR2 activates. To target the generation of 
arachidonic acid metabolites 21 Phospholipase A2 variants and isoforms were 
targeted. To assess the generation of other fatty acids second messenger 18 
Phospholipase C variants and isoforms, 7 Phospholipase D variants and isoforms, 
9 adenylate cyclase variants and isoforms were targeted. Finally, the 2 β-arrestins 
isoforms were targeted to determine whether they are the origin of the signal that 
can open TRPV4 after PAR2 stimulation. 
5.2 Experimental design 
 
This screen was performed as described in the previous chapter (Chapter 4.2). 
However, there were some key differences. Results from the initial screen were 
identified using the previously described criteria: effective siRNA were 
determined as treatments which had no effect on the initial peak response to 
PAR2-AP (50 μM) but reduced the plateau phase (50-80 s) greater than the 
missense control (siOTP-NT). Due to the lower number of targets, the initial 
screen consisted of four biological replicates for each target, unlike the original 
screen for kinases. The increased number of replicates from the initial screen 
allowed for significance to be determined for all effective siRNAs identified.  
The reduced number of effective siRNAs identified from the screen meant that a 
confirmation-deconvolution screen was not required. siRNA SMARTpools for 
identified hits were purchased and tested for function in blocking the PAR2-
dependent opening of TRPV4 and the effective knockdown of target gene was 
determined by qPCR. 
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5.3 Results 
Initial screen results indicated that knockdown of Gα13, Gγ8, PLA2G4A and PLCDX3 
impaired the PAR2-dependent opening of TRPV4 in HEK293 cells. To determine the 
effect of transfection across screening plates on-plate controls were used as an 
indication of successful siRNA transfection. The intracellular calcium levels in 
response to PAR2-AP (50 μM) when compared to the lipid only transfection 
(Mock) were not altered by the missense control (siOTP-NT) (Figure 5.1). 
Knockdown of the kinase PLK-1 induces death in the cells, responses to PAR2-AP 
(50 μM) both the initial peak response and the sustained plateau phase in HEK293 
cells treated with siPLK-1 were abolished (Figure 5.1A, B) due to a greatly reduced 
cell number in the well due to cells death and is indicative of successful siRNA 
transfection. An active siRNA identified in the previous kinome screen was used 
as a positive biological control (siMAPK13) in this screen. Cells transfected with 
MAPK13 showed impaired PAR2-dependent opening of TRPV4 (Figure 5.1A), the 
significant reduction of plateau phase (Figure 5.1B) indicated that the transfection 
protocol was satisfactory and that siRNAs were functional.  
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Figure 5.1. Evaluation of on-plate controls for G-protein siRNA screen. A. The 
relative intracellular Ca2+ levels (fluorescence ratio 340/380 nm) in response to 
PAR2-AP (50 μM) in HEK+TRPV4 treated with SMARTpool siRNA, negative 
missense control (siOTP-NT), positive transfection control (siPLK-1) and an active 
siRNA from the kinase screen siMAPK13 compared to the lipid only treatment 
(Mock) B. Data derived from graph A, the area under the curve from graphs from 
50-80 s which represents the TRPV4 component of the increase in [Ca2+]i showed 
a significant difference between Control siRNA treatment and control treatments, 
* p<0.05 compared to Control, Oneway ANOVA, Dunnett’s posthoc test. (N=4). 
 
Of the 93 targets assessed 4 targets significantly inhibited the PAR2-dependent 
opening of TRPV4: G protein α13 (siGNA13) (Figure 5.2A), G-protein γ8 (siGNG8) 
(Figure 5.2B), phospholipase A2 group 4A (siPLA2G4A)(Figure 5.2C), 
phospholipase C group 10 D3 (siPLCXD3) (Figure 5.2B) when compared to Mock 
treatment with these siRNAs caused a reduction of the PAR2-dependent opening 
of TRPV4 by 40.5%, 53.4%, 31.3% and 39.8% respectively (Figure 5.3). However, 
this was only the initial screen and the results needed to be validated using more 
technical replicates and qPCR needed to be performed to confirm knockdown of 
mRNA. 
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Figure 5.2. Identification of key signalling molecules in the PAR2-dependent 
opening of TRPV4 in HEK293 cells from initial screening process. Graphs A-
D Represent intracellular Ca2+ levels in response to PAR2-AP (50 μM) in 
HEK+TRPV4 treated with SMARTpool siRNA for specific gene targets compared to 
missense control (siOTP-NT). A. siGΝΑ13. B. siGNG8. C. siPLCXD3. D. siPLA2G4A. 
(N=4)  
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Figure 5.3. Effective siRNAs from initial screen significantly inhibited the 
PAR2-dependent opening of TRPV4. Data derived from Figure 5.2, The area 
under the curve from graphs A-E from 50-80 s which represents the TRPV4 
component of the increase in [Ca2+]i showed a significant difference between 
Control siRNA treatment and the four genes of interest, * p<0.05 compared to 
Control, Oneway ANOVA, Dunnett’s posthoc test. (N=4) 
 
SMARTpool validation. Knockdown of Gα13 in HEK+TRPV4 caused a significant 
reduction in the PAR2-dependent opening of TRPV4 (Figure 5.4A), reducing the 
change in [Ca2+]i by 56.7% (Figure 5.5). This knockdown was confirmed using 
qPCR mRNA for Gα13 was detected in samples treated with missense siRNA and 
siRNA targeted to Gα13 caused a significant reduction of the mRNA expressed in 
cells compared to cells treated with missense siRNA(Table 5.1). Cells treated with 
Gγ8 siRNA showed significant reduction, 64.3%, of the TRPV4 dependent change 
in [Ca2+]i in response to PAR2-AP in HEK+TRPV4 cells (Figures 5.4B and 5.5). This 
knockdown was confirmed by qPCR, however Gγ8 was expressed at low levels in 
these cells which made the qPCR quite variable, none the less the difference in 
mRNA expression was significantly different in cells treated with Gγ8 siRNA 
compared to cells treated with missense siRNA (Table 5.1). HEK+TRPV4 cells 
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treated with siRNA targeted at PLA2G4A showed a significantly smaller TRPV4-
dependent response to PAR2-AP (50 μM) than cells treated with missense siRNA 
(Figures 5.4C) the response was reduced by 51.1% (Figure 5.5). This knockdown 
was confirmed using qPCR with the mRNA of PLA2G4A detected in cells treated 
with missense siRNA and siRNA targeted at PLA2G4A and this expression was 
significantly reduced in the later (Table5.1). Lastly, HEK+TRPV4 cells treated with 
siRNA PLCXD3 had a significantly smaller change in [Ca2+]i in TRPV4-dependent 
sustained phase of the PAR2 response (Figures 5.4D) reduced by 51.8% (Figure 
5.5). However, this knockdown was not confirmed by qPCR results as the PLCXD3 
mRNA was not detectable in these samples (Table 5.1) indicating that it is not 
expressed in these cells, or this primer was not effective at detecting PLCXD3 in 
these cells and so we did not include this siRNA pool in further studies. 
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Figure 5.4. SMARTpool Validation of key signalling molecules in the PAR2-
dependent opening of TRPV4 in HEK293 cells. Graphs A-D Represent [Ca2+]i 
levels in response to PAR2-AP (50 μM) HEK+TRPV4 treated with SMARTpool 
siRNA for specific gene targets or the missense control (siOTP-NT). A. the g-alpha 
13 protein (siGNA13). B. the g-gamma 8 protein (siGNG8). C. Phospholipase A2 
group 4A protein (siPLA2G4A). D. Phospholipase C group X D3 protein 
(siPLCXD3). (N=5) 
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Figure 5.5. siRNA knockdown of GNA13, GNG8, PLA2G4A and PLCXD3 blocks 
the PAR2-dependent opening of TRPV4. Data derived from Figure 5.4, the area 
under the curve from graphs A-D from 50-80s which represents the TRPV4 
component of the increase in [Ca2+]i showed a significant difference between 
Control siRNA treatment and the four genes of interest, * p<0.05 compared to 
Control, Oneway ANOVA, Dunnett’s posthoc test. (N=5) 
 
 
 
 
siRNA 
treatment 
PCR Target  Average Ct Fold change  p-value 
siOTP-NT Gα13 24.8 ± 0.6  0.87 ± 0.2 p= 0.022 
Gα13 Gα13 26.5 ± 1.3 0.15 ± 0.05 
siOTP-NT Gγ8 31.4 ± 1.0 1.59 ± 0.8 p= 0.0075 
Gγ8 Gγ8 31.2 ± 2.4 0.46 ± 0.12 
siOTP-NT PLA2G4A 27.7 ± 0.6 0.89 ± 0.3 P= 0.030 
PLA2G4A PLA2G4A 29.4 ± 2.2 0.04 ± 0.00 
siOTP-NT PLCXD3 Undetected N/A N/A 
PLCXD3 PLCXD3 Undetected N/A 
Table 5.1. Quantitative PCR data for relative levels of mRNA expression in 
HEK293 cells treated with siRNA for specific gene targets. Significance was 
defined as a p< 0.05, using one-way ANOVA, Dunnett’s post hoc test compared fold 
change from Mock for siOTP-NT to fold change from Mock for siRNA of each gene, 
N=5. 
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5.4 Discussion 
Similar to the previous chapter the use of siRNA to screen for specific identities of 
the signalling molecules involved in the PAR2-dependent opening of TRPV4 was 
successful. It is important to understand that this study considered the positive 
results for this signalling process, and the targets of siRNA which had no effect 
may be false negative results. Three gene targets Gα13, Gγ8 and PLA2G4A were 
identified by calcium assay and knockdown was confirmed by qPCR analysis of 
mRNA expression.  
These genes are considered to be crucial for the PAR2-dependent opening of 
TRPV4 because the sequence of events for the siRNA technology to be successful 
to the extent seen in our assays requires multiple factors to align. For instance; the 
half-life of a protein in the cell to be shorter than the assay duration so the 
knockdown will sufficiently reduce the protein level in the cell, the expression of 
other isoforms of that specific protein or other signalling pathways that can confer 
redundancy in the system and the efficacy of the siRNA itself must all be taken in 
to account. Ideally, the level of knockdown should be measured from the 
decreased level of protein expression, however, because of the lack of validated, 
specific antibodies for western blot analysis for the identified proteins, the best 
level of analysis we could achieve was to have a relative measure of protein 
expression from mRNA levels using qPCR. Despite these caveats, the use of 
stringent plate based controls and extensive optimisation before the screens were 
performed gave the best chance for success. We used the same controls as 
previously described but in addition we included MAPK13 siRNA on each plate as 
a positive control for inhibition of signalling and for siRNA transfection. These 
controls established confidence in the assay and the results derived from it.  
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Guanidine nucleotide binding protein alpha 13 (Gα13) an alpha subunit in the 
heterotrimeric G-protein subunit  binds to PAR2 and has been linked to PAR2-
activation in multiple cell types (Bunnett, 2006), which suggests that it is a rational 
candidate for signal transduction in the TRPV4 signalling pathway. Gα13 activates 
the RhoA and subsequent rho kinase pathways and a key indicator of the 
downstream activation is the increased MAPK and ERK phosphorylation 
(Ramachandran et al., 2011). PAR2 activation by neutrophil elastase sensitises 
TRPV4 to its agonist GSK1016790A (Sostegni et al., 2015) which, was the first link 
between the Gα13 associated pathways signalling and TRPV4, but this study is the 
first occasion where Gα13 has been directly linked to the opening of TRPV4. 
Although, the rho kinase inhibitor Y27632 does not inhibit the PAR2-dependent 
opening of TRPV4 in HEK293 cells (Poole et al., 2013), so therefore the Gα13 
initiates the opening of TRPV4 through a Rho kinase independent pathway.  
The novel finding that Gα13 signalling is necessary for PAR2 to open TRPV4, 
indicates that disease models where TRPV4 and Gα13 have been independently 
identified as involved, maybe physiologically relevant setting for the receptor-
dependent opening of TRPV4. Recently Gα13, has been linked to the epithelial to 
mesenchymal transition (EMT) of pancreatic cancer cells (Gardner et al., 2013), 
and gastric cancer cells (Zhang et al., 2016). In multiple cell lines derived from 
pancreatic cancer patients Gα13 was crucial for migration of the cell lines, 
inhibition of function via knockdown and the expression of a dominant negative 
form of Gα13 inhibited the lysophosphatidic acid induced migration of these cell 
lines (Gardner et al., 2013). Since the knockdown of TRPV4 in EMT in breast 
cancer cell lines reduced tumour size in xenografts (Lee et al., 2016) it is possible 
that the link between TRPV4 and Gα13 in EMT may be an interesting avenue for 
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better understanding the disease. However, it also highlights the necessity to 
decipher this signalling pathway between GPCRs and TRPV4, because it has also 
been shown that activation of TRPV4 reduces angiogenesis via modulation of rho 
kinase pathway in tumour endothelial cells indicating that the direct 
pharmacological inhibition of TRPV4 may have a negative prognosis in the cancer. 
In this setting it is possible that signalling pathways which can open and sensitise 
TRPV4, will be more promising targets for therapies.  
There is very little information about the functional significance of guanine 
nucleotide binding protein γ8 (Gy8) in the literature, other than it is encoded by a 
gene on chromosome 8. There is no specific information about expression 
patterns in the body or specific signalling processes in which it is involved. All Gγ-
proteins are isoprenylated at a conserved cys residue; motif CAAX, at the carboxyl 
terminus, this modification is responsible for anchoring the Gβγ-complex to the 
membrane and also regulates composition of the Gαβγ-complex and the receptors 
to which it can couple (Schwindinger and Robishaw, 2001). Potentially the Gγ8 
subunit confers specific connection between PAR2-Gα13 and the signalling 
pathway that opens TRPV4. 
The final target that we identified and confirmed was phospholipase-A2-G4A 
(PLA2G4A) which is a cytosolic PLA2α (cPLA2α), a calcium-dependent isoform of 
PLA2. Phosphorylation of cPLA2α induces the translocation of the enzyme from 
the cytosol to the ER, Golgi apparatus and perinuclear vesicles where it associates 
with arachidonic acid releasing it from these membranes enabling the break down 
into critical metabolites by adjacent enzymes (Niknami et al., 2009). Although 
greatly contested since, the initial evidence suggested that TRPV4’s endogenous 
agonist is an arachidonic acid metabolite converted by cytochrome P450s to EETs 
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(Watanabe et al., 2003), there is now clear evidence that indeed EETs can bind to 
TRPV4 (Berna-Erro et al., 2017) the discovery of cPLA2α as a key signalling 
molecule in the PAR2-dependent opening of TRPV4 indicates that the generation 
of EETs maybe be critical for this signalling process. cPLA2α is expressed widely 
in the body, including in the vascular endothelium. In a study of the arachidonic 
acid metabolite profiles from endothelial cells of healthy individuals and two 
siblings that are cPLA2α deficient showed that the generation of eicosanoids was 
significantly reduced in the absence of cPLA2α (Kirkby et al., 2015). Given the 
prevalence of TRPV4 expression and function in the vascular endothelium and 
TRPV4’s endogenous agonist have been postulated as arachidonic acid 
metabolites, the discovery that PLA2G4A knockdown reduces the PAR2-
dependent opening of TRPV4 shows a potentially key role for this signalling 
pathway in vascular function. cPLA2 is activated by TRPV4 in endothelial cells to 
cause aortic contractions in hypertensive mice (Zhang et al., 2018), this is 
evidence of an interaction between TRPV4 and cPLA2 in the vascular endothelium.   
However, the reason why PLA2G4A was the only PLA2 identified in this study was 
not obvious. The subcellular localisation of the enzyme may position it in close 
proximity to TRPV4, association with specific secondary enzymes critical for 
generating the agonist for TRPV4 or potentially the expression of this isoform is 
the predominate form in these HEK293 cells. Although outside the scope of this 
study identifying the characteristics of PLA2G4A which link it to the PAR2-
dependent opening of TRPV4 could help elucidate this signalling pathway.  
We have identified a novel signalling pathway, whereby Gα13 /Gγ8 activation by 
PAR2 leads to the activation of cPLA2α and the opening of TRPV4 (Figure 5.6.). This 
study aimed to elucidate the signalling mechanisms between PAR2 and TRPV4 and 
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now the beginning of the process is emerging. Although no clear links are to be 
found in the current literature, the interactions between the signalling molecules 
identified in this chapter and the kinases identified in the previous chapter could 
help to decipher the molecular mechanisms of TRPV4 opening and these novel 
pathways could be novel therapeutic targets. 
 
Figure 5.6. Novel signalling components in the PAR2-dependent opening of 
TRPV4. The signalling molecules newly identified to be involved in PAR2-
activation in HEK293 cells and that lead to the opening of TRPV4. Abbreviation: 
Protease-activated receptor 2 (PAR2), Guanidine nucleotide binding protein α 13 
(Gα13), Guanidine nucleotide binding protein γ 8 (Gγ8), cytosolic phospholipase 
A2α (PLA2G4A), Transient receptor potential vanilloid-4 (TRPV4).  
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6 Identifying GPCRs that can signal to and open TRPV4 in 
HEK293 cells 
 
6.1 Introduction 
The previous chapters have identified novel signalling pathways by which 
activation of the PAR2 receptor can open TRPV4. This work was completed in 
HEK293 TRex cells, a heterogeneous cellular expression system which results in 
high levels of expressed receptors. Although this system has been useful to 
decipher this complicated signalling pathway it may or may not have physiological 
relevance. In this chapter we will determine which GPCRs that have been 
identified to interact with TRPV4 in a physiological or pathophysiological setting, 
are able to open TRPV4.  
Alessandri-Haber and colleagues (2006) identified TRPV4 as a key mediator in 
mechanical hyperalgesia in the response to multiple GPCR agonists in an 
‘inflammatory soup’ consisting of bradykinin, prostaglandin E2, and substance P 
(Alessandri-Haber et al., 2006). We assessed the predominant receptor subtypes 
for these agonists expressed in dorsal root ganglion. Pain responses to Bradykinin 
and its derivatives are among the most painful substances known, their activities 
are mediated by the BK1 receptor and the BK2 receptors, both of which are 
expressed in dorsal root ganglion neurons, stimulation of these receptors 
sensitizes TRPV4 in mechanical hyperalgesia (Costa et al., 2018). Prostaglandin 
receptors EP1 to 4 are all expressed in dorsal root ganglion neurons (Oida et al., 
1995). The EP4 receptor was shown to mediate behavioural pain sensitivity to 
thermal and mechanical stimuli without altering basal sensitivity (Lin et al., 2006) 
which is similar to the TRPV4-dependent hyperalgesia identified above 
(Alessandri-Haber et al., 2006). Hence, the EP4 receptor was selected as a 
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potential prostaglandin receptor that can open TRPV4. Neurokinin 1 receptor 
(NK1) activation by substance P was assessed for its ability to open TRPV4 
because of its role in pain (Garcia-Recio et al., 2015) and it has been shown to be 
expressed in dorsal root ganglion (Andoh et al., 1996; Li and Zhao, 1998). 
The role of TRPV4 in ACh-induced vasodilatation has been identified in multiple 
studies (Adapala et al., 2011; Bagher et al., 2012). The major functional subtype of 
muscarinic receptor expressed in the vascular endothelium and vasodilatation is 
the M3 receptor (Gericke et al., 2011).  
In addition, differential effects of purinergic receptors in GPCR-dependent 
opening of TRPV4 systems have also been identified. In aldosterone sensitive 
distal nephron cells, P2Y2 receptor activation opened TRPV4 when stimulated 
with ATP (Mamenko et al., 2011). In contrast it has been shown that endogenous 
purinergic receptors in HEK293 cells, most likely P2Y11 and P2Y12 (Atwood et 
al., 2011) were unable to open TRPV4 upon treatment with ATP (Poole et al., 
2013).  
This study aimed to determine if a number of potential GPCRs that have been 
linked to TRPV4 opening could open TRPV4 in our HEK293 cell model and hence 
identify a potential physiological role for the receptor-dependent opening of 
TRPV4. The specific receptor subtypes identified above were transiently 
expressed into the HEK293-TRPV4 cell model in which we have previously 
observed PAR2-dependent opening of TRPV4. This chapter identified; the specific 
GPCRs that when expressed in HEK293 cells can signal to and open TRPV4, also 
that there are some GPCRs that can open TRPV4 in other tissues that cannot open 
TRPV4 in this isolated cell system. 
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6.2 Experimental design 
HEK+TRVPV4 or control HEK cells were transiently transfected with the GPCR 
genes described above, together with green fluorescent protein as a transfection 
control in 384 well plates (Methods chapter 2.1.3). Cells were assayed 48 hr after 
transfection by intracellular calcium assay as described previously (Methods 
chapter 2.1.6) to assess the effect of GPCR agonists.  
Experiments were performed in 384 well plates on the FLIPR plate reading 
fluorimeter (Methods chapter 2.1.6). Results from plates were rejected if less than 
50% of cells showed GFP expression prior to assay measured by visual inspection 
on a fluorescent microscope. Due to the large range of agonists required for the 
multiple GPCRs the FLIPR was technically best suited to handle the multiple 
injections of agonist since it is able to use three agonist injection plates and thus 
allowed large range of compounds and concentrations to be tested on each assay 
plate.  
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6.3 Results 
6.3.1 Proinflammatory GPCRs identified in dorsal root ganglia neurons show 
differential activation of TRPV4 HEK293 cells.  
To determine if bradykinin receptors can signal to and open TRPV4, BK1 and 2 
were transiently transfected into HEK and HEK+TRPV4. HEK293 cells both with 
and without TRPV4 treated with bradykinin (10 μM) caused a small but significant 
increase in [Ca2+]i (Figure 6.1A) which indicated that HEK293 cells do express a 
small amount of functional bradykinin receptors. When BK1 receptors were 
transiently expressed in both cell types there was no significant change in [Ca2+]i 
when stimulated with BK (10 μM) (Figure 6.1 A,B), which doesn’t clearly indicate 
whether that the receptors were functionally expressed. The BK2 receptor, when 
transiently transfected into HEK293 cells and HEK293 cells expressing TRPV4 
caused a significant increase in intracellular calcium (Figure 6.1C) however, in 
HEK cells the free intracellular calcium returned to base line by 50s whereas the 
HEK+TRPV4 had a sustained increase in [Ca2+]i that persisted to the end of the 
assay (Figure 6.1 C,D). This indicated that the BK2 receptor was activating the 
necessary signalling pathways required to open TRPV4.  
To determine the link between NK1 and TRPV4 in allodynia the NK1 receptor was 
transiently transfected into HEK cells and HEK+TRPV4. Both cell lines, did not 
have a significant change in [Ca2+]i in response to substance P before transfection 
(Figure 6.1E). HEK+NK1 cells had a significant increase in [Ca2+]i that returned to 
baseline after 50s, whereas HEK+TRPV4+NK1 had a significant sustained increase 
in [Ca2+]i (Figure 6.1 E,F). Indicating that the NK1 can signal to and open TRPV4 in 
HEK293 cells.  
PGE2 receptor EP4 (PGTR4) is expressed in DRGs and causes allodynia(St-Jacques 
and Ma, 2014). PGTR4 was transfected into HEK cells and HEK+TRPV4, to 
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determine if the signalling from PGTR4 could open TRPV4 in HEK293 cells. PGE2 
(100 μM) did not significantly increase [Ca2+]i in HEK cells and HEK+TRPV4 above 
the level of a vehicle injection (Figure 6.1G)., indicating that HEK293 cells do not 
have endogenous prostaglandin receptors that signal via an increase in [Ca2+]i. The 
transient expression of the PGTR4 receptor did not significantly alter the calcium 
response in both HEK and HEK+TRPV4 (Figure 6.1 G,H), which illustrated that the 
PGTR4 receptor, if expressed, does not signal to and open TRPV4. 
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Figure 6.1. Proinflammatory GPCRs, transiently transfected into HEK293 
cells can signal to and open TRPV4. For all graphs, HEK represents the parental 
cell line and HEK+TRPV4 are cells with TRPV4 stable expressed, subsequently 
Either HEK+ receptor or HEK+TRPV4+receptor. A. Increase in [Ca2+]i in HEK293 
cells after stimulation with bradykinin (10 μM) in cells transiently transfected 
with the BK1 receptor. B. The area under the curve from graph A. from 75-150s 
which represents the TRPV4 component of the increase in [Ca2+]i showed no 
significant difference between HEK+BK1 and HEK+TRPV4+BK1. C. Increase in 
[Ca2+]i in HEK293 cells after stimulation with bradykinin (10 μM) in cells 
transiently transfected with the BK2 receptor. D. The area under the curve from 
graph C. from 75-150s which represents the TRPV4 component of the increase in 
[Ca2+]i showed a significant difference between HEK+BK2 and HEK+TRPV4+BK2. 
E. Increase in [Ca2+]i in HEK293 cells after stimulation with Substance P (1 μM) in 
cells transiently transfected with the NK1 receptor. F. The area under the curve 
from graph E. from 75-150s which represents the TRPV4 component of the 
increase in [Ca2+]i showed a significant difference between HEK+NK1 and 
HEK+TRPV4+NK1. G. Increase in [Ca2+]i in HEK293 cells after stimulation with 
PGE2 (100 μM) in cells transiently transfected with the PGTR4 receptor. H. The 
area under the curve from graph G. from 75-150s which represents the TRPV4 
component of the increase in [Ca2+]i showed no significant difference between 
HEK+PGTR4 and HEK+TRPV4+PGTR4. For graphs B, D, F and G: * is p<0.05 
compared to HEK + TRPV4 AUC, Oneway ANOVA, Dunnett’s posthoc test (N=4). 
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6.3.2 ACh-induced activation of TRPV4 via the M3 receptor.  
ACh-induced calcium flux in endothelial cells is sensitive to TRPV4 
inhibition(Adapala et al., 2011). To assess the ability of the M3R to signal and open 
TRPV4 it was transiently transfected into HEK cells and HEK+TRPV4. In both HEK 
and HEK+TRPV4 there was no significant increase in [Ca2+]i in response to ACh 
(10μM) (Figure 6.2A). Cells transfected with M3R showed a significant increase in 
[Ca2+]i, in HEK cells and that increase returned to baseline at approximately 50s, 
whereas in HEK+TRPV4 had a persistent increase in [Ca2+]i (Figure 6.2 A,B). These 
results indicated that the muscarinic receptor 3 can signal to and open TRPV4 in 
HEK293 cells. 
 
Figure 6.2. The muscarinic receptor M3 can signal to and open TRPV4 in 
HEK293 cells. For all graphs, HEK represents the parental cell line and 
HEK+TRPV4 are cells with TRPV4 stable expressed. A. Increase in [Ca2+]i in HEK 
and HEK+TRPV4 after stimulation with ACh (10 μM) in cells with or without the 
M3 receptor (M3R). B. The area under the curve from graph A. from 75-150s 
which represents the TRPV4 component of the increase in [Ca2+]i showed a 
significant difference between HEK+M3R and HEK+TRPV4+M3R. For graphs B: * 
is p<0.05 compared to HEK + M3R AUC, Oneway ANOVA, Dunnett’s posthoc test 
(N=4). 
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6.3.3 Purinergic receptors signal to and open TRPV4 in HEK293 cells.  
P2Y2 receptors in the aldosterone sensitive distal nephron, when stimulated 
caused a calcium flux that was sensitive to TRPV4 inhibition(Mamenko et al., 
2011). P2Y11 and P2Y12 are reported to be expressed in HEK293 cells (Atwood 
et al., 2011) but we believe that they do not open TRPV4 because we have 
previously found that ATP does not cause sustained intracellular calcium signals 
in TRPV4 transfected compared to untransfected HEK293 cells(Poole et al., 2013). 
To ascertain the ability of different purinergic receptors to signal to and open 
TRPV4, we transiently transfected receptors P2Y 2, 11 and 12 into HEK293 cells. 
As expected, a significant increase in [Ca2+]i in both HEK and HEK+TRPV4 without 
transfected receptor with ATP was observed (Figure 6.3A), but there was no 
significant difference between the signals in each cell type (Figure 6.3D). The P2Y2 
receptor is implicated in opening TRPV4 in the kidney (Mamenko et al., 2011). 
When transfected into HEK293 cells, they responded to ATP (100 μM) with a 
significant increase in [Ca2+]i compared to untransfected cells (Figure 6.3A) and 
when transfected into in HEK293 +TRPV4 cells, they showed a significant 
sustained level of [Ca2+]i (Figure 6.3D). The P2Y11 receptor showed a significant 
increase in [Ca2+]i when expressed in HEK+TRPV4 cells with a significantly 
sustained increase [Ca2+]i compared to HEK cells(Figure 6.3D) whereas the P2Y12 
receptor did not cause a sustained response and there was no significant 
difference in response between HEK and HEK+TRPV4 (Figure 6.3 C,D). Indicating 
that both P2Y2 and P2Y11 can signal to and open TRPV4 where as P2Y12, if 
expressed, does not activate the signalling pathways that open TRPV4 in HEK293 
cells. 
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Figure 6.3. Purinergic receptors that can signal to and open TRPV4 in 
HEK293 cells. For all graphs, HEK represents the parental cell line and 
HEK+TRPV4 are cells with TRPV4 stable expressed, subsequently either HEK+ 
receptor or HEK+TRPV4+receptor. A. Increase in [Ca2+]i in HEK293 cells after 
stimulation with ATP (100 μM) in cells transiently transfected with the P2Y2 
receptor. B. Increase in [Ca2+]i in HEK293 cells after stimulation with ATP (100 
μM) in cells transiently transfected with the P2Y11 receptor. C. Increase in [Ca2+]i 
in HEK293 cells after stimulation with ATP (100 μM) in cells transiently 
transfected with the P2Y12 receptor. D. The area under the curve from graphs 
A,B,C from 75-150s which represents the TRPV4 component of the increase in 
[Ca2+]i showed a significant increase in signal in HEK+TRV4+P2Y2 and 
HEK+TRPV4+P2Y11. For graphs B and D: * is p<0.05 compared to HEK + TRPV4 
AUC, Oneway ANOVA, Dunnett’s posthoc test (N=4). 
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6.4 Discussion 
This work has shown that the HEK293 heterologous cell system contains GPCRs 
signalling pathway components which can lead to the opening of TRPV4 when 
activated. The signalling components and the GPCRs that can open them may be 
responsible for the reported effects of TRPV4 in various proinflammatory 
signalling processes in sensory neurons and vasculature. 
One caveat of this study is that the receptors that were unable to open TRPV4 were 
not assessed for function by any other means nor was the level of protein 
expression for the transiently transfected receptors. So it is possible that these 
receptors may be able to signal to TRPV4 in different cellular backgrounds. For 
instance, the PGTR4 receptor did not cause an increase in intracellular calcium in 
either cell type, it is possible the receptor was not functionally expressed in the 
cells or that it does not signal through intracellular calcium or TRPV4; alternative 
measures of activation and expression would need to be assessed to determine 
this. 
There are many studies linking proinflammatory receptors to TRPV4 but this 
study focused on the work linking TRPV4 to mechanical hyperalgesia post the 
administration of inflammatory ligands (Alessandri-Haber et al., 2006; Grace et 
al., 2014). The ligand PGE2 did not cause the EP4 receptor to open TRPV4 in 
HEK293 cells, this has multiple possible implications, if the receptor was 
expressed, that could provide links to its activity in mechanical hyperalgesia. The 
prostaglandin receptors could be signalling to TRPV4 to sensitise or potentiate its 
response to other activators such as the mechanical stimuli rather than directly 
opening the channel. This echoed the findings of Alessandri Haber (2006) where 
it was identified that 5HT and PGE2 only induced a TRPV4-dependent mechanical 
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hyperalgesia when administered together (Alessandri-Haber et al., 2006). 
Bradykinin via the BK2 receptor and substance P via the NK1 receptor stimulated 
their receptors and caused TRPV4 to open, in the inflammatory setting in the 
dorsal root ganglia these receptors may be causing TRPV4 to open which could 
make the neurons more sensitive to firing in the response to other stimuli, such as 
mechanical forces. The functional expression of BK2 receptors on sensory 
neurons and the vascular endothelium link this receptor to TRPV4 and this study 
has furthered this connection. Bradykinin stimulation of endogenous bradykinin 
receptors in HEK293 cells sensitised TRPV4 to hypotonic activation via a PKC-
dependent mechanism (Fan et al., 2009) which, paired with the work done in 
mechanical hyperalgesia, show that this novel finding of the BK2 receptor causing 
the opening TRPV4 could have wide reaching implications. 
Substance P signalling on the other hand is more complicated and the link 
between TRPV4 and the NK1 receptor remains unclear. Currently there have been 
no direct studies linking these two. In sensory neurons the activation of TRPV4 
causes substance P release , NK1 (Gunjigake et al., 2006) and TRPV4 are expressed 
in the trigeminal neurons where by activation of either leads to pain nosifencive 
pain (Chen et al., 2014). This novel finding that NK1 receptor can signal to and 
open TRPV4 could provide a novel target for algesia in substance P-induced pain. 
Stimulation of NK1 receptor has been shown to cause vasodilatation and increase 
trigeminal ganglia activation and is novel target for migraine pain (Polley et al., 
1997). TRPV4 has also been linked to the activation of dural afferent neurons to 
cause headache behaviour (Wei et al., 2011). 
TRPV4 in the vascular endothelium has been widely reported, the M3 receptor is 
the predominately expressed isoform of the receptor to be expressed in the 
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endothelium (Gericke et al., 2011). These findings showed that the M3 receptor 
transfected into the HEK293 cells can signal to and open TRPV4, which indicates 
that TRPV4 may be vital in the functioning in the endothelium-dependent 
vasodilatation. Given the growing evidence for TRPV4 in pathophysiological states 
in the vascular endothelium, it was determined that this interaction between 
muscarinic receptors and TRPV4 should be investigated further. Therefore to give 
this cellular work a physiological relevance the interactions between TRPV4 and 
muscarinic receptors in the vascular endothelium was investigated in an in vitro 
preparation of rat cremaster arterioles, that will be presented in the following 
chapter of this thesis. 
The purinergic receptors in this cell system, specifically the endogenously 
expressed P2Y12 receptor (Atwood et al., 2011) caused a significant increase in 
intracellular calcium from stores by activating the Gαq pathway but did not signal 
to and open TRPV4, whereas the other two subtypes P2Y2 and P2Y11 when 
transiently-expressed in this system do activate the signal processes required for 
opening TRPV4.  P2Y2 receptors also signal through the Gαq pathway as indicated 
by the release on intracellular calcium from stores in HEK293 cells, but the 
receptors can signal to and open TRPV4 in HEK293 cells where as P2Y12 cannot. 
This indicates that P2Y2 can activate a unique set of signalling pathways from the 
P2Y12, based on the previous result of this thesis would indicate that both P2Y2 
and P2Y11 receptors couple to the Gα13 and hence can open TRPV4. The 
differential results between these purinergic receptors indicate that the opening 
of TRPV4 in this cell model is not an artefact of the system due to the increased 
expression when the receptors are transiently expressed, as the transient 
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expression of the endogenous subtype P2Y12 receptor does not facilitate TRPV4 
opening.  
These purinergic receptors are widely expressed in the body, nearly every 
different tissue type. There are 8 subtypes of P2Y GPCRs officially recognised, the 
selected 3 subtypes in this study were chosen due to expression in the kidney and 
HEK293 cells. However, these findings could prove important in other tissues for 
instance in immune cells such as macrophages where by P2Y2, P2Y11 (Jacob et al., 
2013) and TRPV4 are co-expressed and where by the signal transduction of the 
specific P2Y subtypes are not well understood. Although the specific subtype of 
these receptors could lead to some specificity of antagonism it is our belief that 
targeting the signalling from these receptors to TRPV4 would lead to novel 
therapeutics with tissue specific implications. 
In conclusion, this chapter has identified multiple receptors that can signal to and 
open TRPV4 in this isolated HEK293 cell model. This investigation has searched 
to identify a potential physiological setting for the GPCR-dependent opening of 
TRPV4. The chapter has highlighted multiple systems that could be investigated, 
the remainder of this thesis will identify the function of TRPV4 and the GPCRs that 
can signal to it in the vascular endothelium.  
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7 Shear stress sensitises TRPV4 in endothelium-dependent 
vasodilatation 
 
7.1 Introduction  
The previous chapter identified the M3 muscarinic receptor can signal to and open 
TRPV4 in HEK293 cells, in order to determine if this is a physiological effect the 
function of TRPV4 in the vascular endothelium and the link between GPCRs in the 
endothelium is assessed in this chapter. 
Blood vessels exist in a state of partial contraction, with the vessel tone produced 
by opposing dilator and constrictor factors, blood pressure and flow acting upon 
the vessel. Other factors, such as age, physical activity, obesity and blood glucose 
levels can also alter this balance and perturbed tone can lead to vascular 
dysfunction and disease (Vanhoutte et al., 2009). The endothelial cell lining of 
blood vessels acts as a key regulator of vascular tone by producing different 
constrictor and/or dilator factors in response to a wide range of chemical and 
physical stimuli. The properties of the endothelial cells differ depending on their 
site in the vascular network. Endothelium-derived nitric oxide is the predominant 
dilator in larger arteries while in smaller arterioles, endothelium-dependent 
hyperpolarisation mediated via the calcium sensitive potassium channels (KCa), 
causes a greater contribution to smooth muscle relaxation (Tomioka et al., 1999).  
The non-selective ion channel transient receptor potential vanilloid 4 (TRPV4) 
responds to a diverse range of stimuli encountered by the endothelium (Wegierski 
et al., 2009; White et al., 2016), such as hypo-osmolarity (Liedtke, Wolfgang  et al., 
2000), shear stress (Hartmannsgruber et al., 2007; Mendoza et al., 2010) and 
pressure (Bagher et al., 2012). The endothelium is exposed to many of these 
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stimuli. Endothelial dysfunction resulting from increased age (Du et al., 2016), 
stenosis (Matin et al., 2016), hypertension (Sonkusare et al., 2014) and 
Alzheimer’s disease (Zhang et al., 2013) is characterized by impaired endothelial 
responses to a number of TRPV4 activating stimuli and aberrant TRPV4 function 
is implicated in all of these conditions. 
The effects of TRPV4 activation have been studied in a range of vascular systems. 
Agonist activation of TRPV4 with GSK1016790A or 4α-phorbol 12,13-
didecanoate, leads to the vasodilatation of pre-constricted mesenteric arterioles 
(Sonkusare et al., 2012). TRPV4-dependent vasodilatation is linked to 
endothelium-dependent hyperpolarisation and leads to the opening of calcium-
dependent potassium channels (KCa) that hyperpolarize the membrane of vascular 
smooth muscle cells and cause relaxation independently of the release of nitric 
oxide or cyclooxygenase products (Sonkusare et al., 2012). In human coronary 
arterioles, blood flow-induced vasodilatation is mediated by TRPV4, which is 
accompanied by reactive oxygen species generation (Bubolz et al., 2012). The 
vasodilatation was inhibited by treatment with catalase, which hydrolyses 
hydrogen peroxide, suggesting that TRPV4 may be modulated by reactive oxygen 
species under some conditions. In pulmonary vascular beds, GSK1016790A 
caused a nitric oxide synthase (NOS)-dependent reduction of blood pressure, 
whereas in the systemic circulation, reduction of blood pressure due to 
GSK1016790A was not attenuated by NOS inhibition (Pankey et al., 2014b). In 
addition to regulating vasodilation, TRPV4 activation can also trigger an 
endothelium-dependent contractile response in the aorta (Saifeddine et al., 2015) 
and mesenteric arteries (Mendoza et al., 2010) while in pulmonary vessels TRPV4 
mediated contraction is endothelium independent (Sukumaran et al., 2013). 
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These observations show that TRPV4 activation has multiple effects regulating 
blood flow, with responses and mechanisms varying with the circulatory bed. It 
follows that understanding how signalling from blood flow and soluble factors can 
modulate TRPV4 opening, is key to understanding its function in the 
cardiovascular system.  
There is mounting evidence for the sensitisation and opening of TRPV4 by G 
protein-coupled receptor (GPCR) signalling and TRPV4 appears to be essential for 
some GPCR mediated signalling in blood vessels. An interaction between TRPV4 
and the muscarinic receptor mediating endothelium-dependent relaxation to ACh 
is of particular interest. ACh-induced relaxation is impaired in mouse small 
mesenteric and cerebral vessels from TRPV4-/- mice or in the presence of a TRPV4 
antagonist (Earley et al., 2009a; Saliez et al., 2008; Zhang et al., 2009; Zhang et al., 
2013) however that is not the case in mouse carotid arteries (Hartmannsgruber 
et al., 2007; Kohler et al., 2006; Loot et al., 2008; Sonkusare et al., 2012) suggesting 
that artery size might influence the interaction between TRPV4 and the GPCR; or 
potentially the anatomical location of the arteries and the surrounding tissues 
may influence the GPCR-TRPV4 interactions.  
As noted, the complexity of the TRPV4 crosstalk with GPCRs to regulate vascular 
function in different circulatory beds is apparent because TRPV4 activation is 
tissue dependent and it is opened by distinct GPCRs in each tissue. (Adapala et al., 
2011; Bubolz et al., 2012; Grace et al., 2014; Xia et al., 2013; Zhang et al., 2009). 
For example in pulmonary smooth muscle cells TRPV4 was opened by serotonin 
receptors but not by α1 adrenoceptors or endothelin-1 receptors (Xia et al., 2013), 
while in endothelial cells TRPV4 was apparently opened by the muscarinic agonist 
acetylcholine but not by bradykinin (Bubolz et al., 2012). In the aorta TRPV4 can 
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be regulated by PAR1, PAR2 and angiotensin AT1R signalling (Saifeddine et al., 
2015). 
Shear stress from blood flow has been shown to dilate arterioles, and TRPV4 
contributes to this effect (Mendoza et al., 2010). Flow-dependent dilatation of 
carotid arteries is dependent on endothelial TRPV4 expression in mice whereas in 
the same experiments there was no role for TRPV4 in cholinergic dilatation 
(Hartmannsgruber et al., 2007). Calcium influx through endothelial TRPV4 
channels opens SKCa and IKCa channels to contribute significantly to endothelial 
mechanotransduction (Hartmannsgruber et al., 2007) with a small nitric oxide-
dependent component (Mendoza et al., 2010). Exposing human umbilical vein 
endothelial cells to shear stress increased TRPV4 expression at the cell surface 
and potentiated Ca2+ influx in response to the TRPV4 agonist GSK1016790A 
(Baratchi et al., 2015). However, despite this evidence of functional interaction of 
GPCR signalling and shear stress on TRPV4, the physiological mechanisms of 
TRPV4 activation in endothelial cells remain poorly characterised. In particular, 
the effect of fluid flow on the sensitivity to GPCR-TRPV4 functional coupling is 
unknown.  
We explored the function of TRPV4 in skeletal muscle resistance arterioles, by 
firstly characterising its function at steady state and secondly, by assessing how 
TRPV4 was integrated into endothelium-dependent vasodilatation after the 
endothelium was exposed to shear stress. We hypothesise that TRPV4 function is 
altered by shear stress in the endothelium of resistance arterioles. Here we 
examine the effect of endothelial GPCR ligands and flow-induced shear stress on 
TRPV4-dependent dilatation of rat cremaster arterioles. The findings show how 
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the endothelium could be communicating the effects of shear stress and 
endothelium-dependent vasodilatation by altering TRPV4 function. 
 
7.2 Experimental design 
Skeletal muscle resistance arterioles were dissected from rat cremasters as per 
methods section (2.2.1). Arterioles were then attached to a pressure myograph 
and tested for leaks. The arterioles were then constricted by increasing luminal 
pressure to 70 mmHg and arterioles were assessed as viable if they constricted by 
more than 40% of the maximal diameter. Maximal diameter was assessed as the 
initial diameter of the arterioles when pressurised and then confirmed at the end 
of each experiment series by exposure to Kreb’s solution with no calcium (1 mM 
EGTA). As the arterioles were constricted to pressure alone there was no 
interfering signalling pathways from other constrictor agents that may have 
interfered with TRPV4 function.  
 Once arterioles had reached a stable constriction (>10min stable) vasodilatation 
could be induced with a series of reagents and to determine the role of TRPV4 in 
vasodilatation the specific TRPV4 agonist GSK1016790A was assessed in the 
presence and absence of antagonists . Other agonists which activate GPCRs to 
induce vasodilatation were tested ACh (1 nM-1 µM) as the endothelium-
dependent vasodilator, PAR2-AP (100 nM- 100 µM) to align this work with 
previous chapters and histamine (10 nM- 30 µM) as an endothelium-independent 
agonist. All concentration-effect curves were performed on a minimum of four 
arterioles from separate rats. 
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The response to all agonists was also assessed in the absence of endothelium 
which was achieved by passing a bubble through the arteriole until there was no 
longer a response to ACh (10 µM). 
Lastly, to determine the effect of shear stress on the arteriolar response to 
vasodilators, arterioles were shear conditioned by creating a flow through the 
lumen of the arterioles using a pressure gradient. The gradient of 100 mmHg at 
the proximal end of the arteriole and 40 mmHg at the distal end induced an 
average flow rate of approximately 200 µl/min and arterioles were conditioned 
for 6 min. Flow was stopped and arterioles were allowed to regain myogenic tone 
before agonists were administered. 
Fluorescent immunocytochemistry was performed to assess the TRPV4 
expression on arterioles that had either been constricted to myogenic tone as the 
control arterioles or constricted to myogenic tone then shear conditioned (6 min 
of 200 µl/min). Arterioles were fixed, with paraformaldehyde, to ensure the state 
of receptor expression was preserved. Arterioles were permeabilised and stained 
with an anti-TRPV4 antibody that binds to the intracellular domains of TRPV4 to 
determine the total receptor in the arterioles. The second series of arterioles were 
fixed then stained with an anti-TRPV4 antibody which binds to the extracellular 
domains of TRPV4, which assessed the density of receptors at the cell surface. For 
full description see section (2.2.2)  
Concentration-effect curves are represented as the (ΔDiameter (% maximum)) 
was determined by the change in arteriole diameter from the basal diameter 
(resting myogenic tone) induced by agonists as a percentage of the maximal 
diameter, determined in the absence of calcium in the Kreb’s buffer at the end of 
each experiment. The statistical analysis was tested on the pEC50, ie the negative 
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log10 of the concentration of agonist required to induce a response equivalent to 
50%,of the maximum response, as well as the maximal dilatation that was induced 
by each agonist. Significance was determined with a one-way ANOVA with a 
sidak’s post hoc test (p<0.05). 
When using fluorescent immunocytochemistry quantitation was difficult due to 
the microscopic size of the arterioles. To compare the level of staining between 
arterioles fluorescent values had to be normalised to multiple factors. When fixed 
the internal elastic lamina in arterioles auto fluoresces in the FITC channel (Ex 
Em), this was utilised to determine the amount of arteriole that was imaged, 
intensity in this channel determined the size of the cross section that was imaged 
and was used to normalise the level of TRPV4 intensity in each image (normalised 
mean fluorescent intensity).    
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7.3 Results 
7.3.1 TRPV4 activation causes vasodilatation 
The TRPV4 agonist GSK1016790A caused a concentration-dependent dilatation of 
arterioles from the baseline level of myogenic tone (Figure 7.1A, Table 1). The 
response to GSK1016790A was abolished by the removal of the endothelium 
(Figure 7.1A, Table 1). The concentration effect curve to the TRPV4 agonist, 
GSK1016790A was significantly shifted to the right in the presence of the TRPV4 
antagonists, HC067047 and GSK2193874 (Figure 7.1A, Table 1).  
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Figure 7.1. TRPV4 stimulation in rat cremaster arterioles causes an 
endothelium-dependent vasodilatation through SKCa and IKCa channels 
which is sensitised by shear conditioning. GSK1016790A concentration-effect 
curves in the presence of: A: vehicle control (Control, 0.003% DMSO, N=9), in 
endothelium denuded arterioles (Ex, N=6) in the presence of TRPV4 antagonists 
HC067047 (HC067, 300 nM, N=7) or GSK2193874 (GSK219, 100nM, N=14). B: 
vehicle control (Control, 0.003% DMSO), nitric oxide synthase inhibitors and 
cyclooxygenase inhibition (Indo + LN, L-NAME (100 μM) and indomethacin (10 
μM), N=7) and the further addition of KCa inhibitor (+TRAM+apa, L-NAME (100 
μΜ), Indomethacin (10 μM), TRAM34 (1 μM) and apamin (1 μM), N=5). C: vehicle 
control (Control, 0.003% DMSO, N=7) agonist administration after shear 
conditioning (Shear (<15 min post), N=13) and greater than 30 minutes post shear 
conditioning (Shear (>30 min post)). See Table 7.1 for pEC50 and ΔDmax values 
derived from these curves. (* pEC50, p<0.05 compared to Control, # ΔDmax, p<0.05 
when compared to Control, One-way ANOVA, Sidak’s post hoc test). See Table 7.2 
for pEC50 and ΔDmax values derived from these curves. 
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GSK1016790A     
Treatment N pEC50 (M) ΔDmax (%) 
Control 9 7.72 ± 0.12 97 ± 3 
Ex 6 ND 4 ± 4 b 
HC067047 7 6.44 ± 0.12 a ND 
GSK2193874 14 6.19 ± 0.08 a ND  
L-NAME+ indomethacin 7 7.61 ± 0.44 86 ± 6 
L-NAME+ indomethacin+ 
TRAM34 + apamin 
5 ND 34 ± 15 b 
Shear conditioned 13 8.35 ± 0.10 a 103 ± 2 
40min post shear conditioned 7 8.04 ± 0.13 95 ± 1 
Table 7.1. Mechanism of TRPV4 agonist GSK1016790A dilator effect 
Sensitivity (pEC50) and maximal dilatation from basal tone (ΔDmax) to the TRPV4 
agonist GSK1016790A in the presence of TRPV4 antagonists (HC067047 and 
GSK2193874), L-NAME, indomethacin, TRAM-34, apamin and shear conditioning 
in rat cremaster arterioles. 
a pEC50 significantly different when compared to control (p<0.05, One-way-
ANOVA Sidak’s post hoc test) 
b ΔDmax significantly different when compared to control (p<0.05, One-way-
ANOVA Sidak’s post hoc test) 
ND= not determined 
7.3.2 TRPV4 causes vasodilatation by activating Kca channels. 
Endothelium-dependent vasodilatation is known to involve three major 
mechanisms, the generation of nitric oxide by endothelial NOS, generation of 
prostanoids by COX and/or the opening of calcium sensitive potassium channels. 
GSK1016790A-induced vasodilatation was not significantly affected by treating 
the arterioles with the NOS inhibitor L-NAME and the COX inhibitor indomethacin 
(Figure 7.1B, Table 7.1). However, the maximum response was significantly 
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attenuated when the intermediate and small conductance KCa channels were 
blocked with TRAM-34 plus apamin (Figure 7.1B, Table 7.1). 
7.3.3 Shear conditioned arterioles were sensitised to GSK1016790A. 
The dilator sensitivity to GSK1016790A was significantly enhanced when 
responses were determined within 15 min of shear conditioning compare to 
control (Figure 7.1C, Table 7.1). This sensitisation was rapidly reversed as 
application of GSK1016790A 30 minutes after shear caused similar dilatation to 
that observed in control vessels (Figure 7.1C, Table 7.1). 
7.3.4 ACh-induced vasodilatation is only sensitive to TRPV4 antagonists after shear 
conditioning. 
Cremaster arterioles showed concentration-dependent dilatation to ACh, that was 
not significantly affected by TRPV4 antagonists HC067047 or GSK2193874, which 
showed that TRPV4 was not involved in the ACh-induced vasodilatation under 
basal, no flow conditions (Figure 7.2A, Table 7.2).  
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Figure 7.2. ACh concentration-effect curves in rat cremaster arterioles are 
shifted by TRPV4 antagonists after shear conditioning. ACh concentration-
effect curves in the presence of: A: vehicle control (Control, 0.003% DMSO, N=18), 
HC067047 (HC067, 300 nM, N=8) and GSK2193874 (GSK219, 100 nM, N=10). B: 
vehicle control (Control, 0.003% DMSO) and shear conditioned arterioles with 
vehicle control (Shear, 0.003% DMSO, N=12). C: Arterioles that were shear 
conditioned and treated with HC067047 (HC067 shear, 300 nM, N=7) and 
HC067047 only treated arterioles (HC067, 300 nM). D: Arterioles that were shear 
conditioned and treated with GSK2193874 (GSK219 shear, 100 nM, N=9) and 
GSK2193874 treated (GSK219, 100 nM). (* pEC50, p<0.05 compared to HC067047, 
# pEC50, p<0.05 when compared to GSK219, One-way ANOVA, Sidak’s post hoc 
test). See Table 7.2 for pEC50 and ΔDmax values derived from these curves. 
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ACh Control       Shear conditioned    
Treatment 
N pEC50 ΔDmax 
(%) 
 
N pEC50 ΔDmax (%) 
Control 18 7.20 ± 0.07 93 ± 2 12 6.94 ± 0.08  95 ± 1 
HC067047 8 6.86 ± 0.07 99 ± 1 7 6.33 ± 0.11 a 92 ± 3 
GSK2193874 10 7.24 ± 0.07 97 ± 2 9 6.25 ± 0.12 b 92 ± 4 
Table 7.2. Mechanism of acetylcholine dilator effect 
Sensitivity (pEC50) and maximal dilatation from basal tone (ΔDmax) to ACh and the 
effect of shear conditioning in rat cremaster resistance arterioles. 
a pEC50 significantly different when compared to HC067047 control (p<0.05, One-
way-ANOVA Sidak’s post hoc test) 
b pEC50 significantly different when compared to GSK2193874 control (p<0.05, 
One-way-ANOVA Sidak’s post hoc test) 
 
ACh-induced vasodilatation in shear conditioned arterioles was similar to control 
arterioles (Figure 7.2B, Table 7.2), however, after shear conditioning, the 
responses were significantly attenuated by both TRPV4 antagonists. HC067047 
caused a shift to the right of a half log unit (Figure 7.2C, Table 7.2) and 
GSK2193874 caused a shift of a full log unit (Figure 7.2D, Table 7.2) in shear 
conditioned vessels. These results indicate that TRPV4 is involved in ACh-induced 
vasodilatation within 15 minutes of the exposure of the endothelium to flow-
induced shear forces. 
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7.3.5 PAR2- and histamine-dependent vasodilatation is insensitive to TRPV4 
antagonism and shear conditioning. 
To assess the effect of shear conditioning on other GPCR agonists we investigated 
the vasodilator responses to the protease activated receptor 2 agonist peptide, 
PAR2-AP, on rat cremaster arterioles. PAR2-AP caused a concentration-dependent 
vasodilatation that was abolished when the endothelium was removed (Figure 
7.3A, Table 7.3). Shear conditioning had no effect on the PAR2-AP-induced 
vasodilatation (Figure 7.3B, Table 7.3) nor was PAR2-AP-induced dilatation 
affected by the TRPV4 antagonist GSK2193874 (Figure 7.3C, Table 7.3). 
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Figure 7.3. PAR2-AP and histamine-induced vasodilatation is not sensitive to 
TRPV4 antagonists irrespective of shear conditioning. PAR2-AP concentration 
effect curves in the presence of: A: vehicle control (control, 0.001% DMSO, N=9), 
endothelium denunded arterioles (Ex, N=3) and TRPV4 antagonist GSK2193874 
(GSK219, 300 nM, N=6). B: Vehicle control (Control, 0.001%DMSO) and shear 
conditioned arterioles (Shear, N=11). C: Vehicle control shear conditioned 
arterioles (Shear) and GSK2193874 in shear conditioned arterioles (GSK219 
Shear, 300 nM, N=4). Histamine concentration-effect curves in the presence of: D: 
vehicle control (control, 0.001% DMSO, N=8), endothelium denunded arterioles 
(Ex, N=5) and TRPV4 antagonist GSK2193874 (GSK219, 300 nM, N=8). E: Vehicle 
control (Control, 0001% DMSO) and shear conditioned arterioles (Shear, N=8). F: 
shear conditioned arterioles (Shear) and GSK2193874 in shear conditioned 
arterioles (GSK219 Shear, 300 nM, N=8). For A-C see Table 7.3 and for D-F see 
Table 7.4 for pEC50 and ΔDmax values derived from these curves.
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PAR2-AP Control       Shear conditioned 
Treatment 
N 
pEC50 
ΔDmax 
(%) 
 
N pEC50 ΔDmax (%) 
Control 9 5.93 ± 0.10 97 ± 2 11 5.91 ± 0.19 95 ± 1 
GSK2193874 6 5.55 ± 0.10 97 ± 1 4 5.37 ± 0.18 98 ± 1 
Ex 3 ND 3 ± 5  -  -  - 
Table 7.3. Mechanism of PAR2 dilator effect 
Sensitivity (pEC50) and maximal dilatation from basal tone (ΔDmax) to PAR2-AP and 
the effect of shear conditioning in rat cremaster resistance arterioles. 
a pEC50 significantly different when compared to control (p<0.05, One-way-
ANOVA Sidak’s post hoc test) 
b ΔDmax significantly different when compared to control (p<0.05, One-way-
ANOVA Sidak’s post hoc test) 
 
Secondly we assessed the endothelium-independent vasodilator histamine to 
determine if another GPCR agonist could modulate the observed TRPV4 effect in 
the endothelium. In rat cremaster arterioles histamine induced a concentration-
dependent vasodilatation from resting myogenic tone and the response was not 
altered by the removal of the endothelium (Figure 7.3D, Table 7.4). The histamine-
induced vasodilatation was not significantly affected by treatment with the TRPV4 
antagonist GSK2193874 (Figure 7.3D, Table 7.4) or by shear conditioning (Figure 
7.3E, Table 7.4). In contrast to the effects seen with ACh, histamine-induced 
vasodilatation was not altered by treatment with GSK2193874 after shear 
conditioning (Figure 7.3F, Table 7.4). 
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Histamine Control       Shear conditioned   
Treatment 
N pEC50 ΔDmax 
(%) 
 
N pEC50 ΔDmax (%) 
Control 8 6.11 ± 0.10 96 ± 1 8 6.19 ± 0.07 96 ± 1 
GSK2193874 8 6.19 ± 0.07 98 ± 1 8 5.97 ± 0.10 98 ± 1 
Ex 4 6.12 ± 0.12 98 ± 2 - - - 
Table 7.4. Mechanism of histamine dilator effect 
Sensitivity (pEC50) and maximal dilatation form basal tone (ΔDmax) to histamine 
and the effect of shear conditioning in rat cremaster resistance arterioles. 
a pEC50 significantly different when compared to control (p<0.05, One-way-ANOVA 
Sidak’s post hoc test) 
b ΔDmax significantly different when compared to control (p<0.05, One-way-ANOVA 
Sidak’s post hoc test) 
 
7.3.6 Expression of TRPV4 within the lumen of rat cremaster arterioles 
TRPV4 exerts its effects via the endothelium, so to determine where the channel 
was expressed, arterioles were labelled with TRPV4 antibody and imaged using 
immunofluorescence and confocal microscopy. In permeabilized vessels labelled 
with antibody (ab39260) to an intracellular domain of TRPV4, the staining was 
localised to the cells inside the lumen, indicated by the staining on the luminal side 
of both the transverse nuclei of the smooth muscle cells as well as the longitudinal 
nuclei of the endothelial cells, relative to the long axis of the vessel (Figure 7.4A). 
Shear conditioned arterioles showed no discernible change in TRPV4 expression 
or distribution (Figure 7.4B) and the total level of staining for TRPV4 (normalised 
relative pixel intensity) was not altered by shear conditioning (Figure 7.4C). Thus, 
the acute shear conditioning used in these experiments does not alter the total 
amount of TRPV4 present in the endothelium. To determine if the sensitisation of 
TRPV4 to GSK1016790A and the alteration of TRPV4 function in ACh-dependent 
vasodilatation by shear conditioning is due to increased levels of TRPV4 at the 
endothelial cell surface, non-permeabilized arterioles were labelled with an 
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antibody to an extracellular domain of TRPV4 (Figure 7.4C, D). Shear conditioned 
vessels did not have a significantly higher level of TRPV4 at the luminal 
endothelial cell surface than control vessels (Figure 7.4F), indicating the 
sensitisation observed after shear conditioning does not appear to be due to 
increased expression of TRPV4 at the luminal surface of the endothelium. These 
images do appear different in visual intensity but this is due to these images are a 
two dimensional representation of a curved vessel and hence the required 
normalisation of these images to the internal elastic lamina auto fluorescence to 
account for the amount of arteriole that was imaged and compressed into these 
representative images. 
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Figure 7.4. TRPV4 labelling in rat cremaster arterioles is localised to the 
endothelium (scale bar = 40 m). Rat cremaster arterioles labelled with primary 
TRPV4 antibodies and Alexa555 secondary (red) and Hoescht nuclear stain (blue). 
A, B are arterioles from the same rat which were permeabilized and incubated 
with a primary TRPV4 antibody, arteriole A was the control and arteriole B was 
shear conditioned. C: a comparison of normalised red (TRPV4) fluorescence (N=6) 
between control arterioles and shear conditioned arterioles. Arterioles D, E were 
from the same rat, arteriole D was prepared under control conditions and 
arteriole E was shear conditioned, these were not permeabilized and were treated 
with a primary antibody targeted to the extracellular domain of TRPV4. F: a 
comparison of normalised red (TRPV4) fluorescence (N=6) between control 
arterioles shear conditioned arterioles.(N=6). (p > 0.05 paired Student’s t-test). 
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7.4 Discussion 
We have shown that TRPV4 is expressed in cremaster arteriole endothelial cells, 
as determined by immunocytochemistry, and that these arterioles exhibit 
endothelium-dependent vasodilatation in response to the selective TRPV4 agonist 
GSK1016790A, as assessed by pressure myography. TRPV4-dependent 
vasodilatation requires IKCa and SKCa but not endothelial NOS activity, which is 
consistent with vasodilatation of small vessels being driven by an increase in 
intracellular calcium resulting mainly in endothelium-dependent 
hyperpolarisation rather than products of cyclooxygenase or nitric oxide synthase 
(Sonkusare et al., 2012). Endothelium-dependent hyperpolarisation is the most 
effective form of endothelium-dependent vasodilatation in smaller vessels 
(Tomioka et al., 1999). Functional coupling between TRPV4 and SKCa and IKCa ion 
channels is important in mouse mesenteric (resistance) arteries (Sonkusare et al., 
2012), coronary (conduit) arteries (Hartmannsgruber et al., 2007) and in renal 
collecting duct cells (Li et al., 2017). 
TRPV4-dependent vasodilatation in response to shear stress was demonstrated 
previously in mouse mesenteric arteries (Mendoza et al., 2010) and carotid 
arteries (Hartmannsgruber et al., 2007). In carotid arteries under constant flow 
conditions, both the TRPV4 agonist, 4α-Phorbol 12,13-didecanoate, and ACh 
induced dilatation but a role for TRPV4 was not evident in the ACh-dependent 
dilatation. In that study, the authors found that increasing shear stress by 
increasing the solution viscosity at constant flow, caused a TRPV4-dependent 
vasodilator effect in wildtype but not in TRPV4-/- mice and the effect was abolished 
by buffering of endothelial calcium levels, by inhibition of endothelial SKCa and IKCa 
ion channels, by the TRP antagonist, ruthenium red or by inhibiting production of 
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TRPV4-activating eicosanoids (Hartmannsgruber et al., 2007). However, the effect 
of flow on ACh-induced vasodilation has not previously been examined. 
In the current study, we sought to see if there was a TRPV4-dependent component 
of vasodilatation caused by the GPCR agonists ACh, histamine or PAR2-AP and to 
see if it was affected by prior exposure to flow in vitro. We saw dilatation in 
response to ACh, histamine and PAR2-AP in the absence of prior exposure to flow 
and these responses were unaffected by TRPV4 antagonists. When the 
measurements were performed again after fluid flow through the lumen of the 
arteriole in vitro, the stimulus effect curve of ACh was significantly shifted to the 
right by TRPV4 antagonists but the effect curves of histamine and PAR2-AP were 
unaffected. This TRPV4-mediated sensitisation to GSK-induced vasodilatation was 
present 15 min after cessation of flow but was not apparent 30 min after the 
exposure to shear forces.  
There have been conflicting reports as to the involvement of TRPV4 in muscarinic 
receptor mediated vasodilatation. There are several studies reporting no role for 
TRPV4 in cholinergic dilatation of mouse carotid arteries (Earley et al., 2009a; 
Saliez et al., 2008; Zhang et al., 2009; Zhang et al., 2013). By contrast, in smaller 
mesenteric arterioles, dilatation to muscarinic receptor agonists is impaired by a 
TRPV4 antagonist or where the vessels are from TRPV4-/- mice (Hartmannsgruber 
et al., 2007; Kohler et al., 2006; Loot et al., 2008; Sonkusare et al., 2012). It is 
important to note that in all studies, using either carotid or mesenteric arteries, 
the muscarinic receptor mediated dilatation was demonstrated to be dependent 
on the opening of KCa channels as the experiments in the large carotid arteries 
were conducted in the presence of inhibitors of NOS and COX (Earley, 2011; Earley 
et al., 2009a; Saliez et al., 2008; Zhang et al., 2009; Zhang et al., 2013). Together 
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these observations suggest that the involvement of TRPV4 in muscarinic receptor 
mediated dilatation may be more important in small vessels where endothelium-
dependent hyperpolarisation plays a relatively greater role in dilatation. This 
study using skeletal muscle arterioles supports the interaction of muscarinic 
receptors and TRPV4 channels but in these vessels only after the added stimulus 
of exposure to flow-induced shear forces.  
We speculated that the observed sensitisation may involve shear-dependent 
trafficking of TRPV4 to the cell surface as we have recently described in human 
umbilical vein endothelial cells (Baratchi et al., 2015) or that it could be due to re-
distribution of TRPV4 to myoendothelial projections as reported recently 
(Sonkusare et al., 2012). TRPV4 trafficking was not apparent since non-
permeabilized arterioles labelled with the antibody targeted to the extracellular 
surface of TRPV4 did not show significantly more staining after exposure to shear 
stress. Trafficking of TRPV4 to the myoendothelial projections was not apparent 
in permeabilized arterioles when control arteriole TRPV4 labelling distribution 
was compared to shear conditioned arterioles, although the low magnification 
used for imaging would make this quite difficult, or potentially impossible to 
identify. Therefore, these results do not indicate whether movement of TRPV4 
from an intracellular location to the surface or to myoendothelial projections may 
account for the observed sensitisation of TRPV4, or if TRPV4 is sensitised by 
second messengers generated by shear stress but this will require further 
investigation. 
The identification of TRPV4 as an integrator of multiple stimuli in these arterioles 
suggests that TRPV4 function may be altered in different states of vessel function. 
In fact, in multiple models of hypertension and a model of chronic hypoxia TRPV4 
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function has been shown to differ between heathy and diseased mice and rats 
(Boudaka et al., 2019; Diaz-Otero et al., 2018; Naik and Walker, 2018). In 
spontaneously hypertensive rats (SHR) TRPV4-induced endothelium-dependent 
vasodilatation was impaired (Boudaka et al., 2019). In a angiotensin-II induced 
model of hypertension TRPV4-dependent vasodilatation was impaired and TRPV4 
inhibition altered myogenic tone only in hypertensive mice indicating the altered 
function of TRPV4 in this disease state (Diaz-Otero et al., 2018). The endothelium 
dependent vasodilatation of rats treated with chronic hypoxic was attenuated by 
TRPV4 inhibition but was unaltered in normoxic rats (Naik and Walker, 2018).  
 
This chapter reveals that exposure of cremaster arterioles to shear forces 
increases the sensitivity of endothelial TRPV4 ion channels to a selective agonist 
and reveals their short-lived but profound contribution to muscarinic receptor 
mediated endothelium-dependent vasodilatation. Although the effects of shear 
forces are reversed within 30 minutes in our preparation, since the 
microvasculature is constantly exposed to pulsatile shear forces, sensitisation is 
likely to be present normally in vivo. Thus, shear-dependent sensitisation is likely 
to be a physiologically relevant contributing factor to resting vessel tone that is 
not measured when using pressure myography approaches without shear stress 
which consequently may under estimate the contribution of TRPV4 to the 
regulation of vascular tone. This study shows that understanding the role of 
TRPV4 in the modulation of vessel tone may require more sophisticated 
myography assays, since TRPV4 integrates signals from multiple stimuli, such as 
GPCRs, pressure, shear stress and temperature.  
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8 General discussion 
As identified previously, TRPV4 is widely expressed and implicated in a range of 
physiological and pathophysiological settings. Currently, the mechanism of 
physiological activation of TRPV4 is poorly characterised, mechanism of the 
receptor-dependent opening of the TRPV4 channel was the focus of this thesis.  
8.1 Summary of results 
The results presented in this thesis have identified that in a HEK293 cellular model 
that PAR2 signals to and opens TRPV4, and this signalling pathway requires the 
expression of MAPK13, WNK4, Gα13, Gγ8 or PLA2G4A. Also, PAR2-dependent 
opening of TRPV4 is independent of calcium release from intracellular stores and 
Gαq signalling. To translate this research it was shown that multiple GPCRs can 
signal to and open TRPV4 in the HEK293 cellular model which gave indications of 
the possible physiological settings for the GPCR-dependent opening of TRPV4. 
From these findings it was determined that a potential physiological setting for 
GPCR-TRPV4 axis was the vascular endothelium. The function of TRPV4 in the 
vascular endothelium was assessed and it was identified that TRPV4 dilated 
cremaster arterioles via small and intermediate calcium-dependent potassium 
channels. TRPV4 function is significantly altered when the vessels experience 
shear stress. The response of TRPV4 to its agonist GSK1016790A is sensitised 
when the vessels have experienced shear stress on the endothelium and shear 
stress also alters the state of the channel so it became involved in ACh-induced 
vasodilatation. 
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8.2 Future directions 
  
A key finding of this thesis is the discovery of previously undescribed signalling 
processes in the receptor-dependent opening of TRPV4. To ascertain the function 
of these signalling molecules newly identified in the PAR2-dependent opening of 
TRPV4 it would be preferable to confirm their involvement by multiple 
techniques. For instance, by using CRISPR-cas-9 gene editing technology to 
generate cell lines which no longer express MAPK13, WNK4, PLA2G4A, GNA13, 
GNG8 and testing the ability of PAR2 to open TRPV4 in the absence of these 
proteins. Potentially some of the lower confidence hits which were identified but 
not pursued further in the screening process could also be investigated using this 
technique. The generated knockout cells would also allow researchers to 
determine the order of events in the signalling pathway between PAR2 and TRPV4. 
To elucidate this sequence mass spectrometry could be used, as identified PAR2-
TRPV4 signalling is kinase dependent, therefore by analysing the phosphorylation 
states of proteins with and without stimulation of PAR2 in the various knock out 
cell lines it may be possible determine the order in which these proteins interact 
in the PAR2-dependent opening of TRPV4. 
The establishment of the siRNA screening process in HEK293 cells, opens multiple 
facets of investigation. Allowing for future screens of other signalling molecules. 
For instance, the identification of PLA2G4A opens an avenue for further 
investigation into the downstream enzymes which may generate the ligands of 
TRPV4 from arachidonic acid. Therefore by screening siRNAs for the downstream 
enzymes such as cyclooxygenases, cytochrome P450s and lipoxygenases 
(Watanabe et al., 2003) that process arachidonic acid it may reveal the identity of 
the metabolites which open TRPV4 in this system.  
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Further to this the identification of epoxyeicosanoids and other arachidonic acid 
metabolites that open TRPV4 (Watanabe et al., 2003), cells could be profiled using 
lipidomics to determine the ligands for TRPV4. Lipidomics is the study of the lipid 
profile of samples using mass spectrometry. Clinically it was identified using this 
technique that 5’6’ EETs, the TRPV4 activator was increased in patients with 
irritable bowel syndrome (Cenac et al., 2015). This highlighted the value of this 
technique and the potential applications in this HEK293 model. For instance, 
studying the profile of lipids generated by the purinergic receptors in HEK293 
cells, could identify which lipids are generated by P2Y2 and P2Y11 activation that 
open TRPV4 by comparing that to the lipids generated by P2Y12 do not open 
TRPV4. Therefore, either the lipidomic profiles would identify the key molecules, 
or it would be the same which indicates that the signalling molecules of this 
process require multiple stimuli to be integrated to facilitate the opening of TRPV4 
such as signalling from kinases and the lipid agonists. 
The work presented in this thesis in the ACh-induced vasodilatation and the link 
to TRPV4 opening demonstrated the complexity of these signalling processes. 
Although this process clearly showed the involvement of TRPV4 in a physiological 
process in a tissue, whether this is clinically relevant is difficult to determine. The 
potential for assessing the TRPV4 function in the vasculature in various disease 
states such as hypertension and chronic hypoxia may help reveal the role of 
TRPV4 in integrating multiple stimuli in a physiological system. The key for this 
research and the receptor-dependent opening of TRPV4 is determining its 
physiological relevance and how it participates in the numerous 
pathophysiological conditions linked with TRPV4 function.  
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8.3 Conclusion  
The key findings of this thesis are summarised in Figure 8.1. A range of GPCRs 
were identified that can open TRPV4 in HEK293 cells which suggests the 
possibility that there are multiple physiological systems where the receptor-
dependent opening of TRPV4 may be relevant to signalling. The key signalling 
molecules involved in the receptor-dependent opening of TRPV4 in HEK293 cells 
were identified and show the potential signalling pathways that may be involved 
in other cells types. 
  
Figure 8.1 Summary of key findings for the Receptor-dependent opening 
of TRPV4. G-protein coupled receptor (GPCR), protease activated receptor 2 
(PAR2), purinergic receptors (P2Y2, P2Y11), neurokinin receptor 1 (NK1), 
bradykinin receptor 2 (BK2), muscarinic receptor M3 (M3R), transient receptor 
potential vanilloid-4 (TRPV4), G-protein alpha 13 (Gα13), G-protein gamma 8 
(Gγ8), cytosolic phospholipase A2 (cPLA2), mitogen activated protein kinase 
13 (MAPK13) and with no lysine kinase 4 (WNK4).   
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